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Abstract 
 
Prostate cancer is the one of the major causes of morbidity and mortality in the western 
world.  It affects the prostate gland of males with a significant increase in the disease 
incidence every year. Current diagnostic and prognostic markers, such as prostate 
specific antigen (PSA), rectal examination and Gleason grades have their own limitations 
in a wider context of disease treatment and prediction. There is therefore a pressing need 
for novel and powerful biomarkers at protein or metabolite level. This study attempts to 
profile and identify candidate prostate cancer stage specific markers, within a defined 
population of samples. The samples were classified, based on the pathological 
LQIRUPDWLRQDV³DJJUHVVLYH´*OHDVRQJUDGH!DQG³QRQDJJUHVVLYH³*OHason grade < 
7). The proteomic protocols standardised at the John van Geest Cancer Research Centre, 
were used for the initial characterisation of the samples. The MS spectra obtained from 
the samples were used applied to an artificial neural network (ANN) based algorithm to 
generate predictive ions able to classify the samples. Three ions (m/z 1268.8, 998.6, 
910.4) were able to predict and classify with high specificity and sensitivity.  24 samples 
were immunodepleted and subjected to nano-LC fractionation and MALDI-TOF analysis, 
generating 80-120 protein identities per sample. The three ions predicted previously by 
the ANN identified as Haemopexin, Gelsolin and Apolipoprotein B 100.  Using 
ProfileAnalysis software, this study identified Apolipoprotein isoforms, including 
Apolipoprotein B 100, and Afamin as the proteins which showed differential expression 
in between the groups. This study identifies Apolipoprotein B 100 as a potential marker 
using two different modeling approaches suggesting this protein as the potential 
biomarker candidate. The utility of high throughput proteomic platforms such as Robotic 
liquid handling, MALDI-TOF and LC-MALDI for serum biomarker identification in PCa 
has been shown during this investigation. 
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Abbreviations 
 
 
1-D SDS PAGE/1DGE - 1-Dimensional Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis.  
2-D SDS PAGE/2DGE - 2-Dimensional Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis  
ACN ± Acetonitrile 
ANN ± Artificial Neural Network 
APCI-Atomospheric Pressure Ionisation  
BPH ± Benign Prostate Hyperplasia 
BSA ± Bovine Serum Albumin 
CID ± Collision Induced Dissociation 
CHCA ± Į-Cyano-4-Hydroxy-Cinaminc Acid 
Da- Dalton 
DER-Digital Rectal Exam  
ESI ± Electrospray Ionisation 
FPSA-Free Prostate Specific Antigen 
GC-Gas Chromatography 
HGPIN-High grade Prostatic intraepithelial Neoplasia  
HPLC ± High Performance Liquid Chromatography 
LC-Liquid Chromatography 
LGPIN-Low Grade Prostatic  intraepithelial Neoplasia 
m/z- Mass to charge ratio 
MARS ± Multiple Affinity Removal System 
MALDI ± Matrix assisted Laser Desorption/Ionisation 
MS ± Mass Spectrometry  
MSMS ± Tandem Mass Spectrometry 
MTP ± MALDI Target Plate 
PMF ± Peptide Mass Fingerprint 
PCa ± Prostate Cancer 
PCA-Principle Component Analysis 
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PSA ± Prostate Specific Antigen 
PIN- Prostatic  intraepithelial Neoplasia 
QC ± Quality Control 
RF-Radio Frequency 
ROC ± Response Operator Curve 
TOF ± Time of Flight 
TFA ± Trifluoroacetic Acid  
TRUS-Transrectal ultrasound  
WHO-World Health Organisation 
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1-Introduction  
1.1 Cancer  
Cancer can be defined as an abnormal growth of cells caused by various different 
changes at the genetic and epigenetic level which ultimately leads to uncontrolled cell 
replication, growth and proliferation. This abnormal growth eventually invades other 
adjacent tissues and can metastasise to distant sites causing morbidity or mortality 
(Ruddon 2007). According to the World Health Organisation (WHO) there were around 
12 million new cases of cancer in 2008, and 7 million deaths from cancer in the same 
year. Among the known cancer types, lung cancer is the most common cause of death in 
both genders, followed by breast cancer in females and prostate cancer in males. These 
statistics are obtained from developed and developing countries which are hugely 
different in many factors such as the lifestyle, dietary, pollution and health care 
efficiency. Along with molecular changes, these factors also might contribute towards the 
development of cancer in many parts of the world. 
In the past few decades there have been significant scientific advancements in the field of 
cancer biology, diagnosis and therapeutic intervention, though we still need more 
research effort to be undertaken in different cellular physiologic and developmental 
context to fully understand prostate cancer aetiology. Even though many cancers share a 
common root of disease development, a common strategy of treatment is yet to be 
devised.  Different cancers and individuals respond to the chemo- and immuno-therapy 
differently depending on the stage of the cancer, so it is necessary to identify and define 
each of the patient situations more accurately, if possible at the molecular level prior to 
devising a suitable treatment regime.  
Biomarkers in Prostate Cancer  Bandar Alghanem 
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1.1.1 Prostate cancer  
Prostate cancer is the one of the major causes of death in the western world; in UK there 
were around 35,000 cases in 2007, and 10,200 of men died from prostate cancer in the 
same year (UK Research, Cancer). Like other cancers Prostate cancer is also an 
anomalous growth of cells in prostate gland which leads to abnormally forming tumours. 
The prostate is a walnut sized and shaped gland found in men under the bladder (figure 
1.1) which secretes prostatic fluid which is released during ejaculation. Normally the size 
of prostate gland increases with age and the condition is commonly referred to as benign 
prostatic hypertrophy (BPH) (Evans et al., 2008). The enlargement in the gland causes 
difficulty with urination, with common symptoms of lack and delay in stream, non-
contiguous running, dribbling, and burning during streaming. However, in some cases the 
need to urinate frequently, particularly during sleep which results in lack of sleep and 
poor health in general. In the UK there are 78.000 new cases with these symptoms every 
year (UK Research Cancer). These symptoms do not necessarily indicate prostate cancer, 
because the patients with BPH or infections in their prostate gland have the same 
symptoms. Therefore it is hard for the physicians to diagnose localised cancer with these 
symptoms alone.  
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Figure 1.1.  This shows the location and the shape of the prostate gland. (figure was 
taken from: http://lowerbloodpressurecheap.com/ ) 
 
There are several diagnostic procedures adopted by different clinics around the world. 
Traditional Prostate Specific Antigen (PSA) screening in conjunction with Digital Rectal 
Exam (DRE) has been used for the last two decades (Damber and Aus 2008). Moreover 
the combination of these two tests is more efficient than when they are used individually. 
In DRE the clinician or nurse insert a gloved finger into the rectum to examine if there is 
any enlargement or abnormality in the prostate gland. The efficiency of this test is 
entirely dependent on the examiner who is conducting the examination. In PSA 
screening, patient blood is extracted and the serum tested for the presence and levels of 
PSA in a clinical biochemistry laboratory. 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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1.1.2 Prostate Specific Antigen (PSA) 
PSA is an enzyme of the human glandular kallikrein family, which is formed in the 
prostate gland. PSA is an important compound in the seminal fluid, which causes 
proteolysis in the gel-forming proteins that are found to trap and cleave spermatozoa into 
small fragments, therefore releasing spermatozoa during ejaculation. PSA enters the 
serum at low concentrations by leaking from luminal cells through the epithelial 
membranes. Blood samples from the patient are analysed using an immunoassay system 
based on the reaction between the antigen and the antibody and detect and quantify the 
PSA concentration in the blood. The concentration of PSA measured is at the nanogram 
per millilitre (ng/mL) levels, and the normal range is considered to be less than 4 ng/mL 
(UK Research Cancer). Unfortunately the lack of specificity and sensitivity for PSA leads 
to improper diagnoses which lead to increased risk of false negatives and positives 
(Hellstrom et al., 2007)+RZHYHU PRVWXURORJLVWVZLOO UHTXHVWD ³IUHH36$´ WHVW LI WKH
result of PSA is between the ranges of 4-QJPO ³)UHH36$´ LV WKHFRQcentration of 
PSA that is not bound to any other proteins. Free PSA percentage in the serum can give 
more specificity for the PSA test and determine whether patients need to go for further 
diagnostic procedures such as biopsy examinations. The decreased percentage of free 
PSA is most likely to be a risk factor of prostate cancer, however not all laboratories 
around the world have free PSA test, and most clinicians not satisfied with DRE and PSA 
tests will suggest a biopsy examination.  
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1.1.3 Biopsy test 
$OO WKH SURVWDWH FDQFHU VFUHHQLQJ PHWKRGV PHQWLRQHG DERYH VXSSRUW WKH XURORJLVW¶V
decisions for urgent biopsy study or to repeat these tests (DRE, PSA and FPSA) after a 
period of time. When the clinician recommends a biopsy test, the patient will be asked to 
follow some instructions before the study day. Some medications will be stopped for a 
week prior the biopsy such as aspirin or any non-sterodial anti-inflammatory drugs in 
order to minimise any bleeding during the biopsy. Patients are also asked to take some 
antibiotics before and after the study for minimising any infections. In biopsy operations 
urologists will take some cells specimen from the different places in the prostate gland by 
needle to analyse cancerous cells or tissues under microscope by a pathologist. 
There are three types of prostate biopsies: the transrectal, the transurethral, and the 
transperineal. The transrectal prostate biopsy is guided by the transrectal ultrasound 
(TRUS) through the anus and into the rectum. The transurethral biopsy is tested by a 
lighted cystoscope up through the urethra so it will allow the urologist to see deeply to 
the prostate. The transperineal biopsy collects the cells through a small incision in 
perineum, which is located between the anal sphincter and the scrotum. In most cases 
TRUS will be performed as the primary biopsy, in which ultrasound probe will be 
inserted through the rectum and get waves back from prostate gland then biopsies will be 
obtained. Usually the biopsy collection is carried out several times with 8-12 cores taken 
from different areas in the prostate which depends on the size of prostate gland. The 
biopsies will be analysed by two pathologists for inter-observer agreement. It is rare to 
have different interpretations, in which one pathologist states cancer and the other not, 
However, there is a chance of getting both the diagnoses wrong if the biopsies missed the 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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area of cancerous growth, thus urologists will ask for re-biopsy if they doubt there is 
possibility of prostate cancers based on DRE and PSA screening or even with high family 
history of this cancer. In this case there is 50% possibility to detect prostate cancer with 
repeating biopsy. The common measure of the aggressiveness and invasion of the 
cancerous growth in PC is interpreted by the pathologist by the Gleason grade. 
 
1.1.4 Gleason grade 
Gleason grade was invented in 1987 by the physician and pathologist Dr Donald F. 
Gleason, who was studying the prognostics of prostate cancer. He obtained this score to 
differentiate aggressive from non-aggressive cancer based on the appearance of cancer 
cells and the degree of difference in shape from normal cells. Basically the grade takes 
score from 1 to 5. Score 1 is considered to be very similar to normal cells, and becoming 
more differentiated going up until score 5 which is very different from normal cells 
(figure 1.2). There are two grads, the first one represents the most common pattern of the 
tissue and the second is the next most common pattern of the gland and the sum of two 
grades will give the Gleason score (sum) which is from two to ten. Since the final grade 
is the cumulative of the two most predominant patterns in the tumour section the 
interpretation of the score is also slightly different.  For example when Gleason sum is 7, 
it can be represented in two ways (3+4) and (4+3, both give the same sum, but with 
pattern and the completely of the two cases are entirely different. Gleason 4+3 considered 
to be behave more aggressively than Gleason 3+4, while the primary pattern (grade) can 
give more significant indication of the behaving of the tumour than the secondary pattern.  
However there are many studies still trying to prove this significant difference in tumour 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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interpretation between Gleson grade 3+4 and 4+3 like situations (Lopez-Beltran et al., 
2006).    
                         
 
 
 
Figure 1.2.   Histologic grades been obtained by Dr.Gleason illustrated the differences of 
the cancers cells shape from score 1-5. (The figure was taken from: 
www.malecare.com/gleason-score_58.htm) 
 
However, once the pathologist has obtained the Gleason score in his report the other test 
for the biopsy slides which might be included in the report is the presence of prostatic 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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intraepithelial neoplasia (PIN). In this examination the pathologist will examine how the 
cells look and based on it will decide whether the biopsies specimens have high grade 
prostatic intraepithelial neoplasia (HGPIN), or low grade prostatic intraepithelial neoplasia 
(LGPIN). In LGPIN patients have low risk of cancer, whereas patients with HGPIN have 
high risk of prostate cancer. So usually the urologist will recommended for re-biopsy for 
who those with HGPIN, so the possibility of finding prostate cancer cells is between 35-
45%. However, a comprehensive report will be delivered to the urologist including 
whether prostate cancer present or not, with Gleason scores and the area of the cancers 
cells if they have been found, then if patient has HGPIN or not. The urologist will take his 
final diagnosis based on the pathologist report and with his findings from previous tests 
(PSA, DRE) for any further follow-up or treatments. 
 
1.1.5 Prostate cancer treatment 
Prostate cancer treatment remains a big challenge for all the surgeons and the urologists. 
For patients with metastatic cancer, there is no cure even with the advancement in 
chemotherapy treatments. However, there are many areas that should be considered 
before taking the decision for any particular treatments such as pattern of the cancer, 
spread of the cancer, age, patient health, sexual function of the patient and other factors. 
Furthermore; there should be consideration of the benefit and the risk of each type of 
treatment. Fortunately, prostate cancer cells grow slowly in many cases, in which the 
physician will just monitor the patient and will not go for any treatments (watchful 
waiting) unless the tumor starts to grow significantly. In some cases patients will undergo 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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a surgical option and if the patient is not too old and also has a high grade in Gleason 
score. The surgeon will remove the prostate gland by radical prostatectomy using 
laparoscopic methods to monitor the prostate gland by small camera inserted into the 
body. In this type of treatment the patient might be cured completely if the cancer has not 
already spread. Another type of surgical intervention is removing both testicles 
(orchidectomy) so testosterone will not cause growth of the prostate because most 
testosterone is produced from the testicles, and in this is type of hormone therapy that 
will be followed when the cancer spreads out from the prostate gland such to the bone.  
There is different hormone therapy without surgery, using only medications which inhibit 
testosterone in the body. Chemotherapy is a good option for those who have metastaic 
cancer, in these treatments there is no cure but the spread might be slowed. 
 
1.2 Proteomics 
The enormous advancements in genomics technology in the past decade after the human 
genome sequencing in 2001 paved the way to understanding the molecular framework at 
the genomic sequence level. However, the functional understanding of each gene requires 
the interpretation of these genes at the functional level in the context of various genetic 
physiological and environmental conditions. Post genomic era of modern molecular 
biology such as micro arrays has enabled the scientific community to understand the gene 
expression and its regulation at the transcriptional level. But most of the functional 
understanding of each gene requires its definition at the protein level since proteins are 
Biomarkers in Prostate Cancer  Bandar Alghanem 
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the far end of gene expression which carry hundreds or even thousands of post 
translational modifications. 
Proteomics is the study of all the proteins expressed in a cell, tissue, or organ at any given 
time or condition often using high throughput technologies such as mass spectrometry 
combined with appropriate bioinformatics tools to identify and typify proteins. The 
protein expression studies have been well documented even before the recent 
technological advancement as evidenced by the work of Anderson and colleague in an 
attempt to identify all the proteins in human plasma in 1977. For many years 
polyacrylamide gel based one dimensional size fractionation were widely used for the 
characterisation of differentially expressed proteins.  However, this technique was 
superseded by much more informative two dimensional electrophoresis (2-DE) which 
separates and fractionates the total proteome in two dimensions based on the charge (PI) 
and the mass (mw). The consequence is dramatic, the power of 2D gel electrophoresis 
and mass spectrometry has enabled the identification and characterisation of hundreds of 
proteins differentially expressed in various biological conditions. Despite of all these 
advancements, proteomics has its own inherent problems such as the lack of high 
throughput nature, the information content from each experiments and the 
reproducibility. Even though, importance of protein studies still remains high on the 
agenda because of the post translational complexities which cannot be accounted by 
transcriptional interpretation alone. There are around 30,000 genes in the human genome 
which encode approximately 500,000-1000000 proteins. This disparity indicates one 
gene does not necessarily encode one protein in the cell. Several factors such as the 
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mRNA splicing, phosphorylation, glycosylation and other protein folding mechanisms 
contribute towards the functional diversity of the total proteome. 
Alternative splicing is one of the reasons that make one gene produce different proteins, 
and this is transcriptional level diversification of the protein. Genes contain many exons 
(the coding DNA) and introns (the non-coding DNA) at the DNA sequence level. If a 
gene contains 6 exon, one transcribed mRNA can contain 1-5 exons and another mRNA 
can contain 1-4 and 6 exons by a process called alternate splicing (Domingues et al., 
2007) (figure 1.3)  
 
 
 
Figure 1. 3  illustration showing alternative splicing. 
(http://www.ncbi.nlm.nih.gov/Class/MLACourse/Modules/MolBioReview/alternative_sp
licing.html) 
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Another reason lead to the huge variability of proteins from certain gene is post-
translational modifications. Basically these modifications occur after the translation level 
by proteolytic cleavage or by chemical modifications such as phosphorylation, 
methylation, and acetylation to one or more amino acids. Therefore, these modifications 
lead to more diversity of proteins from the essential synthesised proteins. The importance 
of post-translations modifications becomes clear when determining the activity status, 
protein localizations, protein turnover, and the protein-protein interactions. Thus, the 
analysis of the expression of mRNA poorly indicates the protein function, whereas the 
direct analysis of proteins enhances our understanding of their function. Another 
limitation of proteomics is the low abundance of the proteins; some of the proteins exist 
at very low concentrations so detection of these proteins is very difficult with 
conventional gel based approaches. Lack of a similar technique like polymerase chain 
reaction which increases the mRNA transcript levels is lacking in proteomics which 
makes the scenario more difficult for protein studies in comparison to the mRNA studies.    
There are two approaches in the field of SURWHRPLFV³H[SUHVVLRQ SURWHRPLFV´ZKLFK LV
the analysis of the protein patterns in different conditions (health/illness), and functional 
proteomics which deals with the protein - protein interactions and their activities in the 
cells. These approaches have achieved considerable momentum recently with the massive 
improvement in the instrumentation and fractionation techniques in mass spectrometry 
and chromatography. The data generated in proteomic studies are considerably larger and 
massively parallel compared with the traditional gel based approaches. The revolution in 
technology has generated highly multidimensional data sets and the bioinformatics tools 
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which allow us to increase our understanding of proteomics have made it possible to 
investigate the proteome in a system biology approach. 
 
1.2.1 Mass spectrometry 
During the past decade Mass spectrometry (MS) has been emerged as the mainstay 
instrumentation in all proteomics laboratories around the world. The sensitivity and 
reproducibility allows this technology to identify proteins rapidly, so that it can be used 
in highthroughput screening method to study different biological complexities.  All the 
mass spectrometry analysers are composed of three main parts; 1- ionizations source, 2-
mass analyser, and 3- detector (figure 1.4) 
 
 
 
 
Figure 1.4.  The Basics of mass spectrometry 
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The ionisation source is a device which ionises the protein\peptide molecule which is 
then transported by magnetic or electric fields to the mass analyser. There are many types 
of ionisations such as protonation [M + H] + deprotonation, [M - H] + and cationisation 
[M + Cation] +.  There are different types of the ionisation sources are available such as 
Electrospray ionisation (ESI), Atmospheric pressure chemical ionisation (APCI), Matrix-
assisted laser desorption/ionisation (MALDI), and Desorption/ionisation on silicon 
(DIOS). The major differences among these types of source are the way the analyte is 
ionised, for example, in ESI the ionisation is facilitated by the evaporation of the charged 
droplets by the high voltage electric field, whereas in MALDI the ionisation is mainly by 
photon absorption and proton transfer. After the ionisation, the analyte it is guided to the 
mass analyser. There are many types of these analysers are used in various mass 
spectrometers such as Quadruple, time of flight (TOF), and ion-trap. A Quadrupole 
analyser has four steel rods that are connected to an radio frequency (RF) generator, 
which allows ions with specific m/z to pass through it to the detector. Quadrupoles have a 
significant mass rang with the capability of the analyzing up to an m/z of 4000, which is 
useful because ESI of proteins mostly produces charged distributions from m/z 1000 to 
3500. In ion-trap analyser, the ions are passing through a quadrupole analyser and 
trapped in a radio frequency quadrupole field. The radio frequency is scanned to 
resonantly excite and therefore eject ions through small holes in the endcap to a detector. 
As the RF is scanned to high frequencies, higher m/z are excited, ejected, and detected. 
Another type of mass analyser commonly used is time of flight (TOF). TOF is basically a 
long tube with high vacuum, which has a pulse device used to accelerate the ions into the 
flight tube and all ions enter at the same time. Ions with low m/z travel faster, whereas 
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ions with high m/z travel slower. Once all molecules are ionised and guided by the mass 
analyser to a detector. When the ions hits the detector   spectra (peaks) will be obtained 
which shows the intensity at different masses (m/z values). MALDI- TOF is the most 
widely used method for the characterization of the peptides and the proteins. In peptide 
mass fingerprint (PMF) the peptide mass obtained from MS is matched with abstract 
peptide mass generated from known sequence of proteins or genome using computer 
software like MASCOT to search the database such as SWISSPROT for proteins 
identification. The limitation of this method is that PMF algorithms suggest all peptides 
which come from one protein, so to overcome this problem when we have number of 
peptides from a mixture of proteins is to fragment  each peak by different methods such 
as collision induced dissociation (CID) which allow for tandem MS (MSMS) in order for 
more specificity protein identifications.  
 
1.2.2 MALDI-TOF/TOF mass spectrometry 
It is crucial to choose the appropriate type of MS for any given study, considering all the 
advantages and disadvantages for each type of MS instrumentations and which one of 
them will promise for more accuracy. The new MALDI-TOF/TOF-MS is guarantee with 
high sensitivity and reproducibility. As described in the previous section MALDI-
TOF/TOF is analyser measure the mass to charge ratio (m/z) for protein/peptide ions.  
In MALDI-72) WKHVDPSOH SURWHLQSHSWLGHZLOOEH PL[HGZLWKRUJDQLFDFLG ³PDWUL[´
VXFK DV Į-Cyano-4-hydroxycinnamic acid CHCA), in which will accelerate the 
ionization of the protein/peptide molecules then a dry spot will be fixed in target plate 
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(ground steel plate or Anchorchip plate) and then the laser power will be applied which 
will fire at specific spot and ionise the protein/peptide molecule. Then the ions will be 
guided into mass analyser TOF/TOF. Rather than the liner TOF as mention above, TOF 
reflecton has two flight tubes and reflectron (ion mirror) take place in end of the first 
flight tube and reflect the ions into the second time flight tube which allow for more 
length of the flight tube, and thus enhance the resolution (ions separations).  End of the 
second flight tube there is a detector. Graphical peaks (spectra) will be generated shows 
intensity for all the peptide mass. One of the advantages of MALDI-TOF is its 
operational simplicity, easy maintenance, and its ability to detect high mass range (200-
500,000 Da). 
 
1.2.3 Proteomics biomarkers discovery 
One of the challenging demands of all the clinicians around the world is to find reliable 
biomarkers for specific diseases (cancer) or disease staging which enhance early 
diagnosis and prognosis thereby increasing the chances of better management of the 
disease.  Biomarker can be defined as any biological substance which can indicate the 
state of disease or the treatment efficacy. These biomarkers can be used to predict, 
diagnose, and prognoses disease and detect the response of particular drug or the stage of 
the disease, these markers are genes, metabolites (peptide, amino acids, and 
carbohydrates), or proteins. Although genetic and metabolites markers are good 
indicators, it is highly necessary to identify protein biomarkers because most of the 
disease states are well linked to abnormal proteins mainly modified at the post 
translational level. Some of the  protein biomarkers currently  identified such as CA 125 
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(cancer antigen 125) for ovarian cancer(Hanash et al., 2008)  , CA 15-3 (cancer antigen 
15-3) for breast cancer, CEA (Carcinoembryonic Antigen) (Xue et al., 2008), PSA 
(prostate specific antigen) for prostate cancers to monitor the treatments for certain 
cancers, and troponin I (cTnI) as cardic marker (myocardial infection) (Lescuyer et al., 
2007) are emphasising the importance of noval biomarkers. Several factors decide the 
quality of an ideal biomarker. Primarily, the efficiency of any biomarker relies upon its 
specificity and sensitivity with low false positive and negative rates. Thus, they must be 
robust. Secondly, reproducibility, Candidate biomarkers identified in the clinical 
laboratory settings do not necessarily reproduce their utility when they are taken in to a 
real life scenario. Thirdly, the requirement of biological sampling such as bio-fluid 
(serum, plasma, and urine) markers avoids the need for an invasive sampling and 
clinicians can then investigate rapidly. In the current biomarker discovery scenario, 
serum and plasma are widely used by many laboratories despite their complexities. Apart 
from its easy accessibility, serum is considered to a goldmine for biomarkers because 
serum has the ability to connect with all the cells of the body. In addition to this, serum 
contains many low abundant proteins that leak from diseased tissues, especially during 
illness (cancers). These low abundant proteins promise to be significant biomarkers, in 
particular cancer-related biomarkers. Although it is important to identify proteomics 
biomarkers in serum and other biological fluids, the discovery is particularly challenging 
in the serum due to its complexity.  The changes in protein state from one patient to 
another one due to many factors such as environmental, diet, lifestyle, and stress, making 
protein expression altered even though they have the same disease. Another factor is the 
high dynamic range of protein concentration in serum, in which the serum albumin 
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concentration is 50g/l compared with some other proteins with very low concentration 
such as PSA at ~4ng/ml (more than 10 orders of magnitude for protein concentrations 
reported in human serum) (Jacobs et al., 2005).  Appropriate pre-fractionation methods 
which will selectively eliminate high abundant proteins prior to mass spectrometry 
analysis will enhance the ability to identify potential biomarkers. 
 
1.2.4 Fractionation techniques  
Serum is considered as the greatest source of proteomics markers in human, on other 
hand  it is highly dynamic which means it undergo many biological changes  in a very 
short period of time in patients. Unfortunately these complexities and the high dynamic 
range in serum make it difficult as a starting material for biomarker discovery. However 
the advancement in separation and fractionation methods prior to MS analysis reduce the 
complexity of the spectra obtained from MS especially for the low abundance proteins 
which is has the power for significant biomarkers.  So the biggest challenge facing 
proteomics analysis is the way to separate the low abundance proteome from high 
abundance proteins (such as ALB, and IgG).  
In present day, there are two approaches followed in most proteomics laboratories; first 
bottom-up, in which the mixture of proteins in sample will be enzyme cleavaged into 
small proteins/peptides, then these peptides, will be further separated by GC or LC 
technology (Righetti et al., 2005). This method is highly used and shows a high 
separations of digested peptide and with many proteins been identified. However there 
are limitations in this method also such as the limited number of peptides which is relying 
Biomarkers in Prostate Cancer  Bandar Alghanem 
_____________________________________________________________________________ 
27 
 
on to identify a given protein might not be sufficient especially for protein isoforms. 
Second approach is top-up, which is usually applied by ESI-MS. The ion source (ESI) 
generated proteins ions are fragmented by gas-phase, then be introduced by MS. This 
approach, compared with bottom-up, can give a complete sequence for a given protein. 
On the other hand this approach suffers in isolating proteins because of the complex 
spectra obtained from multiple charged proteins.  
The depletion of high abundance proteins and enrich the low abundance proteins is 
become one of the technique been used recently used as a primary method prior to 
downstream analysis, which shows high ability of detecting proteins with ng/mL 
concentration (Tang et al., 2006). The use of Cibracon blue dye is one of the most basic 
method applied to serum sample which has a specific affinity for ALB (steel et al., 2003). 
Recently, the multiple affinity removal system (MARS) immunodepleted for more than 
one protein has been widely used as an effective protein fractionation technique. This 
immunodepleted column can be found commercially targeting 6 or 14 for the high 
abundance proteins in the serum such as Albumin, Immunoglobulin G, Transferrin, 
+DSWRJORELQ Į-1-$QWLWU\SVLQ ,PPXQRJOREXOLQ $ )LEULQRJHQ Į-2-0DFURJOREXOLQ Į-1-
Acid Glycoprotein, Immunoglobulin M, Apolipoprotein AI, Apolipoprotein AII, 
Complement C3 and Transthyretin (figure 1.5 shows the 12 most abundance proteins in 
serum). Despite the importance of this method, the risk of losing some of low abundance 
proteins during the preferential binding of the high abundant proteins is still considered to 
be a big challenge. Even though many kits are available commercially, the complete 
removal of the high abundant fractions yet to be achieved.  Other fractionation techniques 
for separating proteins are based on their specific properties using electrophoresis or 
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chromatography techniques. In this technique the separation is achieved based on three 
property of protein; (1) the interaction of the protein with stationary phase and the mobile 
phase, then the ability to control this mobile phase by changing of gradient time or pH or 
changing of salt concentration (2) the type of column (for example strong ion exchange, 
reversed phase (based on hydrophobicity interactions) or normal phase (silica) (3) gel 
properties (Issaq et al., 2002). Recently most of the fractionation/separation methods for 
proteins in proteomics laboratories are followed the multidimensional separation 
approach, in which more than one separation method will be applied prior to MS analysis 
(Lee et al., 2006). For example the sample will be separated by 2-DE, then each fraction 
(protein spot) in the gel will be enzymaticly digested (trypsin) followed by LC-MS/MS 
analysis (Meng and Veenstra, 2007). 
 
 
Figure 1.5.  The most 12 abundant proteins in serum, in which ALB represent more than 
50% of total protein in the serum (Appliedbiomics.com image) 
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1.2.5 The application of bioinformatics in proteomics  
The amount of data generated from modern MS analysers is huge and multidimensional 
which make analysis a big challenge for biologists. Appropriate analysis of the data needs 
the integration of computational and statistical tools (Gu and Wong 2008). Fortunately 
the advancement in bioinformatics allows us to overcome the majority of this problem or 
at least help us to gain a satisfactory results with some biological explanations. However, 
WKH XVH RI ELRLQIRUPDWLFV LQ SURWHRPLFV LW¶V QRW RQO\ OLH RQ WKH FKDUDFWHULVDWLRQ DQG
identification of proteins from the already available sequence databases such as Sequest 
and Mascot (Perkings et al., 1998), in which the outcome of the peptide sequence is 
matched with a known peptide generated from proteins or even from genome by some of 
the predefined algorithms. So the experimental peptide will be compared with theoretical 
peptide using this database search, which results in protein identification with some 
indication about the significance of the match provided from the search. The search result 
includes the sequence coverage and other statistics generated with each match. 
Another application of bioinformatics by proteomics is generating a predictive model 
which suitably addresses the question of the study. But before using any bioinformatics 
tool we should address one question; what the purpose of this study? In other words if we 
are looking for a prediction specific site (such as glycosylation) among complex proteins, 
the use of support vector machine classifier shows a good result (Caragea et al., 2007), 
and another approach which shows a good for prediction capability  of new biomarkers is 
artificial neural networks (ANNs) (Wang et al., 2010).  
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ANNs basically is an algorithm learning network aims to predicatively classify two 
groups with prior knowledge. This network contain three layers ; 1- input layer, 2- hidden 
layer , 3- and output layer. The data (m/z values) in the two groups enter as the first step 
forming the input layer, and in this step the system will analysis all the nodes and train 
each nods (m/z values) many cycles based on biological relationship between this node 
and all the other node which can discriminate the two groups. The model is trained for 
each node many times resulting in low error and best predictive percentage. The step-
wise method is then applied by the system which allow for new nodes doing the same 
which in this case gain new nodes have high score predictive value and less error, which 
is in hidden layer. This process will continue form less number of nodes hidden layer for 
less number of nodes have the potential to discriminate between the two investigated 
groups as output (figure 1.6). 
 
 
Figure 1.6.  Illustration showing how the ANN model works. The ANN contains three 
layers: input, hidden, and output layers. 
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The training system in an ANN can generate a huge number of cycles which can lead to 
³RYHUILWWLQJ´ LQ ZKLFK VRPH RI WKH QRGHV ZLOO EH PLVVHG 7here is a development in 
ANNs modeling which are shows the ability to overcome of this problem. By dividing 
the input data into three groups; the first one containing 60% of the population which 
serve as a trained model. Second one contain 20% which is asses the first group to avoid 
overfiting. The last group hold 20% which is responsible of testing unseen data from 
previous steps (Matharoo-Ball et al., 2007) 
 
1.3 Objectives  
The aim of this thesis is to use proteomic and biostatistical methods to identify prostate 
FDQFHU VSHFLILF SURJQRVWLF ELRPDUNHUV WKDW DVVRFLDWH ZLWK ³WLJHU´ YHUVXV ³SXVV\FDW´
(aggressive and non-aggressive) phenotypes of prostate cancer and to validate their 
performance in an independent geographical heterogeneous population. The surrey study 
samples will be used to identify serum prostate cancer biomarkers predictive of 
QRQDJJUHVVLYH ³SXVV\FDW ³YHUVXV DJJUHVVLYH ³WLJHU´ SKHQRW\SHV $ YDULHW\ RI VDPSOH
fractionation and deconvolution techniques and mass-spectrometry based proteomic 
protocols combined with bioinformatic (Artificial Neural Network- ANN) and other 
biostatistical methods for the discovery and identification of protein/peptide biomarkers 
for prostate cancer will be used. A protein/peptide library will be created which will 
allow for further identification of the key proteins associating with cancer progression 
and treatment outcome. The identification of candidate biomarkers will allow the 
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extension of the study to determine whether a second patient cohort (Nottingham) 
stratifies according to the predictive models. 
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2- Materials and methods 
2.1 Reagents list 
Table 2.1.  Proteomic Reagents 
Reagent Company 
Acetonitrile (HPLC grade) Fisher Scientific, Loughborough UK 
Ammonium Bicarbonate Sigma-Aldrich, Gillingham UK 
Trifluoroacetic Acid (HPLC grade) Fisher Scientific, Loughborough UK 
Dichloromethane (HPLC grade) Fisher Scientific, Loughborough UK 
Acetone (HPLC grade) Fisher Scientific, Loughborough UK 
Methanol (HPLC grade) Fisher Scientific, Loughborough UK 
Ethanol (HPLC grade) Fisher Scientific, Loughborough UK 
Į-Cyano-4-Hydroxy-Cinnaminc Acid Laser Bio Labs, Cedex FR 
Sinapinic Acid Laser Bio Labs, Cedex FR 
2,5 Dihydroxybenzoic Acid Sigma-Aldrich, Gillingham UK 
Peptide Calibration Standard Bruker Daltonics, Coventry UK 
Protein Calibration Standard Bruker Daltonics, Coventry UK 
Trypsin (MS grade) 15,000 u/mg Promega, Southampton UK 
MARS equilibration/wash Buffer A Agilent Technologies, Wokingham UK 
MARS elution Buffer B Agilent Technologies, Wokingham UK 
Bovine Serum Albumin Sigma-Aldrich, Gillingham UK 
Acrylamide National Diagnostics, Loughborough UK 
Coomassie Blue Sigma-Aldrich, Gillingham UK 
Sodium Dodecyl Sulphate Sigma-Aldrich, Gillingham UK 
Propanol Fisher Scientific, Loughborough UK 
Glycerol  BioRad, Hemel Hempstead UK 
Temed Fisher Scientific, Loughborough UK 
Ammonium Persulphate Sigma-Aldrich, Gillingham UK 
Resolving Gel (x10) National Diagnostics, Loughborough UK 
Protogel National Diagnostics, Loughborough UK 
Running Buffer (x10) National Diagnostics, Loughborough UK 
Stacking Gel (x10) National Diagnostics, Loughborough UK 
SDS Sigma-Aldrich, Gillingham UK 
DDT Sigma-Aldrich, Gillingham UK 
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2.2 Reagents and buffers  
Table 2.2. Reagent solutions and buffers  
Solution Composition 
1% TFA Solution 1 mL  TFA Stock 
99 mL  ddH2O   
0.1% TFA Solution 100 µL TFA Stock 
99.9 mL  ddH2O 
50% Acetonitrile (ACN) Solution 25 mL  ACN Stock  
25 mL  0.1% TFA 
80% ACN Solution 40 mL ACN Stock 
10 mL 0.1% TFA 
100 mM Ammonium Bicarbonate Solution 0.395 g NH4CHO3 Powder 
50 mL ddH2O 
5 mg/mL CHCA Matrix 0.05 g CHCA Powder 
10 mL 50% Acetonitrile 
0.5 mg/mL Trypsin Protease 100 mg Trypsin Powder 
200 mL 100 mM NH4CHO3 
0.01% BSA Solution 1 mg Stock BSA  
10 mL ddH2O 
0.01% AAG Solution 1 mg Stock AAG  
10 mL ddH2O 
Sample Reducing Buffer 2.5 mL 0.5M Tris HCl buffer (pH 6.8) 
400 mg SDS 
2 mL Glycerol 
200 mg DTT 
A few grains of bromophenol blue 
made up to 20 mL ddH2O 
Running Buffer 100 mL 10x Tris/glycine/SDS- electrophoresis grade 
900 mL ddH2O 
(Resolving Gel Buffer) (pH 8.8) 
 
18.16 g Trizma base 
0.4 g SDS 
make up to 100 mL ddH2O 
adjust pH to 8.8 with HCl    
(Stacking Gel Buffer) (pH 6.8) 
 
6 g Trizma base 
0.4 g SDS 
make up to 100 mL ddH2O 
adjust pH to 6.8 with HCl    
Silver stain  
Fixation solution  
 
Silver reaction  
 
Developing solution 
Sensitizing solution  
 
100 mL Ethanol, 25 mL Acetic acid, 
Make up to 250 mL ddH2O(using 250 mL glass bottle) 
25 mL silver nitrate solution, 
 make up to 250 mL ddH2O 
Sodium carbonate (6.25g) 1 packet, 100 µL of formaldehyde 
(87%), make up to 250 mL ddH2O 
75 mL Ethanol,10 mL sodium thiosulphate (5% w/v) 
1 packet sodium acetate, make up to 250 mL ddH2O 
25 mL glycerol(87%), make up to 250 mL ddH2O 
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2.3 Equipment and software 
Table 2.3  
Equipment Company 
  
1D Electrophoresis Gel Tank GeneFlow, Staffordshire UK 
1D Electrophoresis Power Supply Consort E122, GeneFlow, Staffordshire UK 
Microcentrifuge Minispin ,Eppendorf 
Ultra Low Temperature Freezer (-80ºC) New Brunswick Scientific 
Freezer (-20)  
Incubator D-63450, Heraeus Instruments   
Vortex Whirlimixer, Fisher Brand   
Sonicator Ultrasonic Cleaner, VWR 
C18 ZipTips Millipore 
Xcise liquid handling robot Shimadzu/Proteome Systems, UK 
MARS Hu-14 Immunodepletion Column Agilent Technologies, Wokingham UK 
MALDI Mass Spectrometer UltraFlex III, Bruker Daltonics, Germany 
MALDI Mass Spectrometer UltrafleXtreme, Bruker Daltonics, Germany 
Proxeon Easy-nLC Bruker Daltonics, Germany 
  
Software 
 Table 2.4  
Flex Control Bruker Daltonics, Germany 
Flex analysis Bruker Daltonics, Germany 
ClinProTools Bruker Daltonics, Germany 
BioTools Bruker Daltonics, Germany 
Profile Analysis  Bruker Daltonics, Germany 
Statistica v7 Statsoft Ltd. 
Step-wise launcher v2 NTU Bioinformatics, UK 
Mascot/Mascot Daemon 2.1 Matrix Science, UK 
Microsoft Office 2003 Microsoft Corporation (provide by NTU,UK) 
 
 
2.4  Procedures and protocols 
This section illustrates the protocols that have been followed during the project starting 
from sample collection and storage through preparing the samples for analysis by 
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MALDI-MS using C18 ZipTip (clean up) then digestion of proteins using enzymatic 
technique (trypsinisation) to generate  m/z values. These data were applied to ANN for 
generating a list of peptides that have the ability to discriminate between two groups 
(aggressive vs nonaggressive prostate cancer). Moreover, this section will have an 
overview of our procedures for the next part of our study which is deep proteomic 
analysis using the immunodepletion technique followed by fractionation (LC/MALDI) 
and as a result protein identification. I want to state here that some of the protocols been 
used here were taken from previous work (1HLO'HYHQSRUW¶V05HVWKHVLV 
 
2.5 Samples collection and storage  
The PCa samples in our study were obtained from Surrey hospital, which they take 15-20 
mL of blood from patients before entering theatre for surgery. All samples were left for at 
least 30 min to allow time for the blood in the serum tube to clot. Then the samples left 
for 1 h on ice in order to prevent protein degradation before processing. The samples then 
centrifuged at 22 °C for 15 min and at 2000 rpm. Then the samples were pipetted into 
trays of micronic V tube aliquots. The volume of the serum samples was 150 µL and was 
stored in -80 °C freezer until the day we were. given them. Once we had the samples we 
split them into three aliquots to avoid the freeze-thaw cycles and stored them at -80°C 
freezer until required for use. 
 QCs and BSA samples were used in our study in order to check the reproducibility of 
MALDI-MS and their spectra were compared with previous data either visually or using 
PCA analysis. Along with PCa samples, QCs, and BSA we included blank samples (0.1 
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TFA %) to our MALDI-MS analysis to determine whether there are contaminating 
background peaks or excessive instrument noise.  
 
2.6 Patient details  
The samples obtained in our study were approved by the Nottingham Research and 
Ethics Committee. Surrey hospital provided us with 118 PCa serum samples. Patient 
information was provided which included the PSA results and Gleason grade.  49 patients 
with Gleason grade <7 (3+3), 32 patients samples with Gleason grade >7 (17 with 
Gleason grade (3+4) and 15 with (4+3)), and 41 patients samples without Gleason grade 
(unknown). Anyway in regard to the PSA results the range was from 3.1 to128 ng/mL. 
 
2.7 Integrated protocol for identifying tryptic peptide biomarker ions and sequences 
by MALDI-MS and ANNs  
The first part of our study followed a previously optimised method developed in the John van 
Geest Cancer Research Centre proteomics group to generate tryptic peptide biomarker ions 
from MALDI-MS and ANNs (figure 2.1). 
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Figure 2.1.Optimised methods for predictive tryptic peptide ions markers that were followed in our study. 
 
 
2.7.1 ZipTip processing, tryptic digestion and spotting on the MIP.  
Initially PCa and QCs serum samples were diluted 1:20 with 0.1 TFA% (11 µL of the 
serum samples, and 209 µL of 0.1% TFA) prior to ZipTip processing the samples 
automatically. C18 ZipTip solid phase extraction was performed. The samples were 
ZipTipped automatically using the Xcise robotic liquid handling system (Shimadzu, 
Manchester, UK). Moreover 30 µL of all the serum  samples were placed in two 96 well 
plates including (10 QCs, 10 Blank, and 9 BSA randomly positioned using Microsoft 
Office Excel 2003 to limit the bias that might occurs due to the position on the target 
plate ground steel MTP 384) were used to analyse the samples by MALDI-MS. The 
ZipTips were conditioned by wetting twice with 10 µL with 80 % ACN, and then 
equilibrated using 2 x 10 µL 0.1 % TFA. Next the sample binding step, in which the 
sample was bound to the ZipTip using 15 cycles (aspirate and dispense). The Tip was 
then washed with 10 µL 0.1 %TFA for 2 times, and eluted in 8 µL o f 80% ACN using 
15 aspiration and dispensing cycles. 16.6 µL NH4HCO3 and 7.6 µL dH2O were 
ANNs modelling
C18 ZipTip
Peptide Analysis
800-3500 Da
X
Y
Z
C18 ZipTip
Tryptic 
digestion
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automatically added to all the samples in preparation for adding the trypsin for overnight 
digestion at 37϶ C. 
After the first clean up step all samples were manually digested with 0.7 µL Trypsin gold 
and incubated at 37϶ C overnight. The next day digestion was terminated by adding 0.5 
µL 1 % TFA, then the samples were ZipTipped again (second clean up step) and 
duplicate spotted automatically by mixing 1.1 µL of sample with 1.1 µL CHCA matrix 
solution directly onto MTP plate.  
 
2.7.2 MALDI-MS analysis  
Prior to MALDI-MS analysis we perform external calibration to our MTP plate by 
spotting calibration mixture (Bruker Daltonics, Germany) manually with one centre spot 
for every nine spots. The MTP plate was analysed on the Ultraflex III TOF/TOF Mass 
spectrometer (Bruker Daltonics, Germany) operated in reflectron mode. The laser power 
was optimised and the mass range applied was 800-3500 Da. Furthermore the spectra 
(m/z values) were generated and visually checked in order to assess the final profile for 
all the patients and compare the duplicate spots to each other and remove and bad spectra. 
The data was then pre-processed and used to generate the ANN model.  
 
2.7.3 MS data pre-processing for ANNs modelling 
Initially the MS data for all 118 PCa samples generated from MALDI-TOF/TOF analyser 
was pre-processed prior to submit to the ANN. In house methodology optimised by 
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Proteomics laboratory team protocol (John van Geest Cancer Research Centre) was 
followed to extract only peaks with signal to noise above 2.5 and baseline subtraction 
was applied in the FlexAnalysis software. The program creates a txt file contain all the 
peaks with their charge to ratio and intensity. Using software provided it by our 
bioinformatics team to bin our data to 0.1 Da. Then the file was being opened in Statistica 
and the file transposed in order to open it in Excel. Once in Excel the average intensity 
was taken for all the duplicate samples and reopened this file in Statistica again. In 
Statistica software another variable was added, which 0, 1 for nonaggressive (<7 in 
Gleason sum) and aggressive (>7 in Gleason sum) respectively based upon prior 
information. Finally the data was saved as a txt file, and this file is be submitted to the 
ANN software. 
 
2.7.4 MS data and the ANN analysis 
The idea in ANNs is to find a panel of ions that have the ability to discriminate between 
our two study groups using step-wise algorithm. After submitting the data to the ANN, 
step-wise analysis starts, to assess all the ions to see if they have the power to predict one 
group from the other based on their intensity. The process starts with first loop in which 
the step-wise choose one ion with high performance prediction and low error value and 
selects this ion as the top one and then starts another loop to find the second one which 
will be assessed cumulatively to to the first one. These loops continue until a panel of 
icons is created that is able to predict as much the population as possible.  
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Once we get this panel of predictive ions for all our sample groups, 44 PCa samples (22 
with Gleason sum <7, and 22 with Gleason sum >7) were selected based on their high 
intensities and applied the model to them in order to predict between them and population 
chart was obtained. These 44 PCa samples were used for further proteomic analysis. 
 
2.8 Proteomic analysis  
This section covers the protocols that were followed for proteomic analysis, starting with 
immunodepletion of the abundant proteins followed by LC-MALDI MS/MS and protein 
identifications. Previously established protocols for deep proteomic analysis were used 
(figure 2.2|) 
 
Figure 2.2 Flow chart for well established protocols for proteomics analysis  
Biomarkers in Prostate Cancer  Bandar Alghanem 
_____________________________________________________________________________ 
42 
 
2.8.1 Immunodepletion of high abundant proteins 
44 PCa patient samples (22 with Gleason sum < 7, and 22 with Gleason >7) were 
selected. and these 44 samples were the same samples which we had been identified from 
the ANN model using  for population chart for the top three ions (1268.6, 998.6, and 
910.4) from stepwise ANN analysis. 14 MARS Hu-14 spin column (Agilent 
technologies) was used for all the 44 samples, which is deplete the top 14 serum 
proteins($OEXPLQ ,PPXQRJOREXOLQ * 7UDQVIHUULQ +DSWRJORELQ Į-1-Antitrypsin, 
,PPXQRJOREXOLQ $ )LEULQRJHQ Į-2-0DFURJOREXOLQ Į-1-Acid Glycoprotein, 
Immunoglobulin M, Apolipoprotein AI, Apolipoprotein AII, Complement C3 and 
Transthyretin) for specific polyclonal immunoglobulin.  
Before each run the column was removed from the refrigerator and left for 5 minutes for 
equilibration to room temperature. 2×50 mL falcon tubes were labelled as buffer A and 
B. The Buffer A tube was filled with 6 mL and the buffer B tube with 3 mL. The two 
syringes provided with the kit were labelled as A and B. Dilute the serum sample (1:20) 
with buffer A (8 µL serum sample with 192 µL of buffer A). The diluted sample (200 
µL) was placed in a 0.22 µm filter and spun in a microcentrifuge (make/model) for 90 s 
at 2000 rpm. Screw-top collection tubes were labelled F1 and F2. The spin cartridge was 
then prepared by removing the top cap and bottom cap. The luer lock adaptor was placed 
on the top of the spin column. Using the syringe labelled A and draw 4 mL of buffer A 
and attach to luer lock adaptor spin cartridge. Buffer A was dispensed through spin 
cartridge, and checked to see if there were any bubbles to remove. Then  syringe A and 
luer lock adaptor was removed from column. The spin column was placed into the F1 
tube an 200 µL of diluted sample added to the top of the spin column and cap column 
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was capped loosely. The column was spun in a microcentrifuge for 2 min at 2000 rpm. 
The column was removed from the F1 tube (containing the low abundance proteins) and 
the F1 tube capped. 
The column was incubated for 5 min at room temperature. 400 µL of buffer A was added 
to the column which was placed into F1 tube) and spun for 2 min at 2000 rpm. Fraction 1 
contained 600 µL of low abundance proteins. 400 µL of buffer A was added to the 
column which was placed in tube F2, spun for 2 min at 2000 rpm. Fraction F2 contained 
the higher abundance proteins (400 µL).  
Fractions F1 and F2 were combined and stored at -80 C for further analysis, and then the 
column was eluted with buffer B (2.5 mL of buffer B) using syringe B to waste. The 
column was washed with 4 mL buffer A using syringe A, so the column was ready for 
next use.  
2.8.2 MARS Hu-14 spin column efficiency assessment  
During the depletion of the 44 samples that were applied to the MARS Hu-14 spin 
column, the column was assessed twice by running a human serum QC sample and 
analysing it using 1D gel electrophoresis (1D-SDS-PAGE),  stained with silver stain and a 
digitally photographed.  
The resolving gel was prepared by adding 3 mL of protogel with 1.87 mL of resolving 
gel and 2.54 mL of ddH2O into a 50 mL tube. Mix them and add 75 µL of ammonium 
persulphate (10%) and 7.5 µL of TEMED, and the resolving gel poured between the 
plates. Some drops of hydrated-butanol were added to remove any bubbles. The gel was 
left for 30 min to polymerise. 
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The stacking gel was prepared by adding (0.52 mL  protogel, 1 mL  of stacking gel, and 
2.44 mL ddH2O) mix and add 20 µL of ammonium persulphate, and 4 µL of TEMED. 
This was added it to the top of resolving gel and we drops of hydrated-butanol added to 
avoid any bubble formation. Combs with 10 wells were placed in the gel until it was 
completely polymerised, then   the combs were removed. 
In first lane from the left we add 8 µL of protein standard ladder was added (Bio-Rad 
:HVWHUQ&SUHFLVLRQSOXVSURWHLQVWDQGDUGV). For the next 3 lanes 20 µL of diluted QC 
(1:20) with MARS buffer A was added. Then the next the three lanes, 20 µL depleted QC 
and the gel was stained using silver stain see the table below.  
 
Table 2.5 shows the procedure of silver stain for the 1D gel electrophoresis. 
For the reagents used for this protocol please refers to table 2.2. 
Step  Solutions Time 
Fixation Ethanol   
  
Acetic acid glacial  30 min 
 
H2O  
Sensitizing Ethanol   
  
Sodium thiosulphate (5% w/v) 
Sodium acetate (17 g) 30 min 
 
H2O  
Washing ddH2O  3 x 5 min 
Silver reaction Silver nitrate solution (2.5% w/v)  20 min 
 
H2O  
Washing ddH2O  2 x 1 min 
Developing Sodium carbonate (6.25 g)  
  
Formaldehyde (37% w/v) 2-5  min 
 
H2O  
Stopping 10 % Acetic acid 10 min 
 
10 % Ethanol  
Washing ddH2O  3 x 5 min 
Preserving Ethanol   
  
Glycerol (87 w/w)  2 x 30 min 
 
H2O  
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2.8.3 Cleaning AnchorChipTM targets 
Prior to LC-MALDI MS/MS analysis the 384 AnchorChip MALDI target plate (MTP) 
was cleaned using three chemical compounds Acetone (HPLC grade), Acetonitrile 
(HPLC grade), and Methanol (HPLC grade). The purpose of this step is to avoid any 
contamination that might occur due to the frequent use of the MTP. The procedure starts 
by removing the previous sample from the MTP by rinsing it with acetone (20-30mL 
using squeezy bottele HPLC grade). One thing to take into account is that rinsing should 
go cover the entire MTP surface. It was then rinsed with Acetonitrile (HPLC grade) 
followed by Methanol (HPLC grade). The MTP was placed glass in class jar containing 
50% Methanol in 0.1 %TFA, and Sonicated at 20o C for 15 min. After sonication it was 
rinsed with 100% Methanol (HPLC grade) and air dried following rinsing with 
Acetonitrile (HPLC grade). 
 
2.9 LC-MALDI-MS/MS and proteins mapping of PCa depleted samples. 
24 depleted PCa samples (12 with Gleason sum <7, and 12 with Gleason sum >7) were 
analysed by LC-MALDI-TOFTOF (UltrafleXtreme, Bruker Daltonics, Germany). 
 
2.9.1 nanoLC Fractionation of depleted serum samples 
Depleted serum samples were injected onto a nano-LC system (Bruker badged Proxeon 
Easy nLC) and eluted with an increasing gradient of organic solvent and spotted directly 
onto a Bruker 800-384 AnchorchipTM MTP in 10 second fractions using a Proteineer fcII 
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fraction collector (Bruker Daltonics).  The nano-LC system was set up to run at a flow 
rate of 300 nL/min; mobile phase A 0.1 % TFA in LCMS grade water; mobile phase B 
0.1 % TFA in LCMS grade acetonitrile.  Mobile phase A was 0.1% aqueous TFA and 
mobile phase B was 0.1% TFA in ACN.  Gradient elution conditions were as follows: 
linear gradient 2±45% B, 0±64 min; 100% B, 64±76 min, column conditioning at 2% B, 
76±86 min. Sample loading onto the trap/pre-FROXPQZDV PLQ DWȝ/PLQ IROORZLQJ
LQMHFWLRQRIȝ/RIVDPSOH7KH/&DQDO\WLFDOFROXPQ was a C18 PepMap-ȝP
LGîFPȝP$'LRQH[8.).  The eluant from the nano-LC was mixed, prior 
to spotting, with  a MALDI PDWUL[VROXWLRQRIĮ-Cyano-4-hydroxycinnamic acid (CHCA) 
%UXNHU'DOWRQLFV*HUPDQ\FRQWDLQLQJȝ/RI$&17)$ȝL of CHCA 
VWRFNVROXWLRQ&+&$VDWXUDWHGLQ$&17)$ȝ/RI7)$LQZDWHUDQG
ȝ/RIP01+4H2PO4 in water).  Prior to analysis by MS 96 calibrant spots were 
manually loaded with 0.5 uL of calibrant (1:300 dilution of Bruker peptide standard II in 
the MALDI matrix described above). 
 
2.9.2 MALDI-TOFTOF analysis of LC-fractionated samples 
Mass spectra were acquired using a Bruker UltrafleXtreme MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics, Germany) operating in reflectron positive ion mode. 
FlexControl (version 3.3, Bruker Daltonics) software was used to control the analysis.  
Mass range detected was set to 500-5000 Da with the sampling rate set at 4 Gs/s.  
Automated acquisition of mass spectra (MS and MSMS) of LC-fractions was controlled 
using WARP-LC software (version 3.2, Bruker Daltonics) interfaced with FlexControl. 
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MALDI laser intensity was selected by the operator to provide optimal intensity and 
resolution of acquired mass spectra. Peaks in the MS spectra were detected using 
FlexAnalysis (Version 3.3, Bruker Daltonics) using the SNAP algorithm and the top 14 
MS peaks on each spot were sent for MSMS analysis.  MSMS (LIFT) spectra were 
produced using post-source decay following precursor ion selection induced by 
increasing the laser power by 43 % for the fragment ions. 
 
2.9.2.1 MASCOT search parameters  
MASCOT (ver 2.3 server, Matrix Science) is computer software providing a search tool 
to identify proteins from MS and MSMS data.  The parameters used in the study were 
optimised by the proteomics laboratory group (John van Geest center, NTU) and was as 
follow, the taxonomy searched for the all the samples was for human (homo sapiens).  
Variable modification was oxidation (M) with MS mass tolerance 100 ppm; MSMS 
tolerance 0.8 Da; Trypsin enzyme; Swissprot database (Jul 2010); +1 charge; MALDI-
TOFTOF selected as the instrument. 
 
2.10 Protein expression differences between nonaggressive Vs aggressive  
Following analysis of all the 24 PCa samples a model was generated using 
3URILOH$QDO\VLV1 (Bruker Daltonics, Coventry UK). The ProfileAnalysis is software 
used for data evaluation of LC-MS analysis, which is based on principle component 
analysis (PCA) technique. When we analyse the LC-MS data, the ProfileAnalysis 
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software generates a model for a component list contain mass to charge ratio and 
intensity for significant peaks (P < 0.05). This model can submit to WARP-LC prior to 
MS-MS analysis. Anyway this software looks for a complete folds change between two 
our group study, which can provide peptide expression differences for nonaggressive Vs 
DJJUHVVLYH3&DSDWLHQW¶VVDPSOHV 
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3- Results  
3.1 Prostate cancer (PCa) samples and MALDI-MS results 
3.1.1 BSA spectra and scores 
The PCa samples (118 samples; 49 with Gleason sum <7, 32 with Gleason sum >7, and 
41 with unknown Gleason sum) were spotted (MTP, Bruker Daltonics, Germany)) 
automatically using the Xcise robotic liquid handling system (Shimadzu, Manchester, 
UK) to avoid any variation that might occur if we did it manually. Moreover, the spots on 
the MTP were randomised in order to avoid the risk of biased positioning on the MTP. 9 
BSA digest samples were added to the plate and were spotted automatically and 
randomly among all the serum samples (PCa, and QCs samples) to assess the MALDI-
MS spectra (and including the trypsinisation), in which the BSA score were obtained by 
using MASCOT search as peptide mapping fingerprint PMF. The MOWSE scores were 
positive and above 60 for the nine BSA samples.  Furthermore the spectra generated from 
MALDI-MS were assessed visually (figure 3.1). 
 
Figure 3.1 Four MALDI-TOF/TOF spectra generated from MALDI-MS and shows identical peaks 
for different BSA samples. 
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  3.1.2   Reproducibility of MALDI-MS data 
The reproducibility of MALDI-MS data was assessed during the analysis of the PCa 
samples which included 10 QCs samples. The spectra generated from MALDI-MS show 
identical peaks among these samples and are similar to other QCs data from last year 
(figure 3.2). 
 
 
Figure3.2 Shows 4 different QC samples were added to our PCa serum samples randomly, and they 
show almost identical spectra.  
 
 
3.1.3 MALDI -TOF ± MS analysis of Prostate cancer serum samples  
The assessment of the analysis for all the prostate cancer samples (<7, and >7 in Gleason 
sum) were applied by checking the spectra derived from MALDI-MS visually (figure 
3.3) 
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Figure 3.3 Four different prostate cancer serum samples spectra and shows good spectra 
with trypsin peaks     
 
 
MALDI-MS is not inherently quantitative, in which the identical peaks from duplicate 
samples will not give exactly the same intensity value for specific peak. However all the 
PCa samples were Zip Tipped and digested enzymatically by adding trypsin (0.7 µL) as 
we mentioned in the method section (2.7.1). Thus the trypsin analysis peaks should be 
included in all the spectra to show that reaction has taken placed and a MASCOT search 
for BSA should be successful. Furthermore some PCa serum samples with bad spectra 
were excluded. 
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3.2 PCa samples and ANNs results  
3.2.1 PCa SDWLHQWV¶GDWDDQGSUHGLFWLYHLRQVE\VWHSZLVH$11V 
The bad spectra for few prostate cancer serum samples were excluded and the rest of the 
data submitted to stepwise (ANNs) and predictive peptide ions were generated in table 
3.1. 
 
 
The rank of predictive ions in table 3.1 relies on the intensity for these ions and their 
ability to discriminate between two groups (aggressive Vs nonaggressive) using the ANN 
algorithm. In other word the ion with highest ability to predict between two groups with 
lowest error value will be the top ion, while the last predictive ion with lower power to 
predict and a higher error value. However the top three ions in table 3.1 were used to 
Table 3.1 The top 10 predictive ions obtained from stepwise (ANNs) for two different groups Of our study 
(nonaggressive prostate cancer patients < 7 Vs aggressive prostate cancer <7) 
  
Input 
ID(m/z) 
Average 
Train Perf 
Average 
Test Perf 
Average 
Valid. Perf 
Average 
Train 
Error 
Average Test 
Error 
Average Valid. 
Error 
1 1268.6 0.653846 0.666667 0.555556 0.21965 0.218295 0.268825 
2 998.6 0.730769 0.777778 0.666667 0.19550 0.187192 0.226763 
3 910.4 0.807692 0.777778 0.777778 0.15308 0.152831 0.185394 
4 1452.8 0.807692 0.888889 0.777778 0.13991 0.128612 0.182888 
5 1439.6 0.846154 0.888889 0.777778 0.11535 0.124906 0.175517 
6 2083.2 0.846154 0.888889 0.777778 0.12507 0.111161 0.159141 
7 1717 0.884615 0.888889 0.777778 0.10276 0.108143 0.166488 
8 3495 0.884615 0.888889 0.888889 0.08860 0.095931 0.144493 
9 1423.8 0.884615 0.888889 0.833333 0.09766 0.101593 0.13994 
10 2618.2 0.923077 0.888889 0.777778 0.08187 0.100358 0.157662 
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generate a population chart (for our 44 PCa samples, 22 with Gleason sum >7 and 22 <7) 
which can show the ability to discriminate between  
our two study groups. 
 
*HQHUDWLRQ D PRGHO RI SUHGLFWLRQ EHWZHHQ QRQDJJUHVVLYH ³ *OHDVRQ VXP´
9VDJJUHVVLYH´!*OHDVRQVXP´ 
The three ions 1268.6, 998.6, and 910.4 were processed in Statistica 7 software to 
generate a dataset that could distinguish one group from the other. The reason only these 
three panel ions were used is the fact that there was no improvement in the performance 
of predictions between the two groups after ion number 3 (m/z 910.4) refer to table 3.1. 
Each ion from this panel represents 77% of the total population (44 PCa samples), which 
ion 1 (m/z 1268.6) represents 55%, ion 2 (m/z  998.6) represents 10%, and ion 3 (m/z 
910.4) represents 10 %. The efficiency of the ANN model was tested by using Response 
Operator curve (ROC), which allows testing of the specificity and sensitivity for all the 
predictive 50 models that were used for  panel ions (m/z 1268.6,998.6, and 910.4)  figure 
3.4. The ideal ROC curve for all the 50 models is considered to be close to 1, which is 
true positive. 
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Figure 3.4 ROC curve generated by Statistica 7 software showing all 50 models that were used to train the 
top three ions (1268.6, 998.6, and 910.4) to discriminate between our two study groups (nonaggressive Vs 
aggressive ). The performance of the ROC curve shows a good sensitivity (true positive) and specificity 
(false positive). 
 
 
 
 
The mean of these 50 models were taken along with their area under curve (AUC), and 
the mean curve shows the specificity and sensitivity (figure 3.5). The AUC should be 
above 0.7 for a good prediction performance, which is in our study 0.879219, showing a 
positive result. 
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Figure 3.5 A Roc curve showing the mean of the 50 models that were used to train the model using the 
panel of the three peptide ions (1268.6, 998.6, and 910.4) for prediction between aggressive and 
nonaggressive prostate cancer patients. The area under the curve is 0.879219 which shows a good 
performance for the generated model. The Y axis represents sensitivity (true positive), X axis represents 
specificity (false positive). 
 
After the assessment of the ANN model performance, a population chart was generated using 
from the mean of the 50 models used to train the system in order to discriminate between two our 
groups (figure 3.6). 
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Figure 3.6.  3RSXODWLRQFKDUWIRU3&DSDWLHQWV¶VHUXPVDPSOHVUHGFRORXUrepresents (>7 group in 
Gleason sum) and blue represents (< 7 group in Gleason sum) for three ions m/z 1268.6, 998.6, and 910.4.  
A value of <1.5 = predicts nonaggressive prostate cancer patients, value of >1.5 = predicts aggressive 
prostate cancer patients, x-axis values indicate PCa patients samples. 
 
Clearly, the discrimination between the two groups using these ions (panel ions) is 
obvious, with some samples misclassified. For the PCa samples with <7 Gleason sum 
group, three samples out of 22 are misclassified with prediction reaching to 86 % of the 
population. While the panel ions can predict 81% of the population for the PCa samples 
with Gleason sum >7. As a total, the panel ions (1268.6, 998.6, and 910.4) have the 
power to discriminate between our two study groups for 85% of total prostate cancer 
patients.  
However each predictive ion from our panel ions has the ability to discriminate between 
aggressive and nonaggressive PCa patients with a specific percentage. The top predictive 
ion(1268.8) can predict with 55 % of the population, while the next two ions (998.6, and 
910.4) can predict with10 % of the population for each one of them (figure 3.7). 
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Figure 3.7 Shows the mean intensity for the three predictive ions, y axis represent the 
intensity, x axis represent aggressive and nonaggressive PCa patients (blue plot 
³DJJUHVVLYH´SLQNSORW³QRQDJJUHVVLYH´ 
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 3.3 Assessment of MARS-HU 14 immuno-depleted column  
The efficiency and specifity of MARS-HU 14 immunodepleted column was assessed 
visually using 1-D SDS PAGE. 24 prostate cancer serum samples were depleted (12 
aggressive, and 12 nonaggressive) and after each 10  the MARS column  was assessed by 
running a QC serum sample, then comparing it with an un-depleted QC visually in 1D 
SDS PAGE (figure 3.8).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Digital image for I-D SDS PAGE for undepleted QC serum Vs depleted QC serum by MARS-
Hu 14 spin column. The first lane from the left standard ladder (Bio-5DG :HVWHUQ& SUHFLVLRQ SOXV
protein standards), the next three lanes undepletd QC (QC serum diluted in Buffer A MARS column), the 
last three lanes depleted QC serum 
 
The efficiency of the MARS column was shown by observing a decreased complexity of 
KLJK DEXQGDQFH SURWHLQV $/% LPPXQRJOREXOLQ¶V )XUthermore the proteins 
identifications from LC MALDI-MS/MS shows fewer number of high abundance (the 
high 14 proteins abundance in serum) see the proteins list in appendix section.  
1        2       3        4      5      6        7        8  
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3.4 LC-MALDI-MS/MS and protein identifications 
All the 24 depleted PCa serum samples (12 samples with <7 in Gleason sum 
³QRQDJJUHVVLYH´DQGVDPSOHVZLWK!LQ*OHDVRQVXP³DJJUHVVLYH´ZHUHWU\SWLFDOO\
digested followed by ZipTipped. The tryptic peptides for each sample were fractionated 
using nanoLC then analysed by MALDI-MS/MS. Proteins mapping for each sample 
obtained with a positive MOWSE scores and high peptide sequence coverage for many 
proteins in the list. Some unique proteins were identified for each group (table 3.2) and 
the proteins have been identified for the panel of three predictive ions from the ANN 
(1268.6, 998.8, and 910.4) listed in table 3.3. (for more details for all the proteins 
identified refer to appendix sections). 
Table 3.2 Unique identified proteins for all the 24 depleted (12 nonaggressive, 12 aggressive 
PCa patients) samples analysed by LC-MALDI 
Nonaggressive prostate cancer Aggressive prostate cancer 
Ankyrin repeat and SOCS box protein 18 
 
Ankyrin repeat domain-containing protein 17  
ATP-binding cassette sub-family A member 13 
 
ATP-binding cassette sub-family A member 12 
Corticosteroid-binding globulin  
 
Calcium-transporting ATPase type 2C member 2  
Epsin-2 Calpain-15  
Glial fibrillary acidic protein Focal adhesion kinase 1  
Glutamate receptor-interacting protein 1  FYVE, RhoGEF and PH domain-containing protein 
4  Hemoglobin subunit beta  Golgi-specific brefeldin A-resistance guanine 
nucleotide exchange factor 1  Leucine-rich repeat serine/threonine-protein 
kinase 1  
Myosin-13  
Low affinity immunoglobulin gamma Fc region 
receptor III-A  
Platelet factor 4 variant  
Pregnancy zone protein  Plexin-A4  
Prostaglandin-H2 D-isomerase  Serine/threonine-protein kinase SRPK2  
Protein Z-dependent protease inhibitor  Stabilin-1  
Putative hydroxypyruvate isomerase  Steroid hormone receptor ERR1  
RelA-associated inhibitor  TRIO and F-actin-binding protein 
Retinol-binding protein 4   
Rho GTPase-activating protein 7   
Serotransferrin   
TNF receptor-associated factor 3   
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Table 3.3 predictive peptide ions for PCa samples (12 with <7 in Gleason sum, 12 with >7 in Gleason 
sum) analysed by LC-MALDI-MS/MS and proteins identification generated using MASCOT software 
search (0.05 is the Significant value for MASCOT proteins identification) 
<7 patient id 
Gleason 
sum 
PSA 
(ng/Ml)  
Proteins ID 
(910.4 m/z) 
Protein ID(998.6 
m/z) 
Protein ID (1268.6 m/z) 
 
L1 3+3 7.1 
 
Gelsolin(pep#23) 
Apolipoprotein B-
100(pep#103) 
Hemopexin(pep#27) 
 L2 3+3 7.6   Hemopexin(pep#21) 
 
L2 3+3 3.14  
Gelsolin (pep#19) 
ApolipoproteinB-
100(pep#117) 
ApolipoproteinB-
100(pep#117) 
Hemopexin(pep#23) 
 
L3 3+3 4.7  
Gelsolin(pep#19) 
ApolipoproteinB-
100(pep#137) 
 
Hemopexin(pep#30) 
 L4 3+3 5.9  Gelsolin(pep#19) Hemopexin(pep#23) 
 
L5 3+3 12  Gelsolin(pep#20) 
ApolipoproteinB-
100(pep#96) 
Hemopexin(pep#21) 
 L6 3+3 3.8  Gelsolin(pep#14) Hemopexin(pep#16) 
 L7 3+3 11    
 
L8 3+3 9  
ApolipoproteinB-
100(pep#56) 
Gelsolin(pep#12) 
Hemopexin(pep#21 
 
L9 3+3 7.4  
Gelsolin(pep#25) 
ApolipoproteinB-
100(pep#128) 
 
Hemopexin(pep#52) 
 L10 3+3 8  Gelsolin(pep#19) Hemopexin(pep#33) 
 
L11 3+3 10  Gelsolin(pep#9) 
Hemopexin(pep#20) 
Apolipoprotein B-
100(pep#60) 
 
L12 3+3 6.8  
Gelsolin(pep#16) 
ApolipoproteinB-
100(pep#65) 
 
Hemopexin(pep#31) 
Angiotensinogen(pep#12) 
>7       
 H1 7 6.8  Gelsolin(pep#18) Hemopexin(pep# 34) 
 H2 3+4 5.7  Gelsolin(pep#16) Hemopexin(pep# 19) 
 H3 3+4 8.8  Gelsolin(pep#18) Hemopexin(pep# 24) 
 H4 3+4 6.8   Hemopexin(pep# 21) 
 H5 3+4 14    
 H6 4+3 12    
 H7 3+4 36  Gelsolin(pep#25) Hemopexin(pep# 32) 
 
H8 4+3 22.8  Gelsolin(pep#9) 
ApolipoproteinB-
100(pep#79) 
Hemopexin(pep#21) 
 H9 3+4,4+5 5.9  Gelsolin(pep#13) Hemopexin(pep#22) 
 H10 3+4 5.2   Hemopexin(pep#22) 
 H11 3+4 4.6  Gelsolin(pep#22) Hemopexin(pep#25) 
 
H12 4+4 11 Complement C5(pep#18 Gelsolin(pep#16) 
Hemopexin(pep#27) 
Angiotensinogen(pep#9) 
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3.5 Proteins expression differences between nonaggressive and aggressive prostate 
cancer patients   
The analysis for all the 24 PCa samples (12 nonaggressive, and 12 aggressive) by LC-
MALDI-MS/MS, allow to us to generated a model using ProfileAQDO\VLVsoftware 
(Bruker, Daltonics, UK). This model can show the difference in proteins expression for 
our two group study when we submit it to WARP-LC software prior to MS-MS analysis. 
The 24 samples (12 pooled sample < 7 in Gleason sum, 12 pooled samples >7 in Gleason 
sum) were digested and Zip Tipped followed by nanoLC analysis. The model generated 
from the previous LC-MS run for all the 24 depleted samples individually were applied to 
WARP-LC software and proteins mapping obtained using MASCOT Search software 
(table 3.4, 3.5). 
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Table 3.4 Proteins list for all the 12 pooled samples (<7 in Gleason sum) shows the 
MOWSE score, MW (kDa), and number of peptide coverage 
Protein Score MW [kDa] # Pept. 
Unknown 56.83 0 7 
Unknown 48.31690887 0 3 
Unknown 44.72690887 0 3 
Unknown 43.21 0 3 
Unknown 38.72 0 2 
Unknown 37.55 0 2 
Unknown 36.84 0 2 
Unknown 35.1 0 1 
Unknown 34.62 0 1 
Unknown 31.39 0 1 
Unknown 30.46 0 1 
Actin, cytoplasmic 1 53.63 41.70973 3 
Afamin 140.8969089 69.02401 6 
Alpha-1-antichymotrypsin 1096.42 47.62054 18 
Alpha-1B-glycoprotein 563.01 54.23858 11 
Alpha-2-HS-glycoprotein 353.87 39.29971 7 
Alpha-2-macroglobulin 199.1669089 163.18888 12 
Angiotensinogen 238.95 53.12051 6 
Ankyrin repeat and SOCS box protein 18 47.03 50.77091 2 
Antithrombin-III 804.7669089 52.56886 22 
Apolipoprotein A-I 221.43 30.75893 11 
Apolipoprotein A-IV 976.3 45.37147 22 
Apolipoprotein B-100 4503.159124 515.24085 122 
Apolipoprotein C-I 36.95 9.32609 1 
Apolipoprotein C-III 189.58 10.8455 2 
Apolipoprotein E 179.5469089 36.13175 9 
ATP-binding cassette sub-family A member 12 57.67 293.04884 5 
Beta-2-glycoprotein 1 248.38 38.27266 7 
Carboxypeptidase B2 109.25 48.38141 5 
Carboxypeptidase N subunit 2 119.01 60.57615 3 
Ceruloplasmin 2080.857635 122.12759 38 
Clusterin 129.37 52.46101 6 
Coagulation factor X 72.32 54.69651 3 
Complement C1q subcomponent subunit B 236.59 26.44241 6 
Complement C1q subcomponent subunit C 267.8769089 25.75714 4 
Complement C1s subcomponent 258.8169089 76.6348 10 
Complement C2 133.82 83.21431 7 
Complement C3 527.6907266 187.02987 19 
Complement C4-B 2474.37218 192.67254 59 
Complement C5 625.3869089 188.18613 22 
Complement component C6 99.45 104.718 5 
Complement component C8 alpha chain 70.99 65.12104 4 
Complement component C8 beta chain 267.67 67.00347 9 
Complement component C8 gamma chain 89.11 22.26354 4 
Complement component C9 240.1569089 63.1327 7 
Complement factor B 710.9269089 85.47852 18 
Complement factor H 729.3638177 139.0047 26 
Complement factor H-related protein 1 165.99 37.62596 4 
Cyclin N-terminal domain-containing protein 1 32.15 36.89737 1 
Fibrinogen alpha chain 120.58 94.91441 4 
Fibronectin 957.5448129 262.44208 27 
Gelsolin 444.9 85.64419 14 
Haptoglobin 100.97 45.17656 5 
Biomarkers in Prostate Cancer  Bandar Alghanem 
_____________________________________________________________________________ 
63 
 
Hemopexin 1122.476909 51.64327 27 
Heparin cofactor 2 607.0638177 57.0342 16 
Heterogeneous nuclear ribonucleoprotein A1-like 2 31.52 34.20427 2 
Heterogeneous nuclear ribonucleoproteins A2/B1 31.52 37.40673 2 
Histidine-rich glycoprotein 330.59 59.54087 7 
Insulin-like growth factor-binding protein complex acid labile 
subunit 
220.3838177 65.9938 12 
Inter-alpha-trypsin inhibitor heavy chain H1 1086.040727 101.32561 20 
Inter-alpha-trypsin inhibitor heavy chain H2 1085.876909 106.39661 28 
Inter-alpha-trypsin inhibitor heavy chain H3 284.7169089 99.78653 10 
Inter-alpha-trypsin inhibitor heavy chain H4 1052.876909 103.29298 30 
Interleukin-25 31.89 20.31696 1 
Kallistatin 202.93 48.51116 9 
Keratin, type II cytoskeletal 1 254.6476355 65.999 11 
Keratin, type II cytoskeletal 2 epidermal 45.21 65.39322 2 
Kininogen-1 827.51 71.91215 12 
Leucine-rich alpha-2-glycoprotein 123.07 38.15411 3 
Lumican 109.0269089 38.40479 5 
Pigment epithelium-derived factor 140.89 46.3133 6 
Plasma protease C1 inhibitor 402.46 55.11939 15 
Plasminogen 357.7069089 90.51016 11 
Platelet basic protein 113.62 13.88542 3 
POTE ankyrin domain family member F 49.74690887 121.36669 3 
Protein AMBP 126.75 38.97398 4 
Prothrombin 135.0969089 69.99212 9 
Putative hydroxypyruvate isomerase 39.87 30.38656 2 
Putative zinc-alpha-2-glycoprotein-like 71.69 22.96546 3 
Pyruvate kinase isozymes M1/M2 32.14 57.90002 1 
Retinol-binding protein 4 59.68 22.99526 2 
Serum amyloid P-component 409.81 25.37113 10 
Stromal interaction molecule 1 41.04 77.37529 2 
Sushi, nidogen and EGF-like domain-containing protein 1 44.68 152.10421 3 
Thyroxine-binding globulin 88.08381774 46.29461 4 
Trypsin-1 72.06 26.54109 1 
Vitamin D-binding protein 493.31 52.92903 11 
Vitronectin 277.12 54.27117 8 
Zinc-alpha-2-glycoprotein 320.94 34.2371 10 
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Table 3.5.  Proteins list for all the 12 pooled samples (>7 in Gleason sum) shows the MOWSE 
score, MW (kDa), and number of peptide coverage 
Protein Score MW [kDa] # Pept. 
Unknown 69.05 0 1 
Unknown 62.44 0 2 
60S ribosomal protein L6  95.9 33.54094 2 
Afamin  104.8 69.02401 4 
Alpha-1-antichymotrypsin  672.85 47.62054 14 
Alpha-1B-glycoprotein  433.05 54.23858 11 
Alpha-2-HS-glycoprotein  314.46 39.29971 7 
Alpha-2-HS-glycoprotein  174.01 39.41876 5 
Alpha-2-macroglobulin  444.39691 163.18888 15 
Alpha-enolase  76.14 47.11121 2 
Alpha-S1-casein  126.08 24.51343 3 
Angiotensinogen  73.58 53.34043 2 
Angiotensinogen  196.45 53.12051 5 
Apolipoprotein A-I 235.49 30.75893 10 
Apolipoprotein A-IV  696.99 45.37147 21 
Apolipoprotein B-100  3635.2103 515.24085 114 
Apolipoprotein C-III  182.96 10.8455 2 
Beta-2-glycoprotein 1  103.62 38.27266 2 
Ceruloplasmin  1558.1907 122.12759 31 
Complement C1q subcomponent subunit B  149.08 26.44241 3 
Complement C1q subcomponent subunit C  166.51691 25.75714 3 
Complement C1s subcomponent  189.02691 76.6348 7 
Complement C3  484.45382 187.02987 19 
Complement C4-B  1506.8045 192.67254 47 
Complement C5  396.71382 188.18613 15 
Complement component C6  60.33 104.718 2 
Complement component C7  181.09 93.45729 6 
Complement component C9  111.03 63.1327 3 
Complement factor B  250.29691 85.47852 12 
Complement factor H  507.62764 139.0047 21 
Fibronectin  701.56172 262.44208 23 
Ficolin-3  109.16 32.88199 4 
Gelsolin  269.88 85.64419 10 
Hemopexin  959.77382 51.64327 25 
Heparin cofactor 2  194.10691 57.0342 8 
Histidine-rich glycoprotein  162.03 59.54087 6 
Insulin-like growth factor-binding protein complex acid labile subunit  53.96 66.91791 3 
Inter-alpha-trypsin inhibitor heavy chain H1 714.21382 101.32561 14 
Inter-alpha-trypsin inhibitor heavy chain H2  636.72 106.39661 20 
Inter-alpha-trypsin inhibitor heavy chain H4  710.34 103.29298 22 
Kallistatin  105.12 48.51116 5 
Keratin, type I cytoskeletal 10  239.7 58.79169 9 
Keratin, type I cytoskeletal 9  232.34 62.02681 4 
Keratin, type II cytoskeletal 1  481.88454 65.999 15 
Keratin, type II cytoskeletal 4 86.07 57.24983 4 
Kininogen-1 340.23 71.91215 7 
Leucine-rich alpha-2-glycoprotein  132.85 38.15411 5 
Lumican  70.796909 38.40479 3 
Pigment epithelium-derived factor  94.71 46.3133 5 
Plasma protease C1 inhibitor  104.16 55.57615 3 
Plasminogen  321.12691 90.51016 11 
Platelet basic protein  95.73 13.88542 2 
Prothrombin 111.74691 69.99212 6 
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Retinol-binding protein 4  97.406909 22.99526 4 
Serum amyloid P-component  254.26 25.37113 8 
Trypsin  167.57 24.39381 2 
Trypsin-1  53.52 26.54109 1 
Vitamin D-binding protein  133.27 53.30706 5 
Vitronectin  290.49 54.27117 6 
Zinc-alpha-2-glycoprotein  187.92 34.2371 10 
 
Protein (peptide ion intensity) expression differences between nonaggressive Vs 
aggressive were assessed using ProfileAnalysis, which allow examination of the fold 
change between our two categories (figure 3.9).  
 
 
Figure 3.9 shows the difference in peptide expression between nonaggressive Vs 
aggressive PCa samples generated by ProfileAnalysis software 
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The number of proteins identified for our two pooled samples, one for aggressive and the 
other for nonaggressive, shows several unique and overlapping proteins for each group 
(figure 3.10)    
 
Aggresssive Nonaggressive 
Figure 3.10.   Venn diagram showing the number of proteins identified for two pooled 
samples each category, 12 unique proteins for aggressive prostate cancer patients, 23 
nonaggressive prostate cancer patients, and there are shared 57 proteins. 
 
However there are only five ions that were able to be identified to proteins (Table 3.6).  
Four of them have positive fold change, while only one had negative fold change for the 
nonaggressive PCa group compared with aggressive. 
Table 3.6.   Peptide associated with identified proteins by tandem MS/MS shows the difference in their 
regulation for nonaggressive comparing with aggressive PCa samples.  
Ions (m/z) protein identified peptide sequence  Regulation  
1212.24 Apolipoprotein B-100 NSEEFAAAMSR ј 
1329.45 Apolipoprotein B-100 KLTISEQNIQR ј 
1585.65 Apolipoprotein A-IV  LKEEIGKELEELR ј 
2032.8 Apolipoprotein B-100 HSGSFQSQVELSNDQEK ј 
1887.8 Afamin SDVGFLPPFPTLDPEEK љ 
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4- Discussion  
 
4.1 The Use of automated sample preparation in proteomic studies 
One of the big challenges for researchers in the proteomic field, over the years, is to carry 
out experiments manually with sufficient reproducibility. Manual handling of many of 
the experiments ultimately end up with high incidents of sample to sample variation due 
to several factors which occur during the experimental preparation. This is one of the 
greatest limitations in serum biomarker studies. Fortunately the advancements in 
instrumentation allowed the processing and preparation of serum samples automatically 
prior to MS analysis with automated robotic liquid handling platforms. Recently the 
fractionation and cleaning up of the serum samples by C18 Zip Tipping, as well as 
fractionation (LC-MALDI) can be done automatically. The Xcise robtic system 
(Shimadzu, Manchester UK) has the ability to prepare the sample for proteomics analysis 
automatically, which can reduce any bias due to manual handling. This instrument shows 
a good performance in the discovery process of new biomarkers (Vafadar-Isfahni el at., 
2010). In this study the Xcise robtic system was used in order to prepare the PCa samples 
(nonaggressive Vs aggressive) prior to MS analysis. The system shows good performance 
in which only 3 out of 118 PCa samples were excluded, which showed bad spectra. 
Another advantage of this system is the speed to process this number of samples in short 
time (approximately five hours) without considerable sample to sample variation. 
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4.2 The use of Bioinformatics and ANNs in proteomic approaches  
The data generated from mass spectrometry (MS) remains a big challenge for researchers 
because of its complexity and multidimensionality. Fortunately, the advancement in the 
bioinformatics field allows us to significantly reduce the complexity and make the data 
manageable. Utilisation of any bioinformatics method in proteomics should be carefully 
considered before any study commences. The use of ANNs in proteomics biomarker 
discovery and its ability to discriminate between difference groups study shows 
promising results, such as the study carried out by Vafadar-Isfahni el al., in 2010 .  The 
ANN was employed in this study to generate a model capable of discriminating between 
nonaggressive and aggressive serum peptide profiles, using a stepwise approach. The use 
of a stepwise approach reduces any overlapping that might occur during the generation of 
each new model by the ANN. The benefit of the ANN is to pull out the most 
discriminatory ions as a panel which classifies the two groups with high sensitivity and 
specificity. In this study, the panel of three peptide biomarker ions (m/z 1268.6, 998.6, 
and 910.4) was able to discriminate patients with aggressive PCa from nonaggressive 
patients with accuracy of 77%.      
The population chart (figure 3.6) shows five misclassified patients in both groups 
(nonaggressive Vs aggressive). This could be for several reasons; firstly it should be 
considered that both groups are very similar to each other. In other words, one group with 
(3+3=6) as the Gleason sum and the other one with (3+4, 4+3 =7) in Gleason sum, the 
difference is only one. A second reason could be that the initial diagnostic by the 
pathologist was not accurate. In this case the urologist or the nurse may have missed 
some area of the prostate gland when they took the biopsy sample, which would make the 
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diagnosis by the pathologist not comprehensive. A third reason is the possibility that the 
prostate cancer could have developed from the time of the biopsy examination to the time 
the blood was collected for the clinical trial especially for three of the misclassified 
samples in the nonaggressive group with aggressive patients. The forth reason could be 
ZKDWLVWHUPHG³SURVWDWHFDQFHUYROXPH´VWXGLHVVKRZWKHSDWLHQWVZLWK*OHDVRQVXP
are more likely to increase their prostate cancer volume after radical prostatectomy (Dong 
et al., 2008). Thus the 3 nonaggressive misclassified samples in the aggressive group 
could have increased their prostate cancer volume if they had this kind of treatment.  
Although the model generated by the ANN to discriminate between our groups had a 
good performance, the ANN still suffered from some overfitting even with the use of the 
stepwise method. Another disadvantage of the ANN is the inability to have the same 
predictive panel of ions every time you submit the same data to the ANN, due to the 
random nature of the algorithms. Another limitation for the ANN when we use it as a 
bioinformatic tool to generate a model for MS data is the difficulty in matching the 
output from the ANN to MS spectra, visually (i.e. matching an ANN classifier ion to a 
real peak in the spectrum)  For example if we take one of our predictive ions that can 
discriminate between nonaggressive and aggressive prostate cancer patients and if  we 
checked its spectra for different patients from different groups we could not visualised 
any significant difference, because MALDI-MS is not inherently quantitive. So the future 
direction should concentrate much more on effective and reliable correlation between the 
predicted and experimental data. 
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4.3 The appraisal of the MARS-Hu 14 spin column for our proteomics study   
The high complexity of serum and the high dynamic range of protein concentrations 
make the discovery of new biomarkers obtained from serum a complicated process. As 
the low abundance proteins promise new biomarkers (such as tumor markers), the 
depletion of high abundance proteins has become more important and critical. The 
MARS-Hu 14 spin column used in our study was assessed using 1D-SDS-PAGE 
separation and the results shows its ability to enrich the low abundance proteins and 
deplete most of the 14 proteins targetted. The remaining proteins were identified as 
moderate to low abundance proteins such as; Ankyrin repeat domain-containing protein 
17, Focal adhesion kinase 1,Spermatogenesis-associated protein 7,  Apolipoprotein C-I 
,Apolipoprotein C-III,  Complement C1q subcomponent subunit C, and there are more 
(see the appendix section for more details) (Ahemd  2009) . The main limitation of the 
column is the unanticipated removal of some of the low abundance proteins which a 
specifically or nonspecifically binds or attach to the high abundant proteins such as 
albumin. 
 
4.4 Identification of the predictive ions from the MS profiling of PCa serum samples 
using ANN 
Protein identities of our three predictive ions (1268.6, 998.6, and 910.4 m/z) that were 
obtained from the ANN were found following MSM on the fractionated samples. The 
depletion of high abundance proteins in our PCa samples followed by LC-MALDI 
allowed the identification of several proteins. The top predictive ion - 1268.6 (m/z) was 
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identified as Haemopexin. Haemopxin is a glycoprotein, and it plays an important role as 
a carrier for plasma haeme (Haeme Scavenger).  Haemoglobin is a carrier protein that 
transports oxygen from the lung to all the body tissues through the blood, and this 
haemoglobin consists of four globin subunits each one of them contains a haeme group. 
Each haeme molecule consisting of a porphyrin ring and iron atom has the ability to bind 
with the oxygen atom, which can be transported. The free haeme in plasma indicates 
some pathologic conditions such as haemolysis. Haeme is auto-oxidise molecule which 
can intercalate with the lipid membrane of the cell, so free haeme in the plasma is 
considered a risk for health. Thus Haemopexin has an important role in binding plasma 
haeme, and therefore its expression indicates some pathologic conditions such as 
inflammation and cancer (Piccard et al., 2006). Another role of Haemopexin is activating 
Matrix metalloproteinases (MMPs). MMPs are that have the ability to breakdown the 
extracellular matrix, which facilitate localised cancer to invade to another organ (Pia et 
al., 2005).   
The second predictive ion 998.6 (m/z) was identified as a peptide of the protein Gelsolin. 
Gelsolin is an intracellular protein and a member of actin-binding proteins which are 
found in mitochondria and cytosol with molecular weight 82 (kDa) and found in blood in 
FRQFHQWUDWLRQWRȝ/PO*RHW]HOet al., 2000). Gelsolin can also be found in the 
blood stream (extracellular) and plays important role in motility and differentiation of 
cells and it is stimulated by calcium (ܥܽାା). Gelsolin is found to be a substrate for 
caspase-3, and has the ability to promote apoptosis and protect cells from apoptosis as 
well. The expression of these proteins in prostate cancer has been shown in many studies 
(Nishimura et al., 2003).  
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For the same predictive ion 998.6 (m/z) another possible protein identity was found (there 
are several possible identities as the ANN bins the peptide ion m/z value to the nearest 0.1 
Da, leaving some slight ambiguity as to the exact mass to use in the MSMS/database 
search), which is Apolipoprotein B-100 (apo B100). This protein has a role as primary 
form of very low density lipoproteins (VLDL) and low density lipoprotein (LDL) which 
is responsible of removing insoluble water lipids such as cholesterol from the body. The 
process of transferring the cholesterol to cell membrane occurs when Apo B100 works as 
a receptor to facilitate this process. In the present day some laboratories assess Apo B100 
as a marker of cardiac disease patients.  Studies show a relationship between prostate 
cancer therapy such as androgen deprivation and heart disease (Keatings et al 2006).  
Other studies show that Apo B100 will be increased when the patients have Estrogen 
treatment (Usui et al., 2002). Table 3.2 shows that predictive ion 998.6 (m/z) was 
identified as a peptide of Apo B100 only in nonaggressive patients (<7 in Gleason sum). 
 
4.5 Identification of unique proteins in nonaggressive Vs aggressive PCa samples 
The main aim of this section of the study was to find the protein expression differences 
between nonaggressive and aggressive PCa patients and define prognostic biomarkers.  
24 depleted PCa serum samples (12 aggressive, 12 nonaggressive) were analysed by LC-MALDI 
MS/MS, and the identification of candidate proteins were obtained by tandem MS/MS mass 
spectrometry using MASCOT search dataset. The number of proteins identified in each sample 
was in range of 80 to 140 proteins. The majority of identified proteins are the same in aggressive 
and nonaggressive PCa patients (tables of the entire proteins list were identified for all the 24 PCa 
patients in the appendix section). Some proteins were identified as unique proteins for a specific 
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group.  18 candidate proteins for nonaggressive PCa identified were different from the aggressive 
group, and 14 proteins were identified and expressed only in aggressive PCa patients.  
However, it has been noticed that some of our unique proteins identified have been 
previously associated with prostate cancer. For example (Pregnancy zone protein) which 
has expressed in nonaggressive PCa patients. (Pregnancy zone protein) has been 
LGHQWLILHGWRLQFUHDVHZKHQWKHSDWLHQW¶VKDYHWUHDWHGKRUPRQDOO\Oestrogen is a female 
hormone that has been used in the last few decades as hormone treatment for prostate 
cancer. Although the advantage of the treatment with this hormone, there is high risk to 
have blood clot. Studies show that (Pregnancy zone protein) will be increased if the 
patient has oestrogen treatment (Beckman el al 1973). Another example for a unique 
identified protein for nonaggressive PCa patients is (Rho GTPase-activating protein 7). 
Studies show that (Rho GTPase-activating protein 7) has the ability to downregulate in 
cancers and can inhibit the growth of prostate cancer (Durkin et al., 2007).  
On the other hand the uniquely identified proteins in aggressive PCa patients have been 
found to be associated with prostate cancer, and some candidate proteins are related to 
different types of cancers. One of these proteins is (Focal adhesion kinase 1), which has a 
very important role in the regulation of the migration of cells. Thus (Focal adhesion 
kinase 1) play a critical role in metastatic cancers, which will facilitate cancerous cells 
invading different organs such as bone marrow.  This protein has the ability to cross the 
extracellular matrix (ECM) from one primary organ to another without the help of matrix 
metalloproteinases (MMPs), which are used to breakdown the ECM. Furthermore, 
studies prove that (Focal adhesion kinase 1) can control the advancement phenotype of 
androgen-independent prostate cancer (Johnson et al; 2008). However we should 
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consider that some of these proteins were expressed in only one patient, these types of 
proteins may be identified with many other physiological conditions of the patients 
LQFOXGLQJ DJH DQG LQIHFWLRQV 7KHVH SDWLHQW SURWHLQV VKRXOGQ¶W EH WUHDWHG DV D JRRG
candidate biomarkers since it occurrences were limited only single or few patients. A 
wider population study is necessary to ascertain these types of proteins to a biomarker 
candidate status. 
 
4.6 Differences in peptide expression in nonaggressive (<7 in Gleason sum) Vs 
DJJUHVVLYHLQ*OHDVRQVXPSDWLHQWVIRUDOOWKHSRROHGGHSOHWHGVDPSOHV 
Two pooled samples were used to differentiate between the aggressive and nonaggressive 
3&DVDPSOHVEDVHGRQWKHLU³H[SUHVVLRQ´FRPSDULVRQRISHSWLGHLRQLQWHQVLW\:HKDG
24 PCa samples and pooled 12 nonaggressive PCa samples in one sample, and pooled 12 
aggressive PCa samples in a second sample. These two pooled samples were depleted 
and analysed by LC-MALDI. Prior to analysis of these samples, a model was generated 
by the software (ProfileAnalysis, Bruker Daltonics ). The model contains ions (m/z) and 
their intensities and was obtained based upon data from all 24 samples that were run 
previously by individual LC-MALDI. This model shows the fold change in peptide 
expression for aggressive and nonaggressive PCa pooled samples (figure 3.9). The figure 
shows the difference in peptide expression based on their fold change as interpreted as up 
(positive) or down (Negative) regulation. 13 Ions (m/z) had a positive fold change in the 
nonaggressive PCa patients compared with aggressive group. In contrast 11 ions (m/z) 
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had a negative fold change in the nonaggressive samples compared with aggressive 
sample. 
 These significant ions were subjected to WARP-LC software (Bruker Daltonics) prior to 
tandem MS/MS and list of proteins identified for the two pooled samples. 81 proteins 
were identified for the pooled nonaggressive patients, while 60 proteins were identified in 
the pooled aggressive sample (table 3.3, 3.4).  57 proteins were expressed in both groups, 
while 23 were expressed only on nonaggressive pooled sample and 12 expressed only in 
aggressive pooled sample (figure 3.10). However five of the ions were associated with 
three identified proteins (table 3.5).  1212.24, 1329.45, and 2032.8 (m/z) ions were 
identified as peptide of protein Apo B100, which has been already discussed above. 
These ions had a positive fold change in the nonaggressive sample compared with the 
aggressive. The ion 1585.65 (m/z) was identified as Apolipoprotein A-IV. This ion 
showed increased fold change in the nonaggressive group compared with  the aggressive 
group. Apolipoprotein A-IV is a glycoprotein expressed in intestine and secreted into 
bloodstream, which has very important role in lipid metabolism, especially for 
triglycerides (Tso et al., 2001)) The concentration of Apolipoprotein A-IV in blood is 
dramatically changed due to the dietary. This protein considered as the main component 
of high density lipoprotein HDL (the good cholesterol in the body), and associated with 
cardiac disease. One study shows that Apolipoprotein A-IV is increased in BPH patients 
(Srivastava  2008). The last ion (m/z ZDVLGHQWLILHGDVSURWHLQ³$IDPLQ´$IDPLQ
is one of a glycoprotein family which is synthesised in liver and secreted into the 
circulation. Afamin plays role as a vitamin-E carrier, which is protect the body from 
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oxidative stress (Jerkovic et al., 2005). There are no studies reported which depict any 
relationship between Afamin and prostate cancer. 
As shown above, Apo B 100 protein was identified by two methodolgies - ANNs and 
ProfileAnalysis, indicating its significance as a possible prognostic biomarker to 
differentiate between aggressive and nonaggressive prostate cancer types. 
 
Future work  
Further analysis/validation Apo B 100 protein along with other identified proteins such as 
Enzyme-linked immunosorbent assay (ELISA) or Western blot need to be carried out to 
confirm the MALDI mass spectrometric data. Another analysis can be carried out is the 
quantification of candidate peptides using isobaric tags for relative and absolute 
quantification (iTRAQ) technology (Tonack et al., 2009) .Once it is confirmed as a 
candidate marker, this has to be studied in a separate cohort of patients drawn from 
different geographical distribution or ethnicity to address its validity to use as a universal 
biomarker for prostate cancer staging. 
 
Conclusion 
This study was designed with the objective of the identification of prognostic biomarkers 
in a prostate cancer cohort with two forms of prostate cancer, aggressive and 
nonaggressive. The pathological classification of these two forms based on the popular 
Gleason score identified aggressive types as above seven and the nonaggressive types as 
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below seven.  Reproducibility of the MS spectra were successfully assessed by running 
BSA standards and the serum QC samples along with the test samples in a randomised 
manner using robotic systems. ANN analysis of the MS data shortlisted three ions (m/z 
1268.8, 998.6, 910.4) which have a combined predictive capability of 77% of the total 
population studied. These ions successfully stratified the patients into two groups. The 
sensitivity and the specificity of the model was then assessed by response operator curve 
which gave a value close to one indicating the robustness of the ions as classifiers. In a 
second section of the study, immunodepletion columns were successfully used for the 
selective removal of the major high abundant proteins. Further fractionation by nano-LC 
and MSMS generated 80-120 protein identities with multiple peptides identified for many 
proteins.  The protein and the peptide list generated after the LC MALDI was manually 
searched for the presence of 3 ions shortlisted with ANN and they were identified as 
Haemppexin, Gelsolin and Apolipoprotein 100. Detailed comparison of the protein 
identities classified in to three group 18 proteins were uniquely present in the non 
aggressive group and 14 proteins  were  unique for aggressive group. Literature survey 
suggested that the majority of these proteins are functionally associated with prostate or 
other cancer development and progression. The studies with the pooled samples of 
aggressive and nonaggressive PCa samples with a different model generation approach 
(ProfileAnalysis) also came up with Apolipoprotein B100 suggesting the potential of this 
protein as a potential biomarker candidate for stratifying aggressive and nonaggressive 
PCa.  However, further experiments need to be carried out with a separate PCa 
population prior to envisaging the wider use of this marker in prostate cancer patients.    
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6.  Appendix 
 
List for the identified proteins for all 24 PCa samples (12 nonaggressive and 12 
aggressive) 
 
Patient one (nonaggressive)  
Protein Score MW [kDa] # Pept. 
unknown  78.3009952 0 13 
unknown  76.92 0 7 
unknown  60.0369089 0 5 
unknown  58.69 0 4 
unknown  57.8469089 0 5 
unknown  56.48 0 4 
unknown  55.9469089 0 5 
unknown  54.7 0 4 
unknown  53.6969089 0 6 
unknown  48.77 0 3 
unknown  47 0 3 
unknown  46.42 0 1 
unknown  45.19 0 2 
unknown  41.67 0 1 
unknown  41.23 0 2 
unknown  41.21 0 3 
unknown  37.1369089 0 2 
unknown  36.96 0 2 
unknown  35.67 0 2 
unknown  34.4 0 1 
unknown  34.3569089 0 2 
unknown  32.23 0 1 
unknown  31.55 0 1 
unknown  31.15 0 1 
Afamin  330.446909 69.02401 9 
Alpha-1-antichymotrypsin  1325.92 47.62054 29 
Alpha-1-antitrypsin  459.546909 46.70702 9 
Alpha-1B-glycoprotein  1207.00691 54.23858 31 
Alpha-2-antiplasmin 464.623818 54.53107 15 
Alpha-2-HS-glycoprotein  641.34 39.29971 21 
Alpha-2-macroglobulin  585.886909 163.18888 20 
Angiotensinogen  516.86 53.12051 10 
Ankyrin repeat and SOCS box protein 18  49.07 50.77091 8 
Antithrombin-III  1171.27691 52.56886 24 
Apolipoprotein A-I  1185.47 30.75893 25 
Apolipoprotein A-II  36.41 11.1679 1 
Apolipoprotein A-IV  1489.59 45.37147 32 
Biomarkers in Prostate Cancer  Bandar Alghanem 
_____________________________________________________________________________ 
85 
 
Apolipoprotein B-100  6762.25948 515.24085 128 
Apolipoprotein C-I  100.93 9.32609 2 
Apolipoprotein C-II  217.29 11.27675 4 
Apolipoprotein C-III  323.09 10.8455 3 
Apolipoprotein E  523.706909 36.13175 18 
ATP-binding cassette sub-family A member 13  98.4638177 575.87114 13 
Attractin  92.78 158.43246 5 
Beta-2-glycoprotein 1  259.92 38.27266 7 
Beta-Ala-His dipeptidase  180.48 56.65611 6 
Biotinidase  156.99 61.09326 5 
Carboxypeptidase B2  220.796909 48.38141 7 
Carboxypeptidase N subunit 2  206.84 60.57615 5 
Ceruloplasmin  3730.31073 122.12759 63 
Cholinesterase  87.2169089 68.37427 6 
Clusterin  476.673818 52.46101 8 
Coagulation factor V  218.01 251.51354 9 
Coagulation factor X  118.76 54.69651 4 
Coagulation factor XII  134.48 67.77391 6 
Complement C1q subcomponent subunit A  366.23 26.00019 2 
Complement C1q subcomponent subunit B 243.64 26.44241 8 
Complement C1q subcomponent subunit C  344.856909 25.75714 6 
Complement C1r subcomponent  422.516909 80.06681 12 
Complement C1r subcomponent-like protein  122.78 53.46434 6 
Complement C1s subcomponent  492.576909 76.6348 12 
Complement C2  666.406909 83.21431 15 
Complement C3  1390.49073 187.02987 33 
Complement C4-A  4099.84218 192.65045 85 
Complement C4-B  4179.65218 192.67254 86 
Complement C5  866.563818 188.18613 23 
Complement component C6  468.81 104.718 9 
Complement component C7  384.33 93.45729 5 
Complement component C8 alpha chain  56.52 65.12104 4 
Complement component C8 beta chain  578 67.00347 13 
Complement component C8 gamma chain  202.38 22.26354 5 
Complement component C9  539.476909 63.1327 14 
Complement factor B  1365.20382 85.47852 27 
Complement factor H  930.586909 139.0047 28 
Complement factor H-related protein 1  166.49 37.62596 3 
Complement factor H-related protein 3  69.47 37.29875 2 
Complement factor I  462.416909 65.6766 12 
Corticosteroid-binding globulin  178.47 45.11191 4 
Epsin-2  59.14 68.43928 3 
Fibrinogen alpha chain  135.82 94.91441 6 
Fibronectin  2177.94554 262.44208 51 
Gelsolin  1172.37 85.64419 24 
Glial fibrillary acidic protein  47.06 49.84965 3 
Glutamate receptor-interacting protein 1  67.4469089 122.34728 5 
Glutathione peroxidase 3  74.67 25.5369 3 
Haptoglobin  330.006909 45.17656 9 
Hemoglobin subunit alpha  37.85 15.24793 1 
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Hemoglobin subunit beta  48.95 15.98829 2 
Hemopexin 1540.44382 51.64327 52 
Heparin cofactor 2  1003.68382 57.0342 21 
Hepatocyte growth factor activator  72.8369089 70.63609 4 
Histidine-rich glycoprotein 877.166909 59.54087 19 
Insulin-like growth factor-binding protein complex acid labile subunit  694.514813 65.9938 17 
Inter-alpha-trypsin inhibitor heavy chain H1  1698.40691 101.32561 41 
Inter-alpha-trypsin inhibitor heavy chain H2  2045.54691 106.39661 40 
Inter-alpha-trypsin inhibitor heavy chain H3  740.026909 99.78653 16 
Inter-alpha-trypsin inhibitor heavy chain H4  1959.48691 103.29298 50 
Kallistatin  319.806909 48.51116 15 
Keratin, type II cytoskeletal 1  83.4307266 65.999 7 
Keratin, type II cytoskeletal 4  53.08 57.24983 3 
Keratin, type II cytoskeletal 80  48.8669089 50.49378 4 
Kininogen-1  840.68 71.91215 13 
Leucine-rich alpha-2-glycoprotein  393.04 38.15411 9 
Leucine-rich repeat serine/threonine-protein kinase 1  91.3969089 227.69779 12 
Low affinity immunoglobulin gamma Fc region receptor III-A  40.59 29.07069 1 
Lumican  269.103818 38.40479 7 
Lymphoid-restricted membrane protein  58.87 62.06908 3 
N-acetylmuramoyl-L-alanine amidase 355.61 62.17788 10 
Nebulin  131.763527 772.4543 31 
Pigment epithelium-derived factor  605.51 46.3133 11 
Plasma kallikrein 118.2 71.32284 7 
Plasma protease C1 inhibitor 702.38 55.11939 16 
Plasma serine protease inhibitor  165.29 45.6727 6 
Plasminogen  490.406909 90.51016 14 
Platelet basic protein  157.53 13.88542 4 
Pregnancy zone protein  42.23 163.75958 2 
Prostaglandin-H2 D-isomerase  62.15 21.01534 1 
Protein AMBP 378.89 38.97398 10 
Protein Z-dependent protease inhibitor  86.1869089 50.67422 9 
Prothrombin 416.776909 69.99212 19 
Putative hydroxypyruvate isomerase  57.15 30.38656 4 
Putative trypsin-6  90.62 26.52219 7 
RelA-associated inhibitor  60.78 89.03574 5 
Retinol-binding protein 4  105.62 22.99526 2 
Rho GTPase-activating protein 7  78.27 170.486 6 
Serotransferrin  39.59 76.99961 1 
Serum albumin  229.410727 69.32149 8 
Serum amyloid P-component  567.02 25.37113 11 
Serum paraoxonase/arylesterase 1  120.46 39.72418 2 
Sex hormone-binding globulin  140.64 43.75182 5 
Tetranectin  270.77 22.55228 6 
Thrombospondin-1 380.813818 129.29956 16 
Thyroxine-binding globulin  138.306909 46.29461 5 
TNF receptor-associated factor 3  54.73 64.44808 7 
Transthyretin  91.98 15.87705 3 
Uncharacterised protein C10orf67 53.3369089 21.44912 4 
Uncharacterised protein C10orf90  41.21 77.86188 2 
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Vitamin D-binding protein  809.04 52.92903 16 
Vitronectin  546.536909 54.27117 11 
Zinc-alpha-2-glycoprotein  425.3 34.2371 13 
 
Patient 2 (nonaggressive) 
Afamin  248.98691 70.96274 5 
Alpha-1-antichymotrypsin  822.77 47.7916 11 
Alpha-1B-glycoprotein  666.74 54.8088 10 
Alpha-2-antiplasmin  187.40691 54.87319 6 
Alpha-2-HS-glycoprotein  313.71 40.09801 4 
Alpha-2-macroglobulin  55.51 164.61441 3 
Angiotensinogen  330.24 53.40562 5 
Apolipoprotein A-I  481.94 30.75893 13 
Apolipoprotein A-IV  1429.79 45.37147 26 
Apolipoprotein B-100  2683.1896 516.66639 60 
Apolipoprotein C-III  252.56 10.8455 2 
Apolipoprotein E  189.15691 36.2458 6 
Beta-2-glycoprotein 1  93.35 39.58415 2 
Beta-Ala-His dipeptidase  98.8 56.77015 4 
Biotinidase  36.67 62.0056 1 
Carboxypeptidase B2  132.97 48.95162 3 
Carboxypeptidase N subunit 2  121.09 61.43147 4 
Ceruloplasmin  2158.4969 122.98291 27 
Clusterin  210.49691 53.03122 5 
Coagulation factor X  101.75 56.06503 3 
Complement C1q subcomponent subunit B  237.03 26.67049 6 
Complement C1q subcomponent subunit C  307.59691 25.98522 4 
Complement C1s subcomponent  404.59691 78.17438 12 
Complement C2  210.14 84.58283 9 
Complement C3 405.76 188.56945 6 
Complement C4-A  2566.7384 194.24706 40 
Complement C5  365.01 189.89678 12 
Complement component C6  161.34 108.36738 4 
Complement component C7  122.62691 96.65049 3 
Complement component C8 alpha chain  68.79 66.83168 2 
Complement component C8 beta chain  343.43 68.71412 7 
Complement component C8 gamma chain  62.74 22.43461 2 
Complement component C9  384.57691 64.61526 7 
Complement factor B  1292.0338 86.84704 21 
Complement factor H  802.46691 143.68046 18 
Complement factor H-related protein 1  171.9 38.76639 4 
Complement factor H-related protein 3  49.98 38.4962 2 
Complement factor I  188.31691 68.0715 4 
Corticosteroid-binding globulin  38.36 45.28297 1 
Fibrinogen alpha chain  166.11 95.65569 4 
Fibronectin  1182.4638 266.03443 26 
Ficolin-3  158.88 33.39518 4 
FYVE, RhoGEF and PH domain-containing protein 4  33.03 87.59782 1 
Gelsolin  495.46 86.04334 9 
Glial fibrillary acidic protein  54.84 49.90667 2 
Glutathione peroxidase 3 41.42 25.76499 2 
Hemopexin  969.64 52.38455 20 
Heparin cofactor 2  498.56382 57.20527 12 
Histidine-rich glycoprotein  337.92 60.51023 7 
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Insulin-like growth factor-binding protein complex acid labile subunit  272.26382 66.73507 7 
Inter-alpha-trypsin inhibitor heavy chain H1  1566.7169 101.78179 22 
Inter-alpha-trypsin inhibitor heavy chain H2  1594.1069 106.85278 24 
Inter-alpha-trypsin inhibitor heavy chain H3  377.49691 100.07164 6 
Inter-alpha-trypsin inhibitor heavy chain H4  1279.4769 103.52107 21 
Kallistatin  87.98 48.68222 3 
Keratin, type I cytoskeletal 10  396.54 59.01978 12 
Keratin, type I cytoskeletal 9  232.47 62.2549 8 
Keratin, type II cytoskeletal 1  908.81454 66.17007 15 
Keratin, type II cytoskeletal 2 epidermal  428.16691 65.67832 10 
Keratin, type II cytoskeletal 2 oral  47.49 66.40031 2 
Keratin, type II cytoskeletal 3  56.92 64.63566 2 
Keratin, type II cytoskeletal 4  109.89 57.64898 3 
Keratin, type II cytoskeletal 5  90.556909 62.56806 3 
Keratin, type II cytoskeletal 6B  173.48691 60.3154 4 
Keratin, type II cytoskeletal 7  102.69 51.43037 4 
Keratin, type II cytoskeletal 71  54.49 57.72714 3 
Keratin, type II cytoskeletal 72  50.786909 56.46967 3 
Keratin, type II cytoskeletal 73 71.3 59.45695 4 
Keratin, type II cytoskeletal 74  52.64 58.22879 3 
Keratin, type II cytoskeletal 75  44.6 59.80914 2 
Keratin, type II cytoskeletal 79  47.86 58.05923 2 
Keratin, type II cytoskeletal 8  149.49 53.67113 5 
Kininogen-1  875.49 72.99556 12 
Lumican  111.62 38.74692 2 
Lymphoid-restricted membrane protein 37.55 62.75334 1 
N-acetylmuramoyl-L-alanine amidase  116.66 62.7481 4 
Nebulin  74.65554 775.41942 9 
Pigment epithelium-derived factor  228.29 46.48436 7 
Plasma kallikrein  47.96 73.43264 1 
Plasma protease C1 inhibitor  86.69 55.34748 4 
Plasminogen  497.90691 93.24719 10 
Platelet basic protein  238.31 14.17052 4 
Platelet factor 4 variant 37.82 11.77337 1 
Protein AMBP  170.55 39.88632 4 
Prothrombin  222.80691 71.47468 6 
Putative trypsin-6 80.79 27.0924 2 
Serum amyloid P-component  387.07 25.48517 8 
Spermatogenesis-associated protein 7  58.14 68.18992 2 
Stabilin-1  47.406909 286.92647 2 
Tetranectin  119.34 22.95143 1 
Thrombospondin-1  263.95 133.29106 6 
Titin  113.44338 3843.1187 33 
Vitamin D-binding protein  586.8 54.52563 10 
Vitamin K-dependent protein S  76.54 77.12671 4 
Vitronectin  433.2 55.06947 7 
Zinc-alpha-2-glycoprotein  116.41 34.46519 4 
 
Patient 3 (nonaggressive) 
Protein Score 
MW 
[kDa] # Pept. 
Unknown 85.42382 0 13 
Unknown 63.79691 0 8 
Unknown 63.35 0 4 
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Unknown 55.07691 0 8 
Unknown 52.72 0 4 
Unknown 51.16 0 3 
Unknown 49.28 0 3 
Unknown 48.43 0 3 
Unknown 47.36382 0 5 
Unknown 46.38 0 3 
Unknown 46.3 0 2 
Unknown 45.18 0 3 
Unknown 45.16382 0 4 
Unknown 41.38 0 3 
Unknown 38.86 0 1 
Unknown 36 0 1 
Unknown 31.45 0 1 
Afamin  449.3169 69.02401 13 
Alpha-1-antichymotrypsin  1079.18 47.62054 21 
Alpha-1B-glycoprotein  927.44 54.23858 19 
Alpha-2-antiplasmin  308.8538 54.53107 10 
Alpha-2-HS-glycoprotein  445.09 39.29971 10 
Alpha-2-macroglobulin  309.8069 163.18888 10 
Angiotensinogen  387.89 53.12051 11 
Ankyrin repeat and SOCS box protein 18  46.09 50.77091 3 
Antithrombin-III  627.1869 52.56886 19 
Apolipoprotein A-I  696.1269 30.75893 20 
Apolipoprotein A-IV  1646.23 45.37147 32 
Apolipoprotein B-100  4745.71 515.24085 96 
Apolipoprotein C-III  236.74 10.8455 2 
Apolipoprotein E  369.3469 36.13175 14 
Beta-2-glycoprotein 1  264.36 38.27266 7 
Beta-Ala-His dipeptidase  313.74 56.65611 8 
Biotinidase  58.98 61.09326 2 
C5a anaphylatoxin chemotactic receptor  39.86 39.29501 2 
Carboxypeptidase B2 202.0169 48.38141 7 
Carboxypeptidase N subunit 2  141.87 60.57615 5 
Cartilage acidic protein 1  62.13 71.37581 2 
CD44 antigen  60.05 81.5034 3 
Ceruloplasmin  3324.038 122.12759 49 
Clusterin  246.7369 52.46101 7 
Coagulation factor IX  77.57 51.745 1 
Coagulation factor X  110.33 54.69651 2 
Coagulation factor XII  88.08 67.77391 4 
Complement C1q subcomponent subunit A  163.35 26.00019 3 
Complement C1q subcomponent subunit B  250.12 26.44241 7 
Complement C1q subcomponent subunit C  339.3569 25.75714 6 
Complement C1r subcomponent 208.04 80.06681 10 
Complement C1s subcomponent  571.0369 76.6348 14 
Complement C2  519.5869 83.21431 16 
Complement C3  1024.751 187.02987 26 
Complement C4-A  2830.965 192.65045 54 
Complement C5  672.8869 188.18613 23 
Complement component C6  371.13 104.718 12 
Complement component C7  401.3 93.45729 8 
Complement component C8 alpha chain  110.55 65.12104 4 
Complement component C8 beta chain  549.71 67.00347 15 
Complement component C8 gamma chain  250.66 22.26354 5 
Complement component C9  441.4969 63.1327 14 
Complement factor B  1100.004 85.47852 23 
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Complement factor H  1296.754 139.0047 34 
Complement factor H-related protein 1  137.15 37.62596 4 
Complement factor H-related protein 3 82.2 37.29875 3 
Complement factor I  239.5138 65.6766 9 
Corticosteroid-binding globulin  123.26 45.11191 5 
FERM domain-containing protein 4A 45.58 115.3873 3 
Fibrinogen alpha chain  349.48 94.91441 8 
Fibronectin  1488.839 262.44208 36 
Ficolin-3  190.72 32.88199 6 
Gelsolin  1078.03 85.64419 19 
Glutathione peroxidase 3  56.43 25.5369 3 
Haptoglobin  230.32 45.17656 6 
Hemoglobin subunit alpha  73.67 15.24793 1 
Hemopexin  1300.587 51.64327 33 
Heparin cofactor 2 783.6338 57.0342 15 
Hepatocyte growth factor activator  90.16691 70.63609 2 
Histidine-rich glycoprotein  737.0969 59.54087 18 
Hyaluronan-binding protein 2  55 62.63044 1 
Insulin-like growth factor-binding protein complex acid labile 
subunit  336.6138 65.9938 11 
Inter-alpha-trypsin inhibitor heavy chain H1  1750.164 101.32561 28 
Inter-alpha-trypsin inhibitor heavy chain H2  1472.167 106.39661 32 
Inter-alpha-trypsin inhibitor heavy chain H3  535.3569 99.78653 16 
Inter-alpha-trypsin inhibitor heavy chain H4  1298.327 103.29298 31 
Kallistatin  179.37 48.51116 9 
Kininogen-1  1028.74 71.91215 14 
Leucine-rich alpha-2-glycoprotein  201.46 38.15411 4 
Lumican  225.1738 38.40479 7 
Mannan-binding lectin serine protease 2 100.93 75.68464 5 
Mannose-binding protein C  64.25 26.127 2 
Myosin-13  46.55 223.54012 3 
N-acetylmuramoyl-L-alanine amidase  192.86 62.17788 8 
Neuron navigator 3 72.86 255.46086 6 
Neuronal acetylcholine receptor subunit beta-2  42.7 56.98207 4 
Pigment epithelium-derived factor  309.95 46.3133 9 
Plasma kallikrein  55.46 71.32284 3 
Plasma protease C1 inhibitor 363.03 55.11939 12 
Plasma serine protease inhibitor  98.51 45.6727 4 
Plasminogen  595.8869 90.51016 15 
Platelet basic protein  228.16 13.88542 6 
Platelet glycoprotein V  35.98 60.92068 2 
Protein AMBP  212.3 38.97398 6 
Protein FAM184A  63.55691 132.88315 6 
Protein Z-dependent protease inhibitor  41.83 50.67422 1 
Prothrombin  230.4569 69.99212 11 
Protocadherin-12  33.06691 128.91494 2 
Retinol-binding protein 4  34.57 22.99526 1 
Serum amyloid P-component  406.92 25.37113 7 
Serum paraoxonase/arylesterase 1  36.52 39.72418 1 
Sex hormone-binding globulin  114.4 43.75182 4 
StAR-related lipid transfer protein 9  88.19145 506.43489 10 
Tetranectin  183.05 22.55228 4 
Thrombospondin-1 549.5007 129.29956 17 
Thrombospondin-2  83.34 129.90777 3 
Thyroxine-binding globulin  108.9538 46.29461 4 
Trypsin-1  72.97 26.54109 3 
Vitamin D-binding protein  716.8 52.92903 14 
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Vitamin K-dependent protein S  121.19 75.07393 7 
Vitronectin  515.0838 54.27117 10 
Zinc finger protein 791  43.25 66.82764 2 
Zinc-alpha-2-glycoprotein  396.52 34.2371 14 
 
Patient 4 (nonaggressive)   
Protein Score MW [kDa] # Pept. 
Afamin  108.40691 69.02401 5 
Alpha-1-antichymotrypsin  599.56 47.62054 13 
Alpha-1B-glycoprotein  521.11 54.23858 13 
Alpha-2-HS-glycoprotein  368.65 39.29971 7 
Amyloid-like protein 1  63.53 72.13118 2 
Angiotensinogen  280.97 53.12051 6 
Apolipoprotein A-I  207.42 30.75893 10 
Apolipoprotein A-IV  1306.68 45.37147 30 
Apolipoprotein B-100  1843.2019 515.24085 60 
Apolipoprotein C-III  131.41 10.8455 2 
Apolipoprotein E  100.58691 36.13175 8 
Beta-2-glycoprotein 1  157.84 38.27266 5 
Biotinidase  33.76 61.09326 1 
Carboxypeptidase B2  83.396909 48.38141 3 
Ceruloplasmin  1549.6238 122.12759 31 
Clusterin  228.91382 52.46101 9 
Complement C1q subcomponent subunit B  79.43 26.44241 5 
Complement C1q subcomponent subunit C  196.32691 25.75714 4 
Complement C1s subcomponent 237.07691 76.6348 11 
Complement C2  77.54 83.21431 3 
Complement C3 302.67382 187.02987 8 
Complement C4-B  1663.6915 192.67254 45 
Complement C5 226.82 188.18613 11 
Complement componen 80.33 93.45729 3 
Complement component C8 beta chain 130.12 67.00347 3 
Complement component C8 gamma chain  44.28 22.26354 3 
Complement component C9  230.91691 63.1327 10 
Complement factor B  743.87691 85.47852 23 
Complement factor H  502.50691 139.0047 23 
Complement factor H-related protein 1 137.47 37.62596 4 
Cystatin-C  71.86 15.78908 3 
FERM domain-containing protein 4A  39.47 115.3873 2 
Fibrinogen alpha chain  111.87 94.91441 5 
Fibronectin  507.89481 262.44208 16 
Ficolin-3  61.69 32.88199 3 
Gelsolin  442.19 85.64419 11 
Hemopexin  711.85 51.64327 29 
Heparin cofactor 2  289.97 57.0342 7 
Hepatocyte growth factor activator 36.653818 70.63609 2 
Histidine-rich glycoprotein  264.27 59.54087 8 
Insulin-like growth factor-binding protein complex acid labile subunit  157.07382 65.9938 9 
Inter-alpha-trypsin inhibitor heavy chain H1  992.78073 101.32561 21 
Inter-alpha-trypsin inhibitor heavy chain H2  823.54 106.39661 19 
Inter-alpha-trypsin inhibitor heavy chain H3 301.13691 99.78653 10 
Inter-alpha-trypsin inhibitor heavy chain H4  699.29 103.29298 22 
Kininogen-1  683.2 71.91215 13 
Lumican  98.17 38.40479 3 
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Osteopontin  98.88 35.40124 1 
Pigment epithelium-derived factor  158.57 46.3133 9 
Plasma protease C1 inhibitor 42.9 55.11939 2 
Plasminogen  352.29691 90.51016 12 
Platelet basic protein  88.3 13.88542 4 
Protein AMBP  97.86 38.97398 6 
Prothrombin  85.816909 69.99212 4 
Serum albumin  106.44382 69.32149 5 
Serum amyloid P-component  230.98 25.37113 5 
Spermatogenesis-associated protein 7  34.86 67.67673 1 
Tetranectin  62.3 22.55228 3 
Thrombospondin-1  94.426909 129.29956 8 
Trypsin-1  46.74 26.54109 1 
Trypsin-1  46.24 54.69651 3 
Vitamin D-binding protein  310.15 52.92903 10 
Vitamin K-dependent protein S  79.28 75.07393 5 
Vitronectin  178.78 54.27117 5 
Zinc-alpha-2-glycoprotein  63.15 34.2371 3 
unknown 58.09 0 5 
unknown 49.713818 0 5 
unknown 45.44 0 2 
unknown 33.83 0 2 
 
 
Patient 5 (nonaggressive ) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 52.24 0 3 
unknown 45.17 0 2 
unknown 42.99 0 2 
unknown 41.6 0 1 
unknown 40.3 0 1 
unknown 36.53 0 1 
Afamin  225.66691 70.96274 6 
Alpha-1-antichymotrypsin  934.21 47.7916 14 
Alpha-1B-glycoprotein  1026.27 54.8088 17 
Alpha-2-antiplasmin  330.69691 54.87319 9 
Alpha-2-HS-glycoprotein  325.24 40.09801 8 
Antithrombin-III  500.08691 53.02504 12 
Apolipoprotein A-I  577.14691 30.75893 15 
Apolipoprotein A-IV  1777.2 45.37147 31 
Apolipoprotein B-100  5071.2079 516.66639 103 
Apolipoprotein C-III  253.95 10.8455 2 
Apolipoprotein E  672.21691 36.2458 15 
Beta-2-glycoprotein 1  170.34 39.58415 5 
Beta-actin-like protein 3  36.75 42.33097 3 
Beta-Ala-His dipeptidase  123.47 56.77015 4 
Biotinidase  58.69 62.0056 2 
Carboxypeptidase B2  258.66 48.95162 6 
Carboxypeptidase N catalytic chain  140.08 52.53842 4 
Carboxypeptidase N subunit 2  208.82 61.43147 5 
Cartilage acidic protein 1  48.49 72.17411 2 
Ceruloplasmin  2299.8569 122.98291 36 
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Clusterin  360.18691 53.03122 6 
Coagulation factor IX  83.1 53.11351 1 
Coagulation factor V  103.42691 252.65397 9 
Coagulation factor X  142.86 56.06503 4 
Coagulation factor XIII A chain  121.31 83.7278 1 
Complement C1q subcomponent subunit B  199.6 26.67049 5 
Complement C1q subcomponent subunit C  299.17691 25.98522 5 
Complement C1r subcomponent  57.56 81.60639 3 
Complement C1s subcomponent  413.10691 78.17438 13 
Complement C2  395.04 84.58283 11 
Complement C3  634.46691 188.56945 14 
Complement C4-B  2791.1884 194.21212 50 
Complement C5  544.04 189.89678 19 
Complement component C6  414.95 108.36738 11 
Complement component C7  465.26691 96.65049 12 
Complement component C8 alpha chain 95.53 66.83168 2 
Complement component C8 beta chain 527.25 68.71412 12 
Complement component C8 gamma chain  157.36 22.43461 4 
Complement component C9  513.92691 64.61526 11 
Complement factor B  1115.5438 86.84704 20 
Complement factor H  608.89691 143.68046 20 
Complement factor H-related protein 1  184.29 38.76639 4 
Complement factor H-related protein 3  62.3 38.4962 2 
Complement factor I  298.75691 68.0715 8 
Corticosteroid-binding globulin  124.26 45.28297 4 
Fibrinogen alpha chain  259.72 95.65569 6 
Fibronectin  1166.4338 266.03443 27 
Ficolin-3  226.39 33.39518 7 
Gelsolin  1494.33 86.04334 23 
Hemopexin  1016.85 52.38455 27 
Heparin cofactor 2  731.44382 57.20527 13 
Hepatocyte growth factor activator  43.54 72.85992 2 
Histidine-rich glycoprotein  745.72691 60.51023 14 
Hyaluronan-binding protein 2  57.91 64.74024 1 
Insulin-like growth factor-binding protein complex acid labile subunit  298.90382 66.73507 10 
Inter-alpha-trypsin inhibitor heavy chain H1  1922.7769 101.78179 27 
Inter-alpha-trypsin inhibitor heavy chain H2  1552.4869 106.85278 28 
Inter-alpha-trypsin inhibitor heavy chain H3  744.61691 100.07164 14 
Inter-alpha-trypsin inhibitor heavy chain H4  1390.27 103.52107 28 
Kallistatin  107.67 48.68222 3 
Keratin, type I cytoskeletal 16  90.906909 51.57833 4 
Keratin, type II cytoskeletal 1  182.93382 66.17007 7 
Keratin, type II cytoskeletal 6B  146.02691 60.3154 6 
Kininogen-1  1075.19 72.99556 12 
Lumican  221.86073 38.74692 7 
Mannan-binding lectin serine protease 2  54.55 77.22422 2 
N-acetylmuramoyl-L-alanine amidase  210.17691 62.7481 7 
Pigment epithelium-derived factor  399.53 46.48436 9 
Plasma kallikrein  83 73.43264 3 
Plasma protease C1 inhibitor  120.03 55.34748 8 
Plasminogen  469.96382 93.24719 13 
Platelet basic protein  204.68 14.17052 3 
Platelet factor 4 variant  57.64 11.77337 1 
Platelet glycoprotein V  36.65 61.43388 1 
POTE ankyrin domain family member E  48.32 122.88226 4 
Protein AMBP  163.21 39.88632 5 
Prothrombin  291.54691 71.47468 7 
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Putative trypsin-6  41.78 27.0924 3 
Serum amyloid P-component  605.66 25.48517 8 
Sex hormone-binding globulin  191.29 43.9799 7 
Spermatogenesis-associated protein 7 51.6 68.18992 2 
Tetranectin  97.54 22.95143 2 
Thrombospondin-1  373.66691 133.29106 11 
Thrombospondin-2  83.43 133.78523 3 
Vitamin D-binding protein  521.13 54.52563 13 
Vitamin K-dependent protein S  114.4 77.12671 5 
Vitronectin  408.36 55.06947 9 
Zinc-alpha-2-glycoprotein  381.42 34.46519 11 
 
 
Patient 6 (nonaggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 39.52 0 1 
unknown 36.52 0 1 
Afamin  100.3369 70.96274 5 
Alpha-1-antichymotrypsin  750.95 47.7916 15 
Alpha-1B-glycoprotein  618.31 54.8088 11 
Alpha-2-antiplasmin  86.51691 54.87319 3 
Alpha-2-HS-glycoprotein  288.74 40.09801 5 
Apolipoprotein A-IV  1387.42 45.37147 25 
Apolipoprotein B-100  2578.86 516.6664 64 
Apolipoprotein C-III  233.83 10.8455 3 
Apolipoprotein E  297.2769 36.2458 9 
ATP-binding cassette sub-family A member 12 37.08 295.3867 1 
Beta-2-glycoprotein 1  110.04 39.58415 2 
Carboxypeptidase B2  111.71 48.95162 3 
Carboxypeptidase N subunit 2  93.5 61.43147 4 
Ceruloplasmin  1530.467 122.9829 25 
Clusterin  252.1269 53.03122 6 
Complement C1q subcomponent subunit B  102.22 26.67049 3 
Complement C1q subcomponent subunit C  182.1569 25.98522 4 
Complement C1r subcomponent  114.51 81.60639 6 
Complement C1s subcomponent 138.8869 78.17438 7 
Complement C3  345.16 188.5695 9 
Complement C4-A  1272.485 194.2471 35 
Complement C5 207.7 189.8968 9 
Complement component C6  134.1 108.3674 5 
Complement component C8 beta chain  144.48 68.71412 7 
Complement component C8 gamma chain  100.06 22.43461 3 
Complement component C9  392.1769 64.61526 9 
Complement factor B 607.5269 86.84704 16 
Complement factor H 614.7138 143.6805 16 
Complement factor H-related protein 1  156.72 38.76639 2 
Complement factor I  91.95691 68.0715 3 
Fibronectin  867.1138 266.0344 21 
Gelsolin  321.85 86.04334 7 
Haptoglobin  279.31 45.86082 7 
Hemopexin  899.02 52.38455 21 
Heparin cofactor 2  544.4769 57.20527 11 
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Histidine-rich glycoprotein  362.4 60.51023 6 
Insulin-like growth factor-binding protein complex acid labile subunit 224.6138 66.73507 9 
Inter-alpha-trypsin inhibitor heavy chain H1  1131.147 101.7818 19 
Inter-alpha-trypsin inhibitor heavy chain H2  911.11 106.8528 15 
Inter-alpha-trypsin inhibitor heavy chain H3  302.3369 100.0716 8 
Inter-alpha-trypsin inhibitor heavy chain H4 678.8969 103.5211 17 
Keratin, type I cytoskeletal 10  94.24 59.01978 5 
Keratin, type I cytoskeletal 9 122.0569 62.2549 6 
Keratin, type II cytoskeletal 1  437.9345 66.17007 11 
Keratin, type II cytoskeletal 2 epidermal  77.98691 65.67832 4 
Keratin, type II cytoskeletal 7  61.16 51.43037 2 
Keratin, type II cytoskeletal 8  70.09 53.67113 3 
Kininogen-1  772.34 72.99556 12 
Leucine-rich alpha-2-glycoprotein  145.05 38.3822 4 
Lumican  151.75 38.74692 3 
N-acetylmuramoyl-L-alanine amidase  41.22 62.7481 1 
Pigment epithelium-derived factor  120.98 46.48436 3 
Plasma protease C1 inhibitor 233.64 55.34748 6 
Plasminogen  290.3769 93.24719 8 
Platelet basic protein  157.78 14.17052 3 
Protein AMBP 168.82 39.88632 6 
Prothrombin  147.4569 71.47468 8 
Putative trypsin-6  66.9 27.0924 2 
Serum amyloid P-component 195.24 25.48517 5 
Tetranectin  70.67 22.95143 2 
Thrombospondin-1  227.3869 133.2911 11 
Vitamin D-binding protein  479.79 54.52563 9 
Vitronectin  343.4 55.06947 7 
Zinc-alpha-2-glycoprotein 103.94 34.46519 4 
 
 
Patient 7 (nonaggressive) 
Protein Score 
MW 
[kDa] 
# 
Pept. 
unknown 52.24 0 3 
unknown 45.17 0 2 
unknown 42.99 0 2 
unknown 41.6 0 1 
unknown 40.3 0 1 
unknown 36.53 0 1 
Afamin  225.6669 70.96274 6 
Alpha-1-antichymotrypsin  934.21 47.7916 14 
Alpha-1B-glycoprotein  1026.27 54.8088 17 
Alpha-2-antiplasmin  330.6969 54.87319 9 
Antithrombin-III  500.0869 53.02504 12 
Apolipoprotein A-I  577.1469 30.75893 15 
Apolipoprotein A-IV  1777.2 45.37147 31 
Apolipoprotein B-100  5071.208 516.6664 103 
Apolipoprotein C-III  253.95 10.8455 2 
Apolipoprotein E  672.2169 36.2458 15 
Beta-2-glycoprotein 1  170.34 39.58415 5 
Beta-actin-like protein 3 36.75 42.33097 3 
Beta-Ala-His dipeptidase 123.47 56.77015 4 
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Biotinidase  58.69 62.0056 2 
Carboxypeptidase B2  258.66 48.95162 6 
Carboxypeptidase N catalytic chain  140.08 52.53842 4 
Carboxypeptidase N subunit 2  208.82 61.43147 5 
Cartilage acidic protein 1  48.49 72.17411 2 
Ceruloplasmin  2299.857 122.9829 36 
Clusterin 360.1869 53.03122 6 
Coagulation factor IX  83.1 53.11351 1 
Coagulation factor V  103.4269 252.654 9 
Coagulation factor X  142.86 56.06503 4 
Coagulation factor XIII A chain 121.31 83.7278 1 
Complement C1q subcomponent subunit B  199.6 26.67049 5 
Complement C1q subcomponent subunit C  299.1769 25.98522 5 
Complement C1r subcomponent  57.56 81.60639 3 
Complement C1s subcomponent 413.1069 78.17438 13 
Complement C2  395.04 84.58283 11 
Complement C3  634.4669 188.5695 14 
Complement C4 (Fragments)  224.39 103.0177 8 
Complement C4-B  2791.188 194.2121 50 
Complement C5  544.04 189.8968 19 
Complement component C6  414.95 108.3674 11 
Complement component C7  465.2669 96.65049 12 
Complement component C7  323.8869 96.65671 9 
Complement component C8 alpha chain  95.53 66.83168 2 
Complement component C8 beta chain  527.25 68.71412 12 
Complement component C8 gamma chain  157.36 22.43461 4 
Complement component C9  513.9269 64.61526 11 
Complement factor B O 1115.544 86.84704 20 
Complement factor H  608.8969 143.6805 20 
Complement factor H-related protein 1  184.29 38.76639 4 
Complement factor H-related protein 3  62.3 38.4962 2 
Complement factor I  298.7569 68.0715 8 
Corticosteroid-binding globulin  124.26 45.28297 4 
Fibrinogen alpha chain  259.72 95.65569 6 
Fibronectin  1166.434 266.0344 27 
Ficolin-3  226.39 33.39518 7 
Gelsolin  1494.33 86.04334 23 
Hemopexin  1016.85 52.38455 27 
Heparin cofactor 2  731.4438 57.20527 13 
Hepatocyte growth factor activator  43.54 72.85992 2 
Histidine-rich glycoprotein  745.7269 60.51023 14 
Hyaluronan-binding protein 2 57.91 64.74024 1 
Insulin-like growth factor-binding protein complex acid labile subunit  298.9038 66.73507 10 
Inter-alpha-trypsin inhibitor heavy chain H1  1922.777 101.7818 27 
Inter-alpha-trypsin inhibitor heavy chain H2  1552.487 106.8528 28 
Inter-alpha-trypsin inhibitor heavy chain H3  744.6169 100.0716 14 
Inter-alpha-trypsin inhibitor heavy chain H4  1390.27 103.5211 28 
Kallistatin  107.67 48.68222 3 
Keratin, type I cytoskeletal 16  90.90691 51.57833 4 
Keratin, type II cytoskeletal 1  182.9338 66.17007 7 
Keratin, type II cytoskeletal 6B  146.0269 60.3154 6 
Kininogen-1  1075.19 72.99556 12 
Lumican  221.8607 38.74692 7 
Mannan-binding lectin serine protease 2  54.55 77.22422 2 
N-acetylmuramoyl-L-alanine amidase  210.1769 62.7481 7 
Pigment epithelium-derived factor  399.53 46.48436 9 
Plasma kallikrein 83 73.43264 3 
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Plasma protease C1 inhibitor  120.03 55.34748 8 
Plasminogen 469.9638 93.24719 13 
Platelet basic protein 204.68 14.17052 3 
Platelet factor 4 variant  57.64 11.77337 1 
Platelet glycoprotein V  36.65 61.43388 1 
POTE ankyrin domain family member E  48.32 122.8823 4 
Protein AMBP 163.21 39.88632 5 
Prothrombin  291.5469 71.47468 7 
Putative trypsin-6  41.78 27.0924 3 
Serum amyloid P-component  605.66 25.48517 8 
Sex hormone-binding globulin  191.29 43.9799 7 
Tetranectin  97.54 22.95143 2 
Thrombospondin-1  373.6669 133.2911 11 
Thrombospondin-2  83.43 133.7852 3 
Vitamin D-binding protein  521.13 54.52563 13 
Vitamin K-dependent protein S  114.4 77.12671 5 
Vitronectin  408.36 55.06947 9 
Zinc-alpha-2-glycoprotein  381.42 34.46519 11 
 
Patient 8 (nonaggressive) 
Protein Score 
MW 
[kDa] 
# 
Pept. 
unknown 60.87 0 4 
unknown 56.11 0 3 
unknown 52.81 0 3 
unknown 52.75 0 2 
unknown 52.52691 0 3 
unknown 50.70691 0 5 
unknown 49.95 0 3 
unknown 48.28 0 3 
unknown 47.78691 0 2 
unknown 47.68 0 2 
unknown 37.6 0 3 
unknown 36.49 0 1 
unknown 33.15 0 2 
unknown 32.19 0 1 
unknown 31.75 0 2 
Afamin 311.1669 69.02401 9 
Alpha-1-antichymotrypsin  865.68 47.62054 18 
Alpha-1B-glycoprotein  795.38 54.23858 14 
Alpha-2-antiplasmin  143.3469 54.53107 4 
Alpha-2-HS-glycoprotein  334.76 39.29971 7 
Alpha-2-macroglobulin  76.3 163.1889 5 
Angiotensinogen  381.02 53.12051 7 
Ankyrin repeat and SOCS box protein 18  51.09 50.77091 1 
Antithrombin-III  187.5969 52.56886 8 
Apolipoprotein A-I 277.3669 30.75893 10 
Apolipoprotein A-IV  1387.23 45.37147 25 
Apolipoprotein B-100  2226.595 515.2409 63 
Apolipoprotein C-I  63.14 9.32609 2 
Apolipoprotein C-III 103.6 10.8455 2 
Apolipoprotein E  196.26 36.13175 10 
ATP-binding cassette sub-family A member 12  45.14 293.0488 4 
Beta-2-glycoprotein 1  188.79 38.27266 6 
Calcium-transporting ATPase type 2C member 2  34.8 103.1209 1 
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Carboxypeptidase N catalytic chain  106.17 52.25331 4 
Carboxypeptidase N subunit 2  145.93 60.57615 3 
Ceruloplasmin O 2693.634 122.1276 45 
Clusterin  217.1369 52.46101 7 
Coagulation factor X  145.05 54.69651 4 
Coiled-coil and C2 domain-containing protein 1A  40.18 103.9983 3 
Complement C1q subcomponent subunit B  202.27 26.44241 5 
Complement C1q subcomponent subunit C  163.9069 25.75714 5 
Complement C1r subcomponent  135.91 80.06681 6 
Complement C1r subcomponent-like protein  44.76 53.46434 1 
Complement C1s subcomponent  298.6969 76.6348 8 
Complement C2  507.5769 83.21431 13 
Complement C3  361.82 187.0299 8 
Complement C4-B  2506.131 192.6725 46 
Complement C5  295.43 188.1861 11 
Complement component C6  213.84 104.718 6 
Complement component C7 325.85 93.45729 7 
Complement component C8 alpha chain  89.32 65.12104 6 
Complement component C8 beta chain  354.62 67.00347 17 
Complement component C8 gamma chain  209.97 22.26354 4 
Complement component C9  503.04 63.1327 10 
Complement factor B  719.5207 85.47852 18 
Complement factor D  58.37 27.01586 2 
Complement factor H  685.0569 139.0047 20 
Complement factor H-related protein 1  184.71 37.62596 4 
Complement factor H-related protein 2  92.61 30.63063 2 
Complement factor I  123.4969 65.6766 4 
Corticosteroid-binding globulin 144.37 45.11191 4 
Dynein heavy chain 10, axonemal  56.88481 514.484 7 
FERM domain-containing protein 4A 77.05 115.3873 8 
Fibrinogen alpha chain  150.7 94.91441 6 
Fibronectin OS=Homo sapiens  771.2248 262.4421 21 
Ficolin-3  109.78 32.88199 3 
Gelsolin  885.97 85.64419 12 
Glutathione peroxidase 3  45.94 25.5369 4 
Hemopexin  1112.78 51.64327 26 
Heparin cofactor 2  737.7338 57.0342 16 
Hepatocyte growth factor activator  54.14691 70.63609 3 
Histidine-rich glycoprotein  245.44 59.54087 5 
Insulin-like growth factor-binding protein complex acid labile subunit  394.8838 65.9938 11 
Inter-alpha-trypsin inhibitor heavy chain H1  1421.844 101.3256 21 
Inter-alpha-trypsin inhibitor heavy chain H2  1078.75 106.3966 20 
Inter-alpha-trypsin inhibitor heavy chain H3  379.1769 99.78653 11 
Inter-alpha-trypsin inhibitor heavy chain H4  911.2469 103.293 19 
Intercellular adhesion molecule 3  31.22 59.50283 2 
Kallistatin  152.47 48.51116 5 
Keratin, type I cytoskeletal 10  277.64 58.79169 10 
Keratin, type I cytoskeletal 28 67.88 50.53592 3 
Keratin, type I cytoskeletal 9  310.3469 62.02681 10 
Keratin, type II cuticular Hb4  59.76 64.85455 3 
Keratin, type II cytoskeletal 1  686.8576 65.999 13 
Keratin, type II cytoskeletal 2 epidermal  497.9938 65.39322 11 
Keratin, type II cytoskeletal 2 oral  62.68 65.8301 4 
Keratin, type II cytoskeletal 3  94.39 64.46459 5 
Keratin, type II cytoskeletal 6B  163.9069 60.03029 6 
Keratin, type II cytoskeletal 7  123.26 51.37335 4 
Keratin, type II cytoskeletal 72  62.64691 55.84244 4 
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Keratin, type II cytoskeletal 73  50.04 58.88674 3 
Keratin, type II cytoskeletal 74  64.68 57.82964 5 
Keratin, type II cytoskeletal 75  106.06 59.52403 5 
Keratin, type II cytoskeletal 79  94.88 57.77412 4 
Keratin, type II cytoskeletal 8  119.89 53.67113 4 
Kininogen-1  812.34 71.91215 11 
Leucine-rich alpha-2-glycoprotein  209.28 38.15411 4 
Lumican  227.8869 38.40479 5 
Lymphoid-restricted membrane protein  36.09 62.06908 1 
Mannan-binding lectin serine protease 2  40.1 75.68464 1 
N-acetylmuramoyl-L-alanine amidase  166.55 62.17788 6 
Pigment epithelium-derived factor  320.29 46.3133 7 
Plasma kallikrein  48.63691 71.32284 2 
Plasma protease C1 inhibitor  257.89 55.11939 7 
Plasminogen  534.0269 90.51016 16 
Platelet basic protein  213.65 13.88542 5 
Protein AMBP 167.6 38.97398 7 
Prothrombin 213.8969 69.99212 8 
Putative trypsin-6  78.68 26.52219 2 
Serum amyloid P-component  398.1 25.37113 7 
Sex hormone-binding globulin  92.43 43.75182 4 
Spermatogenesis-associated protein 7  63.26 67.67673 2 
Thrombospondin-1 167.81 129.2996 6 
Thyroxine-binding globulin  48.06 46.29461 1 
Uncharacterised protein C10orf67 31.13691 21.44912 4 
Uncharacterised protein C10orf92  32.52 95.43611 1 
Vitamin D-binding protein  633.2 52.92903 13 
Vitamin K-dependent protein S  77.84 75.07393 4 
Vitronectin  330.36 54.27117 5 
Zinc finger protein 791  45.77691 66.82764 3 
Zinc-alpha-2-glycoprotein  235.64 34.2371 8 
 
Patient 9 (nonaggressive) 
Protein Score MW [kDa] # Pept. 
unknown  79.684439 0 13 
unknown  54.75 0 4 
unknown  52.88 0 4 
unknown  49.38 0 5 
unknown  46.29 0 3 
unknown  41.45 0 3 
unknown  39.2 0 1 
unknown  38.23 0 1 
unknown  38.036909 0 3 
unknown  36.48 0 2 
unknown  35.696909 0 4 
unknown  35.04 0 2 
unknown  34.64 0 1 
unknown  34.25 0 1 
unknown  33.88 0 1 
unknown  30.51 0 1 
Afamin  230.03691 70.96274 8 
Alpha-1-antichymotrypsin  1206.89 47.7916 24 
Alpha-1B-glycoprotein 936.92 54.8088 15 
Alpha-2-antiplasmin  306.44691 54.87319 8 
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Alpha-2-HS-glycoprotein  330.72 40.09801 7 
Alpha-2-macroglobulin  376.89 164.61441 17 
Angiotensinogen  230.61 53.40562 10 
Antithrombin-III  900.39691 53.02504 18 
Apolipoprotein A-I  593.99691 30.75893 19 
Apolipoprotein A-IV  1320.77 45.37147 30 
Apolipoprotein B-100  6769.0779 516.66639 133 
Apolipoprotein C-III  210.47 10.8455 2 
Apolipoprotein E  469.24691 36.2458 12 
ATP synthase subunit alpha, mitochondrial  65.56 59.82764 5 
ATP-binding cassette sub-family A member 12  80.716909 295.38672 10 
Beta-2-glycoprotein 1  151.54 39.58415 5 
Beta-Ala-His dipeptidase  95.97 56.77015 5 
Carboxypeptidase B2  262.25 48.95162 8 
Carboxypeptidase N subunit 2  256.24 61.43147 7 
Cartilage acidic protein 1  87.17 72.17411 5 
Ceruloplasmin  2846.6548 122.98291 57 
Chordin  46.58 104.70335 4 
Clusterin  245.37691 53.03122 6 
Coagulation factor X  139.06 56.06503 6 
Coagulation factor XII  53.85 70.05477 3 
Complement C1q subcomponent subunit A  163.98 26.28529 3 
Complement C1q subcomponent subunit B  232.86 26.67049 6 
Complement C1q subcomponent subunit C  223.89691 25.98522 3 
Complement C1r subcomponent  195.98 81.60639 7 
Complement C1r subcomponent-like protein  39.43 54.20562 2 
Complement C1s subcomponent  389.44691 78.17438 12 
Complement C2  492.07691 84.58283 14 
Complement C3  1719.1284 188.56945 44 
Complement C4-B  3350.0753 194.21212 73 
Complement C5 1115.4369 189.89678 32 
Complement component C6 322.17 108.36738 10 
Complement component C7  410.93691 96.65049 11 
Complement component C8 beta chain  484.76 68.71412 16 
Complement component C8 gamma chain  235.13 22.43461 7 
Complement component C9  491.16691 64.61526 14 
Complement factor B  826.85691 86.84704 20 
Complement factor H  747.27691 143.68046 24 
Complement factor H-related protein 1 170.26 38.76639 4 
Complement factor H-related protein 2  102.63 31.54298 5 
Complement factor H-related protein 3  57.52 38.4962 2 
Complement factor I 255.94382 68.0715 9 
Condensin-2 complex subunit D3  41.166909 170.95017 4 
Cyclin N-terminal domain-containing protein 1  32.71 37.2395 1 
Fibrinogen alpha chain  229.21691 95.65569 9 
Fibronectin  1099.8945 266.03443 30 
Ficolin-3  149.67 33.39518 6 
Gelsolin  899.29691 86.04334 19 
Glial fibrillary acidic protein  66.42 49.90667 5 
Glutathione peroxidase 3  67.4 25.76499 3 
Haptoglobin  124.01 45.86082 4 
Hemopexin  925.54 52.38455 30 
Heparin cofactor 2  779.38382 57.20527 16 
Hepatocyte growth factor activator  40.67 72.85992 1 
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 453.02 60.51023 14 
Insulin-like growth factor-binding protein complex acid labile subunit  496.75481 66.73507 18 
Inter-alpha-trypsin inhibitor heavy chain H1  1586.2607 101.78179 30 
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Inter-alpha-trypsin inhibitor heavy chain H2  1576.55 106.85278 38 
Inter-alpha-trypsin inhibitor heavy chain H3  266.41691 100.07164 11 
Inter-alpha-trypsin inhibitor heavy chain H4 1599.8969 103.52107 41 
Kallistatin 324.52 48.68222 12 
Keratin, type I cytoskeletal 10  144.78 59.01978 7 
Keratin, type I cytoskeletal 9  67.45 62.2549 7 
Keratin, type II cytoskeletal 1  336.90073 66.17007 9 
Keratin, type II cytoskeletal 2 epidermal  65.046909 65.67832 3 
Keratin, type II cytoskeletal 4  55.47 57.64898 4 
Keratin, type II cytoskeletal 7  63.926909 51.43037 4 
Keratin, type II cytoskeletal 8  85.91 53.67113 7 
Keratin, type II cytoskeletal 80  58.69 51.00697 2 
Kininogen-1  964.62 72.99556 10 
Leucine-rich alpha-2-glycoprotein  371 38.3822 10 
Lumican  231.42691 38.74692 5 
Lymphoid-restricted membrane protein  41.51 62.75334 4 
Myosin-XV  145.21764 397.43458 18 
N-acetylmuramoyl-L-alanine amidase 153.41691 62.7481 7 
Neuropilin-1  39.22 104.32307 4 
Pigment epithelium-derived factor  222.48 46.48436 5 
Plasma kallikrein  53.72 73.43264 2 
Plasma protease C1 inhibitor  418.96 55.34748 15 
Plasminogen  385.16382 93.24719 11 
Platelet basic protein  199.56 14.17052 5 
Protein AMBP  166.82 39.88632 5 
Protein FAM102A  62.26 42.2151 3 
Prothrombin  257.02 71.47468 7 
Putative trypsin-6  70.16 27.0924 3 
Retinol-binding protein 4  97.48 23.33739 2 
Serum amyloid P-component  558.05 25.48517 11 
Sex hormone-binding globulin  101.83 43.9799 5 
Spectrin beta chain, brain 3  86.700995 290.00505 10 
Tetranectin  207.9 22.95143 5 
Threonyl-tRNA synthetase, mitochondrial  73.79 81.84076 5 
Thrombospondin-1 476.24691 133.29106 15 
Thrombospondin-2  77.55 133.78523 5 
Thyroxine-binding globulin  147.06382 46.63674 7 
Trifunctional enzyme subunit alpha, mitochondrial  64.05 83.68815 7 
Vitamin D-binding protein  458.86 54.52563 10 
Vitamin K-dependent protein S  91.91 77.12671 6 
Vitronectin  508.88 55.06947 14 
Zinc-alpha-2-glycoprotein  295.84 34.46519 12 
 
Patient 10 (nonaggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown  91.25691 0 13 
unknown  61.15 0 6 
unknown  53.27 0 3 
unknown  52.56382 0 4 
unknown  46.98691 0 5 
unknown  46.7479 0 4 
unknown  46.45 0 2 
unknown  45.62691 0 4 
unknown  43.43691 0 4 
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unknown  42.84 0 2 
unknown  42.7 0 1 
unknown  42.53691 0 3 
unknown  38.27 0 1 
unknown  36.33 0 2 
unknown  36.17 0 2 
unknown  33.06 0 1 
unknown  32.62 0 1 
unknown  31.92691 0 2 
Afamin  157.8569 70.96274 7 
Alpha-1-antichymotrypsin  817.4 47.7916 14 
Alpha-1-antitrypsin  98.46 46.87808 3 
Alpha-1B-glycoprotein  522.68 54.8088 9 
Alpha-2-antiplasmin  211.9569 54.87319 8 
Alpha-2-HS-glycoprotein  286.81 40.09801 6 
Alpha-2-macroglobulin  527.61 164.6144 16 
Amyloid-like protein 1  31.72 72.81544 1 
Angiotensinogen  287.36 53.40562 6 
Antithrombin-III  443.6469 53.02504 13 
Apolipoprotein A-I  303.4069 30.75893 12 
Apolipoprotein A-IV  1554.28 45.37147 30 
Apolipoprotein B-100  2539.289 516.6664 70 
Apolipoprotein C-III  214.34 10.8455 2 
Apolipoprotein E  195.6669 36.2458 10 
Beta-2-glycoprotein 1  101.5 39.58415 2 
Biotinidase  34.02 62.0056 1 
Carboxypeptidase B2  154.16 48.95162 3 
Carboxypeptidase N subunit 2  136.28 61.43147 4 
CDC45-related protein 40.51 66.21084 2 
Ceruloplasmin  2487.188 122.9829 43 
Clusterin  185.6669 53.03122 6 
Coagulation factor X 117.6 56.06503 4 
Complement C1q subcomponent subunit B  188.63 26.67049 4 
Complement C1q subcomponent subunit C  275.0869 25.98522 5 
Complement C1r subcomponent  148.13 81.60639 7 
Complement C1s subcomponent  378.8969 78.17438 11 
Complement C2  342.2338 84.58283 15 
Complement C3  532.1607 188.5695 14 
Complement C4-B  2314.348 194.2121 47 
Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 418.5669 189.8968 15 
Complement component C6  202.14 108.3674 8 
Complement component C7 510.1838 96.65049 10 
Complement component C8 alpha chain 65.09 66.83168 1 
Complement component C8 beta chain 280.01 68.71412 8 
Complement component C8 gamma chain 148.76 22.43461 3 
Complement component C9  287.9469 64.61526 8 
Complement factor B  1177.214 86.84704 24 
Complement factor H 889.2369 143.6805 24 
Complement factor H-related protein 1  192.16 38.76639 5 
Complement factor I  204.6269 68.0715 6 
Corticosteroid-binding globulin 66.75 45.28297 4 
Dedicator of cytokinesis protein 11 63.99073 240.1422 8 
Fibrinogen alpha chain  211.18 95.65569 8 
Fibronectin  739.0338 266.0344 22 
Ficolin-3 112.22 33.39518 3 
Gelsolin 821.47 86.04334 18 
Glutathione peroxidase 3  32.48 25.76499 2 
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Haptoglobin  149.0869 45.86082 8 
Hemoglobin subunit alpha  45.13 15.30495 1 
Hemopexin  1036.95 52.38455 23 
Heparin cofactor 2  564.5738 57.20527 14 
Hepatocyte growth factor activator  64.33 72.85992 4 
Histidine-rich glycoprotein  560.57 60.51023 10 
Insulin-like growth factor-binding protein complex acid labile subunit  165.2069 66.73507 6 
Inter-alpha-trypsin inhibitor heavy chain H1  1457.164 101.7818 24 
Inter-alpha-trypsin inhibitor heavy chain H2  1282.237 106.8528 23 
Inter-alpha-trypsin inhibitor heavy chain H3 632.8869 100.0716 12 
Inter-alpha-trypsin inhibitor heavy chain H4  1025.667 103.5211 23 
Kallistatin  85.75 48.68222 4 
Keratin, type I cytoskeletal 10 79.28 59.01978 5 
Keratin, type II cytoskeletal 1  175.1807 66.17007 8 
Kininogen-1  824.47 72.99556 10 
Leucine-rich alpha-2-glycoprotein  63.85 38.3822 3 
Lumican  178.3238 38.74692 5 
Mannan-binding lectin serine protease 2  42.25 77.22422 1 
N-acetylmuramoyl-L-alanine amidase  71.64 62.7481 4 
Neuronal acetylcholine receptor subunit beta-2  31.69 57.78037 1 
Osteopontin  96.42 35.5723 1 
Phosphatidylinositol-glycan-specific phospholipase D  46.91 92.9052 4 
Pigment epithelium-derived factor  238.3169 46.48436 10 
Plasma kallikrein  44.99691 73.43264 3 
Plasma protease C1 inhibitor  193.8 55.34748 7 
Plasminogen  407.3269 93.24719 11 
Platelet basic protein  224.34 14.17052 4 
Protein AMBP  203.82 39.88632 4 
Prothrombin  134.2269 71.47468 5 
Protocadherin-12  36.13 129.5992 3 
Serine/threonine-protein kinase haspin  39.39 89.6592 4 
Serine/threonine-protein kinase LMTK2  42.03 165.9964 3 
Serum albumin 72.56691 71.31725 3 
Serum amyloid P-component  376.1 25.48517 7 
Sialic acid-binding Ig-like lectin 10  47.28 77.45596 4 
Spermatogenesis-associated protein 73 38.06 68.18992 2 
Stabilin-1  62.91691 286.9265 4 
Talin-1  53.77 271.7659 4 
Talin-2  89.28 273.7813 8 
Tetranectin  134.14 22.95143 2 
Thrombospondin-1  160.8138 133.2911 9 
TRIO and F-actin-binding protein  67.15382 264.125 10 
Vitamin D-binding protein  502.66 54.52563 12 
Vitamin K-dependent protein S 102.91 77.12671 7 
Vitronectin  530.97 55.06947 10 
Zinc-alpha-2-glycoprotein 140.78 34.46519 6 
 
Patient 11 (nonaggressive) 
Protein Score MW [kDa] # Pept. 
unkown  51.01 0 4 
unkown  50.12 0 4 
unkown  46.74 0 3 
unkown  38.97 0 2 
unkown  35.8 0 1 
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unkown  35.75 0 1 
unkown  32.65 0 1 
Antithrombin-III  241.94 53.02504 5 
Apolipoprotein A-I  207.937 30.75893 8 
Apolipoprotein A-IV  1323.27 45.37147 29 
Apolipoprotein B-100  2575.83 516.66639 65 
Apolipoprotein C-I  73.83 9.32609 3 
Apolipoprotein C-III  162.87 10.8455 2 
Apolipoprotein E  418.807 36.2458 15 
Beta-2-glycoprotein 1 123.84 39.58415 4 
Beta-Ala-His dipeptidase  202 56.77015 7 
Biotinidase  102.987 62.0056 4 
Carboxypeptidase B2  142.9 48.95162 5 
Carboxypeptidase N catalytic chain 137.23 52.53842 4 
Carboxypeptidase N subunit 2  155.81 61.43147 4 
Ceruloplasmin  2150.24 122.98291 44 
Clusterin  149.047 53.03122 6 
Coagulation factor IX  43.8 53.11351 3 
Coagulation factor V 49.1169 252.65397 3 
Coagulation factor X  125.28 56.06503 2 
Complement C1q subcomponent subunit A 174.96 26.28529 2 
Complement C1q subcomponent subunit B  217.12 26.67049 6 
Complement C1q subcomponent subunit C 328.247 25.98522 7 
Complement C1r subcomponent  125.37 81.60639 7 
Complement C1r subcomponent-like protein  44.03 54.20562 2 
Complement C1s subcomponent  357.227 78.17438 11 
Complement C2  286.657 84.58283 10 
Complement C3  373.891 188.56945 12 
Complement C4-B  2351.45 194.21212 50 
Complement C5  346.627 189.89678 15 
Complement component C6  174.32 108.36738 8 
Complement component C7  264.537 96.65049 5 
Complement component C8 beta chain  386.04 68.71412 13 
Complement component C8 gamma chain 132.32 22.43461 3 
Complement component C9  379.84 64.61526 10 
Complement factor B  910.924 86.84704 17 
Complement factor H  790.727 143.68046 22 
Complement factor H-related protein 1  180.43 38.76639 5 
Complement factor H-related protein 3  60.72 38.4962 2 
Complement factor I  173.497 68.0715 8 
Corticosteroid-binding globulin  134.95 45.28297 4 
Fibrinogen alpha chain  166.25 95.65569 4 
Fibronectin  1140.39 266.03443 30 
Ficolin-3  268.97 33.39518 8 
Gelsolin  838.44 86.04334 16 
Glutathione peroxidase 3  60.88 25.76499 5 
Hemopexin  998.69 52.38455 31 
Heparin cofactor 2  419.957 57.20527 12 
Hepatocyte growth factor activator  49.83 72.85992 4 
Histidine-rich glycoprotein  514.48 60.51023 13 
Insulin-like growth factor-binding protein complex acid labile subunit  501.274 66.73507 12 
Inter-alpha-trypsin inhibitor heavy chain H1  1766.39 101.78179 29 
Inter-alpha-trypsin inhibitor heavy chain H2  1457.41 106.85278 33 
Inter-alpha-trypsin inhibitor heavy chain H3  572.034 100.07164 11 
Inter-alpha-trypsin inhibitor heavy chain H4  1109.83 103.52107 25 
Kallistatin  158.43 48.68222 3 
Kininogen-1  565.73 72.99556 13 
Biomarkers in Prostate Cancer  Bandar Alghanem 
_____________________________________________________________________________ 
105 
 
Leucine-rich alpha-2-glycoprotein  146.81 38.3822 4 
Lumican  147.044 38.74692 4 
Mannan-binding lectin serine protease 2  39.71 77.22422 2 
Mitogen-activated protein kinase 3  35.31 43.45024 1 
Myelin transcription factor 1  45.7169 123.90716 3 
N-acetylmuramoyl-L-alanine amidase  93.9 62.7481 4 
Nebulin  108.501 775.41942 20 
Neuropilin-1  52.7 104.32307 3 
Pigment epithelium-derived factor  440.49 46.48436 11 
Plasma kallikrein  41.97 73.43264 2 
Plasminogen  459.194 93.24719 12 
Platelet basic protein  150.81 14.17052 3 
Platelet glycoprotein V  47.81 61.43388 2 
Protein AMBP  176.31 39.88632 5 
Protein deltex-3  39.29 38.64782 2 
Prothrombin  129.847 71.47468 5 
Putative trypsin-6  78.9 27.0924 3 
Serum amyloid P-component  496.12 25.48517 8 
Tetranectin  45.75 22.95143 2 
Thrombospondin-1  340.834 133.29106 15 
Titin  151.285 3843.1187 48 
Uncharacterised protein C10orf92  43.5669 96.51952 3 
Vitamin D-binding protein 413.34 54.52563 10 
Vitamin K-dependent protein S  64.24 77.12671 3 
Vitronectin  384.32 55.06947 8 
Zinc-alpha-2-glycoprotein  213.15 34.46519 9 
 
Patient 12 (nonaggressive) 
Protein Score 
MW 
[kDa] 
# 
Pept. 
Alpha-1-antichymotrypsin  710.29 47.7916 12 
Alpha-1B-glycoprotein  532.21 54.8088 11 
Alpha-2-antiplasmin  95.6969 54.8732 3 
Alpha-2-HS-glycoprotein  254.09 40.098 6 
Angiotensinogen  136.63 53.4056 4 
Apolipoprotein A-IV  810.87 45.3715 22 
Apolipoprotein B-100  1653.14 516.666 46 
Apolipoprotein C-III  193.03 10.8455 2 
Apolipoprotein E  231.837 36.2458 10 
Beta-2-glycoprotein 1  35.84 39.5842 1 
Beta-Ala-His dipeptidase  79.42 56.7702 4 
Carboxypeptidase B2  202.56 48.9516 4 
Carboxypeptidase N subunit 2  108.53 61.4315 2 
Cartilage acidic protein 1  46.92 72.1741 3 
Centrosomal protein of 290 kDa  121.049 290.892 12 
Ceruloplasmin  1765.08 122.983 27 
Clusterin  223.877 53.0312 6 
Coagulation factor X  108.98 56.065 3 
Coagulation factor XIII A chain  68.73 83.7278 2 
Complement C1q subcomponent subunit B  134.05 26.6705 4 
Complement C1q subcomponent subunit C ] 198.547 25.9852 3 
Complement C1s subcomponent  132.687 78.1744 5 
Complement C2  115.71 84.5828 6 
Complement C3  246.314 188.569 9 
Complement C4-A  1238.15 194.247 31 
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Complement C5  134.02 189.897 6 
Complement component C6  90.13 108.367 4 
Complement component C7 122.784 96.6505 5 
Complement component C8  343.95 68.7141 8 
Complement component C9  242.027 64.6153 7 
Complement factor B  578.677 86.847 17 
Complement factor H  374.957 143.68 12 
Complement factor H-related protein 1  142.9 38.7664 3 
Complement factor H-related protein 3  35.02 38.4962 2 
Complement factor I  107.527 68.0715 4 
FERM domain-containing protein 4A  37.18 115.958 1 
Fibrinogen alpha chain 108.03 95.6557 4 
Fibronectin  874.884 266.034 22 
Ficolin-3  115.4 33.3952 4 
Gelsolin  650.43 86.0433 14 
Haptoglobin  72.15 45.8608 2 
Hemopexin  650.66 52.3846 16 
Heparin cofactor 2  375.987 57.2053 11 
Histidine-rich glycoprotein  198.12 60.5102 5 
Insulin-like growth factor-binding protein complex acid labile subunit  196.014 66.7351 9 
Inter-alpha-trypsin inhibitor heavy chain H1  1066.11 101.782 18 
Inter-alpha-trypsin inhibitor heavy chain H2 868.87 106.853 18 
Inter-alpha-trypsin inhibitor heavy chain H3  391.547 100.072 8 
Inter-alpha-trypsin inhibitor heavy chain H4 730.52 103.521 16 
Kallistatin  46.41 48.6822 3 
Kininogen-1  671.28 72.9956 12 
Lumican  54.58 38.7469 1 
Lymphoid-restricted membrane protein  30.78 62.7533 1 
Mannan-binding lectin serine protease 2  44.05 77.2242 1 
N-acetylmuramoyl-L-alanine amidase  53.9 62.7481 3 
Pigment epithelium-derived factor 170.91 46.4844 6 
Plasma kallikrein  42.93 73.4326 2 
Plasminogen  328.077 93.2472 10 
Platelet basic protein  159.71 14.1705 3 
Protein AMBP  68.6 39.8863 4 
Prothrombin  152.15 71.4747 5 
Serine/threonine-protein kinase LMTK2  38.45 165.996 2 
Serum amyloid P-component  353.23 25.4852 7 
Spermatogenesis-associated protein 7  61.38 68.1899 2 
Structural maintenance of chromosomes protein 3  53.3158 141.853 6 
Tetranectin  122.29 22.9514 2 
Thrombospondin-1  179.31 133.291 8 
Trypsin-1  41.76 27.1113 2 
Vitamin D-binding protein  280.83 54.5256 8 
Vitronectin  245.94 55.0695 6 
Zinc-alpha-2-glycoprotein  85.11 34.4652 3 
 
Patient 13 (aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 45.0379 0 3 
unknown 41.38 0 1 
Afamin  465.7569 70.9627 12 
Alpha-1-acid glycoprotein 1  52.67 23.7249 2 
Alpha-1-antichymotrypsin  877.55 47.7916 15 
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Alpha-1B-glycoprotein  915.39 54.8088 14 
Alpha-2-antiplasmin  208.3969 54.8732 7 
Alpha-2-HS-glycoprotein  308.55 40.098 6 
Angiotensinogen  367.22 53.4056 8 
Apolipoprotein A-I  431.2569 30.7589 14 
Apolipoprotein A-IV  1593.1 45.3715 30 
Apolipoprotein B-100  4825.461 516.666 104 
Apolipoprotein C-III 243.77 10.8455 2 
Apolipoprotein E  447.7369 36.2458 14 
Beta-2-glycoprotein 1  91.96 39.5842 2 
Beta-Ala-His dipeptidase  160.24 56.7702 6 
Carboxypeptidase B2  209.69 48.9516 5 
Carboxypeptidase N subunit 2  203.56 61.4315 5 
Ceruloplasmin  2281.268 122.983 39 
Clusterin  461.1969 53.0312 8 
Coagulation factor IX  59.2 53.1135 2 
Coagulation factor V  117.31 252.654 6 
Coagulation factor X  106.04 56.065 3 
Coagulation factor XII  75.43 70.0548 2 
Complement C1q subcomponent subunit A  143.7 26.2853 2 
Complement C1q subcomponent subunit B  152.83 26.6705 3 
Complement C1q subcomponent subunit C  271.5569 25.9852 5 
Complement C1r subcomponent  233.56 81.6064 7 
Complement C1s subcomponent  414.6469 78.1744 10 
Complement C2  421.3969 84.5828 13 
Complement C3  749.0438 188.569 23 
Complement C4-B  2854.281 194.212 53 
Complement C5  610.42 189.897 21 
Complement component C6  324.77 108.367 8 
Complement component C7  232.3669 96.6505 5 
Complement component C8 alpha chain  68.37691 66.8317 3 
Complement component C8 beta chain  378.31 68.7141 10 
Complement component C8 gamma chain  154.19 22.4346 3 
Complement component C9 332.4869 64.6153 9 
Complement factor B  996.7569 86.847 21 
Complement factor H  984.4569 143.68 24 
Complement factor H-related protein 1  178.74 38.7664 5 
Complement factor H-related protein 3  73.8 38.4962 2 
Complement factor I  218.0769 68.0715 6 
Fibrinogen alpha chain  211.39 95.6557 6 
Fibronectin  1916.985 266.034 40 
Ficolin-3  137.81 33.3952 5 
Gelsolin 922.2469 86.0433 18 
Haptoglobin  64.84 39.2407 3 
Hemopexin  999.61 52.3846 24 
Heparin cofactor 2  661.0338 57.2053 18 
Hepatocyte growth factor activator  95.2 72.8599 3 
Histidine-rich glycoprotein  445.95 60.5102 7 
Hyaluronan-binding protein 2  62.44 64.7402 2 
Insulin-like growth factor-binding protein complex acid labile subunit  653.3248 66.7351 16 
Inter-alpha-trypsin inhibitor heavy chain H1  1759.954 101.782 26 
Inter-alpha-trypsin inhibitor heavy chain H2  1537.587 106.853 31 
Inter-alpha-trypsin inhibitor heavy chain H3  386.9369 100.072 7 
Inter-alpha-trypsin inhibitor heavy chain H4  1234.207 103.521 28 
Kallistatin  139.42 48.6822 5 
Keratin, type II cytoskeletal 1  278.3876 66.1701 7 
Keratin, type II cytoskeletal 2 epidermal  46.80691 65.6783 2 
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Kininogen-1  975.18 72.9956 13 
Lumican  233.4469 38.7469 5 
N-acetylmuramoyl-L-alanine amidase  152.1069 62.7481 5 
Pigment epithelium-derived factor  368.5 46.4844 10 
Plasma kallikrein  70.54691 73.4326 5 
Plasma protease C1 inhibitor  171 55.3475 5 
Plasminogen 435.1538 93.2472 11 
Platelet basic protein  147.69 14.1705 3 
Protein AMBP  189.36 39.8863 5 
Prothrombin  275.0569 71.4747 9 
Serine/threonine-protein kinase MARK1  42.07 89.4604 2 
Serum amyloid P-component  497.6 25.4852 7 
Tetranectin  123.45 22.9514 2 
Thrombospondin-1  466.9369 133.291 12 
Thrombospondin-2  68.57 133.785 2 
Thyroxine-binding globulin 57.62691 46.6367 2 
Trypsin-1  61.76 27.1113 1 
Vitamin D-binding protein  608.3 54.5256 11 
Vitamin K-dependent protein S 74.34 77.1267 5 
Vitronectin  531.09 55.0695 11 
Zinc-alpha-2-glycoprotein  304.95 34.4652 11 
 
Patient 14(aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 56.923818 0 7 
unknown 38.17 0 3 
unknown 33.73 0 1 
unknown 32.33 0 2 
unknown 31.35 0 1 
Afamin  134.17691 70.96274 5 
Alpha-1-antichymotrypsin  613.83 47.7916 15 
Alpha-1B-glycoprotein  676.09 54.8088 14 
Alpha-2-antiplasmin  67.826909 54.87319 4 
Alpha-2-HS-glycoprotein  285.77 40.09801 7 
Alpha-2-macroglobulin  327.46 164.6144 12 
Angiotensinogen  143.5 53.40562 3 
Apolipoprotein A-I  710.24 30.75893 19 
Apolipoprotein A-IV  1168.06 45.37147 28 
Apolipoprotein B-100  3974.8199 516.6664 100 
Apolipoprotein C-III  220.57 10.8455 2 
Apolipoprotein E  222.33691 36.2458 10 
Beta-2-glycoprotein 1  93 39.58415 2 
Biotinidase  55.23 62.0056 3 
Carboxypeptidase B2  84.6 48.95162 3 
Carboxypeptidase N subunit 2  134.18 61.43147 3 
Ceruloplasmin  1788.8238 122.9829 31 
Clusterin  133.52 53.03122 4 
Coagulation factor X  72.4 56.06503 2 
Complement C1q subcomponent subunit A  64.78 26.28529 4 
Complement C1q subcomponent subunit B  124.31 26.67049 6 
Complement C1q subcomponent subunit C  188.56691 25.98522 3 
Complement C1r subcomponent 124.56 81.60639 4 
Complement C1s subcomponent  244.67691 78.17438 11 
Complement C2  173.98 84.58283 5 
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Complement C3  521.72382 188.5695 19 
Complement C4-B  1602.1176 194.2121 45 
Complement C5  301.37 189.8968 15 
Complement component C6  174.08 108.3674 7 
Complement component C7  219.13382 96.65049 7 
Complement component C8 alpha chain  29.35 66.83168 1 
Complement component C8 beta chain  192.74 68.71412 6 
Complement component C9  164.36 64.61526 7 
Complement factor B  426.75382 86.84704 12 
Complement factor H  445.08691 143.6805 18 
Complement factor H-related protein 1  55.67 38.76639 5 
Complement factor H-related protein 3  44.35 38.4962 2 
Corticosteroid-binding globulin  82.13 45.28297 5 
Fibrinogen alpha chain  78.43 95.65569 6 
Fibronectin 493.35382 266.0344 15 
Ficolin-3  98.95 33.39518 4 
Gelsolin  753.15691 86.04334 16 
Haptoglobin  53.3 45.86082 3 
Hemoglobin subunit alpha  46.24 15.30495 1 
Hemopexin  725.27 52.38455 19 
Heparin cofactor 2  271.97 57.20527 9 
Hepatocyte growth factor activator  53.45 72.85992 2 
Histidine-rich glycoprotein 283.57 60.51023 7 
Insulin-like growth factor-binding protein complex acid labile subunit 291.83382 66.73507 11 
Inter-alpha-trypsin inhibitor heavy chain H1  1427.1138 101.7818 24 
Inter-alpha-trypsin inhibitor heavy chain H2  1009.31 106.8528 21 
Inter-alpha-trypsin inhibitor heavy chain H3  211.20691 100.0716 7 
Inter-alpha-trypsin inhibitor heavy chain H4  754.59 103.5211 22 
Keratin, type I cytoskeletal 10  92.66 59.01978 5 
Keratin, type I cytoskeletal 28  39.73 51.16315 2 
Kininogen-1  625.73 72.99556 11 
Leucine-rich alpha-2-glycoprotein  100.65 38.3822 3 
Lumican  86.22 38.74692 2 
Myb-binding protein 1A  40.34 149.731 2 
N-acetylmuramoyl-L-alanine amidase  76.356909 62.7481 4 
Pigment epithelium-derived factor 215.59 46.48436 8 
Plasma kallikrein  43.31 73.43264 1 
Plasma protease C1 inhibitor  146.88 55.34748 8 
Plasminogen  231.88 93.24719 8 
Probable tRNA (uracil-O(2)-)-methyltransferase  36.62 85.9441 2 
Protein AMBP  105.72 39.88632 3 
Prothrombin 92.036909 71.47468 6 
Serum amyloid P-component  212.29 25.48517 6 
Serum paraoxonase/arylesterase 1  55.83 39.89525 2 
Sex hormone-binding globulin  46.47 43.9799 3 
Tetranectin  66.23 22.95143 2 
Thrombospondin-1  46.58 133.2911 6 
Vitamin D-binding protein  382.25 54.52563 10 
Vitamin K-dependent protein S  47.75 77.12671 5 
Vitronectin  235.57 55.06947 8 
Zinc-alpha-2-glycoprotein  73.05 34.46519 4 
 
Patient 15 (aggressive) 
Protein Score 
MW 
[kDa] 
# 
Pept. 
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Afamin  242.0669 70.96274 8 
Alpha-1-antichymotrypsin  906.58 47.7916 16 
Alpha-1B-glycoprotein  924.86 54.8088 13 
Alpha-2-antiplasmin  165.3669 54.87319 5 
Alpha-2-HS-glycoprotein  372.44 40.09801 7 
Alpha-2-macroglobulin  316.13 164.6144 12 
Angiotensinogen  293.42 53.40562 6 
Apolipoprotein A-I  836.6069 30.75893 20 
Apolipoprotein A-IV  1374.83 45.37147 26 
Apolipoprotein B-100  6430.523 516.6664 124 
Apolipoprotein C-III  249.5 10.8455 2 
Apolipoprotein E  491.3769 36.2458 14 
Beta-2-glycoprotein 1  135.54 39.58415 3 
Beta-Ala-His dipeptidase  177.75 56.77015 7 
Biotinidase  80.43 62.0056 2 
Carboxypeptidase B2  211.37 48.95162 7 
Carboxypeptidase N subunit 2  204.18 61.43147 6 
Ceruloplasmin  2723.865 122.9829 39 
Clusterin  276.5769 53.03122 6 
Coagulation factor V  96.04 252.654 6 
Coagulation factor X  101.61 56.06503 3 
Complement C1q subcomponent subunit A  146.22 26.28529 1 
Complement C1q subcomponent subunit B  182.28 26.67049 4 
Complement C1q subcomponent subunit C  272.0669 25.98522 5 
Complement C1r subcomponent  321.46 81.60639 7 
Complement C1s subcomponent  314.7769 78.17438 11 
Complement C2  403.1969 84.58283 9 
Complement C3  640.0838 188.5695 18 
Complement C4-B  3464.688 194.2121 55 
Complement C5  742.2569 189.8968 26 
Complement component C6  253.08 108.3674 7 
Complement component C7  294.4969 96.65049 6 
Complement component C8 alpha chain  74.44 66.83168 2 
Complement component C8 beta chain  398.19 68.71412 11 
Complement component C8 gamma chain  148.76 22.43461 2 
Complement component C9  309.28 64.61526 9 
Complement factor B  691.5238 86.84704 18 
Complement factor D  58.77 27.52906 3 
Complement factor H  892.5569 143.6805 23 
Complement factor H-related protein 1  153.77 38.76639 5 
Complement factor I  152.8969 68.0715 5 
Corticosteroid-binding globulin  117.71 45.28297 3 
Fibrinogen alpha chain  143.49 95.65569 6 
Fibronectin  1390.188 266.0344 32 
Ficolin-3  175.11 33.39518 5 
Gelsolin  1118.337 86.04334 19 
Glutathione peroxidase 3  41.15 25.76499 2 
Hemopexin  1047.73 52.38455 24 
Heparin cofactor 2 603.0669 57.20527 12 
Hepatocyte growth factor activator  73.23 72.85992 2 
Histidine-rich glycoprotein  684.53 60.51023 12 
Insulin-like growth factor-binding protein complex acid labile subunit  496.8548 66.73507 15 
Inter-alpha-trypsin inhibitor heavy chain H1  1613.397 101.7818 23 
Inter-alpha-trypsin inhibitor heavy chain H2  1553.21 106.8528 28 
Inter-alpha-trypsin inhibitor heavy chain H3  505.2969 100.0716 12 
Inter-alpha-trypsin inhibitor heavy chain H4  1277.79 103.5211 25 
Kallistatin  149.33 48.68222 6 
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Kininogen-1  863.37 72.99556 11 
Leucine-rich alpha-2-glycoprotein  266.13 38.3822 4 
Lumican  167.6069 38.74692 5 
N-acetylmuramoyl-L-alanine amidase  166.7969 62.7481 6 
Pigment epithelium-derived factor  283.94 46.48436 7 
Plasma kallikrein  54.47 73.43264 1 
Plasma protease C1 inhibitor  357.02 55.34748 12 
Plasma serine protease inhibitor  104 45.78674 6 
Plasminogen  403.5438 93.24719 12 
Platelet basic protein 118.86 14.17052 3 
Protein AMBP  155.22 39.88632 3 
Prothrombin  252.3169 71.47468 8 
RNA-binding motif protein, Y chromosome, family 1 member A1/C  39.94 56.09176 2 
Serum amyloid P-component  534.55 25.48517 9 
Serum paraoxonase/arylesterase 1  34.86 39.89525 1 
Sex hormone-binding globulin  93.77 43.9799 5 
Tetranectin  226.36 22.95143 4 
THO complex subunit 2 69.70382 184.5411 5 
Thrombospondin-1 259.2569 133.2911 11 
Thrombospondin-2  77.33 133.7852 4 
Trypsin-1  78.22 27.1113 1 
Vitamin D-binding protein  464.41 54.52563 10 
Vitamin K-dependent protein S  88.48 77.12671 6 
Vitronectin  311.55 55.06947 6 
Zinc-alpha-2-glycoprotein  196.99 34.46519 10 
 
Patient 16 (aggressive) 
Protein Score MW [kDa] # Pept. 
unknown 65.537904 0 4 
unknown 59.5 0 5 
unknown 57.436909 0 4 
unknown 57.13 0 4 
unknown 55.2 0 4 
unknown 52.58 0 3 
unknown 51.28 0 3 
unknown 48.7 0 3 
unknown 46.61 0 2 
unknown 45.510995 0 6 
unknown 44.62 0 2 
unknown 41.91 0 2 
unknown 38.95 0 2 
unknown 38.27 0 2 
unknown 37.056909 0 4 
unknown 36.1 0 2 
unknown 35.11 0 2 
unknown 35.05 0 2 
unknown 32.29 0 1 
unknown 32.08 0 1 
unknown 31.79 0 1 
unknown 31.21 0 1 
unknown 30.26 0 1 
Afamin  376.17691 69.02401 10 
Alpha-1-antichymotrypsin 1108.71 47.62054 21 
Alpha-1B-glycoprotein  827.46 54.23858 18 
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Alpha-2-antiplasmin  232.81382 54.53107 8 
Alpha-2-HS-glycoprotein  490.12 39.29971 8 
Alpha-2-macroglobulin  431.99691 163.18888 14 
Angiotensinogen  491.94 53.12051 10 
Antithrombin-III  786.29691 52.56886 17 
Apolipoprotein A-I  725.62 30.75893 17 
Apolipoprotein A-IV  1664.49 45.37147 29 
Apolipoprotein B-100  5972.4455 515.24085 119 
Apolipoprotein C-I  55.88 9.32609 2 
Apolipoprotein C-III  265.93 10.8455 3 
Apolipoprotein E  532.06691 36.13175 16 
Apolipoprotein M  39.58 21.23944 2 
ATP-binding cassette sub-family F member 1  55.750995 95.86647 5 
ATP-binding cassette sub-family G member 5  36.62 72.45688 2 
Attractin  67.96 158.43246 4 
Beta-2-glycoprotein 1  167.56 38.27266 5 
Beta-Ala-His dipeptidase 138.64 56.65611 5 
Biotinidase  50.86 61.09326 3 
Calcium-transporting ATPase type 2C member 2  57.22 103.12085 4 
Calpain-15  46.51 117.23917 3 
Carboxypeptidase B2  212.90691 48.38141 5 
Carboxypeptidase N catalytic chain 161.82 52.25331 8 
Carboxypeptidase N subunit 2  218.65 60.57615 5 
Ceruloplasmin  3250.0476 122.12759 48 
Clusterin  451.52382 52.46101 9 
Coagulation factor IX  73.99 51.745 3 
Coagulation factor V  155.3 251.51354 9 
Coagulation factor X  109.35 54.69651 4 
Coagulation factor XII  63.74 67.77391 5 
Complement C1q subcomponent subunit A  211.17 26.00019 2 
Complement C1q subcomponent subunit B  228.63 26.44241 4 
Complement C1q subcomponent subunit C 274.99691 25.75714 6 
Complement C1r subcomponent  338.71 80.06681 11 
Complement C1r subcomponent-like protein  54 53.46434 3 
Complement C1s subcomponent  388.70691 76.6348 13 
Complement C2  535.69382 83.21431 10 
Complement C3  942.57073 187.02987 24 
Complement C4-B  2896.2922 192.67254 53 
Complement C5  668.73382 188.18613 20 
Complement component C6  299.03 104.718 8 
Complement component C7  347.52 93.45729 8 
Complement component C8 alpha chain  126.61 65.12104 6 
Complement component C8 beta chain  445.68 67.00347 12 
Complement component C8 gamma chain  124.06 22.26354 3 
Complement component C9  384.06691 63.1327 10 
Complement factor B  912.93382 85.47852 23 
Complement factor H  885.79382 139.0047 22 
Complement factor H-related protein 1  164.82 37.62596 2 
Complement factor H-related protein 3  80.49 37.29875 2 
Complement factor I  162.97691 65.6766 9 
Cytoplasmic dynein 1 heavy chain 1  100.66764 532.07184 12 
Fibrinogen alpha chain  190.84691 94.91441 7 
Fibronectin  928.03172 262.44208 25 
Ficolin-3  95.42 32.88199 5 
Gelsolin  1349.6669 85.64419 25 
Glutathione peroxidase 3  73.99 25.5369 1 
Hemopexin  1306.3438 51.64327 32 
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Heparin cofactor 2  709.37382 57.0342 16 
Hepatocyte growth factor activator  56.126909 70.63609 3 
Hepatocyte growth factor-like protein  85.45 80.26753 7 
Histidine-rich glycoprotein  500.39 59.54087 8 
Hyaluronan-binding protein 2  49.29 62.63044 3 
Insulin-like growth factor-binding protein complex acid labile 
subunit  467.07481 65.9938 13 
Inter-alpha-trypsin inhibitor heavy chain H1  1574.5407 101.32561 22 
Inter-alpha-trypsin inhibitor heavy chain H2  1495.8669 106.39661 31 
Inter-alpha-trypsin inhibitor heavy chain H3  300.20691 99.78653 8 
Inter-alpha-trypsin inhibitor heavy chain H4  1183.69 103.29298 25 
Kallistatin  196.5 48.51116 9 
Kininogen-1  1070.18 71.91215 16 
Leucine-rich alpha-2-glycoprotein  295.98 38.15411 4 
Lumican  160.18691 38.40479 3 
Lymphoid-restricted membrane protein  48.82 62.06908 4 
Myosin-13  71.113818 223.54012 8 
N-acetylmuramoyl-L-alanine amidase  232.6 62.17788 6 
Nebulin  105.42504 772.4543 19 
Pigment epithelium-derived factor  341.35 46.3133 6 
Plasma kallikrein  75.72 71.32284 3 
Plasma protease C1 inhibitor  336.44 55.11939 11 
Plasminogen  453.50691 90.51016 14 
Platelet basic protein  142.98 13.88542 2 
Protein AMBP  172.17 38.97398 4 
Prothrombin  351.56691 69.99212 12 
Serine/threonine-protein kinase SRPK2  35.35 77.49418 1 
Serum amyloid P-component  482.63 25.37113 8 
Sex hormone-binding globulin  194.49 43.75182 8 
Sterol regulatory element-binding protein 1  40.44 121.59908 2 
Sulfhydryl oxidase 1  62.13 82.52551 6 
T-cell surface glycoprotein CD3 epsilon chain  31.22 23.13247 1 
Tetranectin  64.12 22.55228 2 
Thrombospondin-1  499.43382 129.29956 14 
Thyroxine-binding globulin  181.40382 46.29461 7 
Transthyretin  115.85 15.87705 3 
Tripeptidyl-peptidase 2  64.466909 138.26262 6 
Tubby-related protein 2  37.83 58.62737 3 
Tyrosine-protein phosphatase non-receptor type 11  69.626909 68.39332 7 
Uncharacterised protein C10orf67  40.516909 21.44912 3 
Vitamin D-binding protein  515.42 52.92903 11 
Vitamin K-dependent protein S  112.52 75.07393 6 
Vitronectin  410.18382 54.27117 9 
Zinc-alpha-2-glycoprotein  299.68 34.2371 11 
 
Patient 17 (aggressive)  
Protein Score MW [kDa] # Pept. 
unknown 139.72454 0 15 
unknown 81.843818 0 9 
unknown 53.106909 0 3 
unknown 51.32 0 3 
unknown 45.05 0 3 
unknown 44.873818 0 4 
unknown 44.57 0 1 
unknown 43.08 0 2 
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unknown 39.2 0 2 
unknown 37.03 0 2 
unknown 35.97 0 1 
unknown 35.69 0 2 
unknown 34.07 0 1 
unknown 34.07 0 1 
unknown 33.57 0 1 
unknown 33.31 0 1 
unknown 31.996909 0 1 
unknown 30.09 0 1 
Afamin  305.69691 70.96274 6 
Alpha-1-antichymotrypsin  984.82 47.7916 16 
Alpha-1B-glycoprotein  714.79 54.8088 11 
Alpha-2-antiplasmin  245.23691 54.87319 7 
Alpha-2-HS-glycoprotein  294.54 40.09801 5 
Alpha-2-macroglobulin  199.9 164.61441 5 
Angiotensinogen  351.61 53.40562 6 
Antithrombin-III  394.95691 53.02504 9 
Apolipoprotein A-I  1194.9969 30.75893 26 
Apolipoprotein A-II  42.36 11.28194 1 
Apolipoprotein A-IV  1617.5 45.37147 30 
Apolipoprotein B-100  5149.441 516.66639 99 
Apolipoprotein C-I  146.21 9.32609 3 
Apolipoprotein C-III  298.1 10.8455 3 
Apolipoprotein E  745.21691 36.2458 16 
Beta-2-glycoprotein 1  113.44 39.58415 3 
Beta-Ala-His dipeptidase  217.42 56.77015 6 
Biotinidase  39.31 62.0056 1 
Carboxypeptidase B2  203.92 48.95162 4 
Carboxypeptidase N catalytic chain  91.25 52.53842 3 
Carboxypeptidase N subunit 2  187.06 61.43147 4 
Ceruloplasmin  2386.4869 122.98291 30 
Clusterin  280.96691 53.03122 8 
Coagulation factor V  128.40691 252.65397 7 
Coagulation factor X  114.89 56.06503 3 
Coiled-coil domain-containing protein 148  57.04 71.62924 5 
Complement C1q subcomponent subunit B  184.04 26.67049 4 
Complement C1q subcomponent subunit C  329.64691 25.98522 4 
Complement C1r subcomponent  163.05 81.60639 6 
Complement C1r subcomponent-like protein  45.57 54.20562 2 
Complement C1s subcomponent  491.08691 78.17438 12 
Complement C2  340.53 84.58283 11 
Complement C3  1002.7538 188.56945 21 
Complement C4-B  2738.0515 194.21212 49 
Complement C5  483.26 189.89678 15 
Complement component C6  283.46 108.36738 7 
Complement component C7  403.43382 96.65049 7 
Complement component C8 alpha chain 51.06 66.83168 3 
Complement component C8 beta chain  399.29 68.71412 11 
Complement component C8 gamma chain 159.32 22.43461 4 
Complement component C9  460.13691 64.61526 9 
Complement factor B  1119.9169 86.84704 22 
Complement factor H  828.53691 143.68046 21 
Complement factor H-related protein 1  202.58 38.76639 5 
Complement factor H-related protein 3  57.83 38.4962 2 
Complement factor I  255.32691 68.0715 6 
Corticosteroid-binding globulin  139.61 45.28297 6 
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Dixin  43.69 77.88639 2 
Fibrinogen alpha chain  130.09 95.65569 3 
Fibronectin  1495.8138 266.03443 34 
Ficolin-3  110.62 33.39518 4 
Gelsolin  1059.86 86.04334 18 
Glutathione peroxidase 3 53.88 25.76499 2 
Haptoglobin  97.93 45.86082 4 
Hemoglobin subunit alpha 88.39 15.30495 1 
Hemopexin  1078.46 52.38455 22 
Heparin cofactor 2  589.23382 57.20527 13 
Hepatocyte growth factor activator  59.33 72.85992 2 
Histidine-rich glycoprotein  383.95 60.51023 6 
Insulin-like growth factor-binding protein complex acid labile subunit  487.51481 66.73507 12 
Inter-alpha-trypsin inhibitor heavy chain H1  1913.6276 101.78179 29 
Inter-alpha-trypsin inhibitor heavy chain H2  1535.73 106.85278 27 
Inter-alpha-trypsin inhibitor heavy chain H3  596.96691 100.07164 13 
Inter-alpha-trypsin inhibitor heavy chain H4 1277.53 103.52107 23 
Interferon omega-1  30.07 22.53259 1 
Kallistatin  145.49 48.68222 4 
Keratin, type I cytoskeletal 10  93.04 59.01978 5 
Keratin, type II cytoskeletal 1  180.71073 66.17007 4 
Keratin, type II cytoskeletal 2 epidermal  88.636909 65.67832 5 
Kininogen-1  829.83 72.99556 11 
Leucine-rich alpha-2-glycoprotein  101.13 38.3822 2 
Leucine-rich repeat-containing protein 40  51.82 68.72032 3 
Lumican  159.28691 38.74692 3 
Mannan-binding lectin serine protease 2  37.67 77.22422 2 
Max-like protein X  46.74 33.56483 3 
N-acetylmuramoyl-L-alanine amidase  75.67 62.7481 3 
Necdin  34.38 36.11966 1 
Pigment epithelium-derived factor  438.54 46.48436 10 
Plasma kallikrein  90.486909 73.43264 3 
Plasma protease C1 inhibitor  325.15 55.34748 9 
Plasminogen  450.77691 93.24719 10 
Platelet basic protein  180.51 14.17052 3 
Probable cation-transporting ATPase 13A1  35.62 134.52325 1 
Protein AMBP  150.43 39.88632 4 
Prothrombin  212.45691 71.47468 5 
Putative trypsin-6  38.04 27.0924 2 
Serum amyloid P-component  503.78 25.48517 10 
Serum paraoxonase/arylesterase 1  61.58 39.89525 2 
Sex hormone-binding globulin  80.5 43.9799 4 
Smoothelin  39.79 100.0298 2 
Spermatogenesis-associated protein 7  57.66 68.18992 3 
Structural maintenance of chromosomes protein 3  60.234813 141.85298 4 
Tetranectin  218.26 22.95143 3 
Thrombospondin-1  300.74691 133.29106 9 
Thrombospondin-2  62.88 133.78523 3 
Thyroxine-binding globulin  74.286909 46.63674 2 
Titin  102.8173 3843.1187 46 
Trypsin-1 48.71 27.1113 2 
Uncharacterised protein C10orf92  30.51 96.51952 1 
Vitamin D-binding protein  569.63 54.52563 11 
Vitamin K-dependent protein S  35.3 77.12671 2 
Vitronectin  339.5 55.06947 6 
Zinc-alpha-2-glycoprotein 171.86 34.46519 6 
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Patient 18 (aggressive) 
Protein Score MW [kDa] # Pept. 
Unknown 45.69 0 2 
Unknown 41.19 0 1 
Unknown 39.51 0 1 
Unknown 37.75 0 2 
Unknown 36.5 0 1 
Unknown 35.8769089 0 1 
Afamin  306.976909 70.96274 7 
Alpha-1-antichymotrypsin  1026.32 47.7916 18 
Alpha-1B-glycoprotein  673.07 54.8088 9 
Alpha-2-antiplasmin  308.386909 54.87319 9 
Alpha-2-HS-glycoprotein  321.48 40.09801 4 
Angiotensinogen  431.74 53.40562 9 
Apolipoprotein A-I  621.26 30.75893 16 
Apolipoprotein A-IV  1782.22 45.37147 30 
Apolipoprotein B-100  4473.27886 516.66639 96 
Apolipoprotein C-III  295.47 10.8455 3 
Apolipoprotein E  623.226909 36.2458 15 
Beta-2-glycoprotein 1  131.86 39.58415 3 
Beta-Ala-His dipeptidase  166.11 56.77015 5 
Biotinidase  44.85 62.0056 1 
Carboxypeptidase B2  214.43 48.95162 5 
Carboxypeptidase N subunit 2  171.99 61.43147 5 
Ceruloplasmin 1741.59691 122.98291 27 
Clusterin  446.800727 53.03122 9 
Coagulation factor X  117.88 56.06503 3 
Complement C1q subcomponent subunit B  243.23 26.67049 6 
Complement C1q subcomponent subunit C  303.326909 25.98522 5 
Complement C1r subcomponent  153.97 81.60639 10 
Complement C1s subcomponent  441.836909 78.17438 12 
Complement C2  199.2 84.58283 10 
Complement C3  911.936909 188.56945 21 
Complement C4-B  2733.48836 194.21212 50 
Complement C5  625.466909 189.89678 21 
Complement component C6  156.46 108.36738 6 
Complement component C7 324.016909 96.65049 9 
Complement component C8 alpha chain  80.08 66.83168 5 
Complement component C8 beta chain  408.86 68.71412 11 
Complement component C8 gamma chain  109.65 22.43461 4 
Complement component C9  388.886909 64.61526 10 
Complement factor H  923.236909 143.68046 23 
Complement factor H-related protein 1  131.51 38.76639 3 
Complement factor H-related protein 3  58.26 38.4962 2 
Complement factor I  214.356909 68.0715 7 
Fibrinogen alpha chain  191.01 95.65569 5 
Fibronectin  1675.41073 266.03443 36 
Ficolin-3 120.42 33.39518 5 
Gelsolin  1028.49 86.04334 22 
Glutathione peroxidase 3  72.49 25.76499 5 
Haptoglobin  107.9 45.86082 4 
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Hemopexin  1065.42 52.38455 25 
Heparin cofactor 2  645.813818 57.20527 14 
Hepatocyte growth factor activator  54.78 72.85992 2 
Histidine-rich glycoprotein  415.23 60.51023 7 
Hyaluronan-binding protein 2  58.65 64.74024 1 
Insulin-like growth factor-binding protein complex acid labile subunit  484.573818 66.73507 13 
Inter-alpha-trypsin inhibitor heavy chain H1  216.1 101.68631 6 
Inter-alpha-trypsin inhibitor heavy chain H2  1478.98691 106.85278 25 
Inter-alpha-trypsin inhibitor heavy chain H3  399.986909 100.07164 11 
Inter-alpha-trypsin inhibitor heavy chain H4  1272.57 103.52107 26 
Kallistatin  66.76 48.68222 2 
Keratin, type I cytoskeletal 9  236.89 62.2549 7 
Keratin, type II cytoskeletal 1  368.367635 66.17007 11 
Keratin, type II cytoskeletal 2 epidermal  82.71 65.67832 3 
Keratin, type II cytoskeletal 6A  61.72 60.29338 2 
Kininogen-1  997.31 72.99556 11 
Leucine-rich alpha-2-glycoprotein  134.03 38.3822 3 
Lumican  199.52 38.74692 3 
Pigment epithelium-derived factor  488.616909 46.48436 12 
Plasma kallikrein  89.77 73.43264 5 
Plasma protease C1 inhibitor  403.59 55.34748 10 
Plasminogen  415.256909 93.24719 11 
Platelet basic protein  187.75 14.17052 4 
Protein AMBP  233.54 39.88632 6 
Prothrombin  219.786909 71.47468 7 
Putative trypsin-6  88.67 27.0924 2 
Serum amyloid P-component  509.83 25.48517 9 
Tetranectin  170.56 22.95143 3 
Thrombospondin-1  480.946909 133.29106 14 
Thyroxine-binding globulin  88.3338177 46.63674 4 
Transthyretin  38.56 15.99109 2 
Uncharacterised protein C10orf90 51.15 79.00231 2 
Vitamin D-binding protein  522.25 54.52563 9 
Vitamin K-dependent protein S  112.16 77.12671 7 
Vitronectin 556.79 55.06947 9 
Zinc-alpha-2-glycoprotein  302.18 34.46519 10 
 
Patient 19 (aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 61.26 0 6 
unknown 48.54073 0 4 
unknown 48.22 0 2 
unknown 46.84 0 4 
unknown 46.7 0 2 
unknown 42.94 0 4 
unknown 37.12691 0 2 
unknown 35.63 0 1 
unknown 34.44 0 1 
unknown 33.5 0 1 
unknown 33.28 0 1 
unknown 33.27 0 2 
unknown 32.29 0 1 
unknown 32.03691 0 1 
Afamin  163.3769 70.96274 7 
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Alpha-1-antichymotrypsin  1065.48 47.7916 15 
Alpha-1B-glycoprotein 673.23 54.8088 13 
Alpha-2-antiplasmin  151.6169 54.87319 2 
Alpha-2-HS-glycoprotein  207.62 40.09801 4 
Alpha-2-macroglobulin  1344.84 164.6144 26 
Angiotensinogen  361.84 53.40562 9 
Antithrombin-III  704.0369 53.02504 12 
Apolipoprotein A-I  627.6169 30.75893 14 
Apolipoprotein A-IV  1558.25 45.37147 28 
Apolipoprotein B-100  3342.462 516.6664 82 
Apolipoprotein C-I  63.32 9.32609 1 
Apolipoprotein C-II  32.09 11.27675 1 
Apolipoprotein C-III  219.12 10.8455 2 
Apolipoprotein E  206.01 36.2458 9 
Beta-2-glycoprotein 1  40.37 39.58415 1 
Beta-Ala-His dipeptidase  71.42 56.77015 2 
Biotinidase  30.47 62.0056 1 
Carboxypeptidase B2  172.81 48.95162 6 
Carboxypeptidase N subunit 2  138.41 61.43147 3 
Ceruloplasmin  1944.467 122.9829 35 
Clusterin  149.7169 53.03122 6 
Coagulation factor X  138.02 56.06503 3 
Coiled-coil domain-containing protein 148  47.01691 71.62924 6 
Complement C1q subcomponent subunit B  224.67 26.67049 4 
Complement C1q subcomponent subunit C  296.3169 25.98522 7 
Complement C1s subcomponent  246.8469 78.17438 9 
Complement C2  207.66 84.58283 7 
Complement C3  811.0707 188.5695 19 
Complement C4-A  2679.448 194.2471 53 
Complement C5  680.7269 189.8968 18 
Complement component C6  178.25 108.3674 6 
Complement component C7 290.8969 96.65049 4 
Complement component C8 alpha chain  57.75 66.83168 4 
Complement component C8 beta chain 366.27 68.71412 9 
Complement component C8 gamma chain  201.36 22.43461 5 
Complement component C9  352.55 64.61526 9 
Complement factor B  773.3369 86.84704 17 
Complement factor H  614.9838 143.6805 20 
Complement factor H-related protein 1  161.68 38.76639 3 
Complement factor I  75.46691 68.0715 3 
Fanconi anemia group J protein  43.3 142.7846 2 
Fibrinogen alpha chain  71.76 95.65569 3 
Fibronectin  769.6807 266.0344 22 
Gelsolin  644.04 86.04334 11 
Glutamate [NMDA] receptor subunit 3A  35.1 126.5254 2 
Glutathione peroxidase 3  60.23 25.76499 3 
Haptoglobin  297.34 45.86082 8 
Hemopexin  1008.54 52.38455 27 
Heparin cofactor 2  530.9969 57.20527 13 
Histidine-rich glycoprotein  424.66 60.51023 8 
Inter-alpha-trypsin inhibitor heavy chain H1  1219.477 101.7818 22 
Inter-alpha-trypsin inhibitor heavy chain H2  1018.52 106.8528 25 
Inter-alpha-trypsin inhibitor heavy chain H3  340.8469 100.0716 7 
Inter-alpha-trypsin inhibitor heavy chain H4  973.65 103.5211 19 
Kallistatin  136.99 48.68222 7 
Kininogen-1  682.03 72.99556 9 
Leucine-rich alpha-2-glycoprotein  157.25 38.3822 4 
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Lumican  150.2638 38.74692 4 
Pigment epithelium-derived factor  465.87 46.48436 9 
Plasma kallikrein  68 73.43264 3 
Plasma protease C1 inhibitor  234 55.34748 9 
Plasminogen  344.3138 93.24719 9 
Platelet basic protein  129.83 14.17052 3 
Protein AMBP  138.02 39.88632 4 
Prothrombin  79.07 71.47468 2 
Putative hydroxypyruvate isomerase  36.63 30.50061 2 
Putative trypsin-6 49.49 27.0924 3 
Serum amyloid P-component  404.83 25.48517 8 
Sex hormone-binding globulin  84.41 43.9799 4 
Stabilin-1  46.39691 286.9265 2 
Thyroxine-binding globulin  66.69 46.63674 2 
Titin  156.9572 3843.119 46 
TRIO and F-actin-binding protein  61.33382 264.125 7 
Vitamin D-binding protein  560.69 54.52563 12 
Vitronectin  346.42 55.06947 7 
Zinc-alpha-2-glycoprotein  223.82 34.46519 7 
 
Patient 20 (aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 72.577904 0 5 
unknown 35.08 0 1 
Afamin  188.64691 70.96274 6 
Alpha-1-antichymotrypsin  868.48 47.7916 18 
Alpha-1B-glycoprotein  671.31 54.8088 12 
Alpha-2-antiplasmin  153.82691 54.87319 8 
Alpha-2-HS-glycoprotein  277.06 40.09801 5 
Alpha-2-macroglobulin  81.33 164.61441 4 
Angiotensinogen  436.98 53.40562 8 
Apolipoprotein A-I  744.20691 30.75893 19 
Apolipoprotein A-IV  1442.91 45.37147 28 
Apolipoprotein B-100  3953.9348 516.66639 98 
Apolipoprotein C-III 236.49 10.8455 3 
Apolipoprotein E  302.53691 36.2458 13 
Beta-2-glycoprotein 1  95.18 39.58415 2 
Beta-Ala-His dipeptidase  144.66 56.77015 6 
Carboxypeptidase B2  67.94 48.95162 2 
Carboxypeptidase N subunit 2  146.08 61.43147 3 
Ceruloplasmin  2329.8879 122.98291 35 
Clusterin  287.34691 53.03122 6 
Coagulation factor X  105.8 56.06503 3 
Coagulation factor XIII A chain  60.12 83.7278 1 
Complement C1q subcomponent subunit A  170.49 26.28529 3 
Complement C1q subcomponent subunit B  160.15 26.67049 5 
Complement C1q subcomponent subunit C  245.05691 25.98522 4 
Complement C1r subcomponent  107.16 81.60639 5 
Complement C1s subcomponent  254.54691 78.17438 9 
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Complement C2  260.76691 84.58283 12 
Complement C3  671.57 188.56945 19 
Complement C4-B 1612.3715 194.21212 41 
Complement C5  236.73 189.89678 9 
Complement component C6  186.18 108.36738 7 
Complement component C7 172.25382 96.65049 5 
Complement component C8 alpha chain  52.82 66.83168 3 
Complement component C8 beta chain  298.24 68.71412 9 
Complement component C8 gamma chain  141.77 22.43461 2 
Complement component C9  259.6 64.61526 6 
Complement factor B  859.71382 86.84704 19 
Complement factor H  585.78691 143.68046 18 
Complement factor H-related protein 1 148.68 38.76639 3 
Complement factor I  96.256909 68.0715 3 
Corticosteroid-binding globulin  88.5 45.28297 4 
Fibrinogen alpha chain  98.94 95.65569 4 
Fibronectin  1258.4276 266.03443 31 
Ficolin-3  96.55 33.39518 4 
Gelsolin  883.57 86.04334 17 
Hemopexin  955.6 52.38455 21 
Heparin cofactor 2  555.47382 57.20527 13 
Hepatocyte growth factor activator  60.5 72.85992 2 
Histidine-rich glycoprotein  422.01 60.51023 6 
Hyaluronan-binding protein 2  40.88 64.74024 1 
Insulin-like growth factor-binding protein complex acid labile subunit  376.56382 66.73507 11 
Inter-alpha-trypsin inhibitor heavy chain H1  1582.3507 101.78179 24 
Inter-alpha-trypsin inhibitor heavy chain H2  1299.91 106.85278 25 
Inter-alpha-trypsin inhibitor heavy chain H3  341.17691 100.07164 11 
Inter-alpha-trypsin inhibitor heavy chain H4  1059.4269 103.52107 26 
Kallistatin  134.03 48.68222 5 
Kininogen-1  946.64 72.99556 11 
Leucine-rich alpha-2-glycoprotein  82.46 38.3822 3 
Lumican  113.44 38.74692 3 
Monocyte differentiation antigen CD14  34.19 40.67798 1 
N-acetylmuramoyl-L-alanine amidase  110.71 62.7481 6 
Pigment epithelium-derived factor  202.58691 46.48436 8 
Plasma protease C1 inhibitor  187.12 55.34748 7 
Plasminogen  348.92691 93.24719 10 
Platelet basic protein  192.03 14.17052 3 
Protein AMBP  134.33 39.88632 5 
Prothrombin  233.66691 71.47468 8 
Putative trypsin-6  86.84 27.0924 2 
Serum amyloid P-component  344.99 25.48517 7 
Spermatogenesis-associated protein 7  55.37 68.18992 2 
Tetranectin  159.36 22.95143 3 
Thrombospondin-1  369.76691 133.29106 11 
Thrombospondin-2  60.07 133.78523 3 
Vitamin D-binding protein  546.66 54.52563 10 
Vitamin K-dependent protein S  95.71 77.12671 6 
Vitronectin  384.1 55.06947 8 
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Zinc-alpha-2-glycoprotein  214.91 34.46519 7 
 
 
Patient 21 (aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 54.03 0 1 
unknown 52.67 0 2 
unknown 50.02 0 2 
unknown 43.4469 0 5 
unknown 31.3 0 1 
Afamin  118.48 70.9627 3 
Alpha-1-antichymotrypsin  474.77 47.7916 9 
Alpha-1B-glycoprotein  172.41 54.8088 4 
Alpha-2-HS-glycoprotein  223.35 40.098 5 
Angiotensinogen  83.19 53.4056 1 
Ankyrin repeat domain-containing protein 17  33.07 275.97 1 
Antithrombin-III  102.57 53.025 5 
Apolipoprotein A-IV  424.12 45.3715 18 
Apolipoprotein B-100  2481 516.666 55 
Apolipoprotein C-III  101.24 10.8455 1 
Apolipoprotein E 98.44 36.2458 4 
Calpain-15  35.41 119.862 1 
Ceruloplasmin  1315.69 122.983 21 
Clusterin  236.927 53.0312 5 
Coiled-coil domain-containing protein 148  40.95 71.6292 3 
Complement C1q subcomponent subunit B  69.11 26.6705 2 
Complement C1q subcomponent subunit C  54.92 25.9852 1 
Complement C1s subcomponent 55.5 78.1744 2 
Complement C3  297.957 188.569 7 
Complement C4-B  1343.5 194.212 24 
Complement C5  313.75 189.897 8 
Complement component C8 beta chain  61.4 68.7141 1 
Complement component C8 gamma chain  116.31 22.4346 4 
Complement component C9  191.727 64.6153 3 
Complement factor B  426.557 86.847 10 
Complement factor H  289.68 143.68 7 
Complement factor H-related protein 1  73.64 38.7664 1 
Complement factor I  56.1269 68.0715 2 
Fibrinogen alpha chain  309.18 95.6557 7 
Fibronectin  209.637 266.034 6 
Focal adhesion kinase 1  32.99 119.956 2 
Gelsolin  307.9 86.0433 7 
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1  54.5969 208.367 4 
Hemopexin  644.58 52.3846 14 
Heparin cofactor 2 173.22 57.2053 3 
Histidine-rich glycoprotein  194.06 60.5102 3 
Insulin-like growth factor-binding protein complex acid labile subunit  49.0269 66.7351 2 
Inter-alpha-trypsin inhibitor heavy chain H1  485.29 101.782 8 
Inter-alpha-trypsin inhibitor heavy chain H2  461.64 106.853 10 
Inter-alpha-trypsin inhibitor heavy chain H3  163.38 100.072 4 
Inter-alpha-trypsin inhibitor heavy chain H4  345.37 103.521 9 
Keratin, type II cytoskeletal 1  56.17 66.1701 2 
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Kininogen-1 436.15 72.9956 6 
Leucine-rich alpha-2-glycoprotein  138.11 38.3822 3 
Mannose-binding protein C  64.49 26.5262 3 
Pigment epithelium-derived factor  54.46 46.4844 3 
Plasminogen  99.1269 93.2472 4 
Platelet factor 4 variant  60.58 11.7734 2 
Plexin-A4  44.78 215.682 3 
Protein AMBP  44.87 39.8863 2 
Prothrombin  120.997 71.4747 5 
Serum amyloid P-component  144.94 25.4852 3 
Spermatogenesis-associated protein 7  32.49 68.1899 1 
Stabilin-1  45.6 286.926 3 
TRIO and F-actin-binding protein  62.3169 264.125 4 
Vitamin D-binding protein  268.84 54.5256 8 
Vitamin K-dependent protein Z  36.7 46.0262 1 
Vitronectin  352.847 55.0695 6 
Zinc-alpha-2-glycoprotein  97.19 34.4652 4 
 
Patient 22 (aggressive) 
Protein Score MW [kDa] # Pept. 
unkown 42.76 0 2 
unkown 42.4 0 4 
unkown 39.89 0 1 
unkown 38.126909 0 2 
unkown 36.56 0 2 
unkown 35.47 0 2 
unkown 35.45 0 1 
unkown 34.836909 0 1 
unkown 33.89 0 1 
unkown 33.7 0 1 
unkown 33.64 0 1 
unkown 32.35 0 1 
unkown 32.35 0 1 
unkown 31.74 0 1 
Afamin  143.13 70.96274 5 
Alpha-1-antichymotrypsin  922.48 47.7916 14 
Alpha-1B-glycoprotein3 671.2 54.8088 11 
Alpha-2-antiplasmin  217.70691 54.87319 6 
Alpha-2-HS-glycoprotein  305.38 40.09801 4 
Alpha-2-macroglobulin  57.4 164.61441 2 
Angiotensinogen  307.07 53.40562 6 
Antithrombin-III  112.47 53.02504 5 
Apolipoprotein A-I  156.75 30.75893 6 
Apolipoprotein A-IV  1012.12 45.37147 23 
Apolipoprotein B-100  3442.8403 516.66639 79 
Apolipoprotein C-I  61.35 9.32609 2 
Apolipoprotein C-III  251.16 10.8455 3 
Apolipoprotein E 372.41691 36.2458 10 
ATP-binding cassette sub-family A member 12 51.576909 295.38672 4 
Beta-2-glycoprotein 1  131.31 39.58415 3 
Beta-Ala-His dipeptidase  86.91 56.77015 4 
Calpain-15 1 30.36 119.86215 1 
Carboxypeptidase B2  191.81 48.95162 4 
Carboxypeptidase N subunit 2  77.77 61.43147 2 
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CDC45-related protein  34.35 66.21084 1 
Ceruloplasmin  1952.3369 122.98291 29 
Coagulation factor X  116.46 56.06503 4 
Complement C1q subcomponent subunit B  158.94 26.67049 3 
Complement C1q subcomponent subunit C  284.90691 25.98522 4 
Complement C1s subcomponent  321.54691 78.17438 10 
Complement C2  241.43 84.58283 7 
Complement C3  434.05691 188.56945 11 
Complement C4-A  2165.9053 194.24706 44 
Complement C5 336.68 189.89678 9 
Complement component C6  112 108.36738 4 
Complement component C7  182.32691 96.65049 5 
Complement component C8 beta chain  447.59 68.71412 11 
Complement component C8 gamma chain  93.08 22.43461 2 
Complement component C9  307.66691 64.61526 7 
Complement factor B  1050.6369 86.84704 19 
Complement factor H  731.44691 143.68046 17 
Complement factor H-related protein 1  146.64 38.76639 3 
Complement factor H-related protein 3  73.04 38.4962 2 
Complement factor I  254.74691 68.0715 5 
FERM domain-containing protein 4A  42 115.95752 2 
Fibrinogen alpha chain  155.17 95.65569 4 
Fibronectin  1115.0338 266.03443 22 
Ficolin-3  207.9 33.39518 7 
FYVE, RhoGEF and PH domain-containing protein 4  40.726909 87.59782 3 
Gelsolin  483.7 86.04334 9 
Haptoglobin  151.8 45.86082 4 
Hemopexin  914.98 52.38455 20 
Heparin cofactor 2  378.50382 57.20527 10 
Histidine-rich glycoprotein  120.8 60.51023 4 
Insulin-like growth factor-binding protein complex acid labile subunit  274.79382 66.73507 10 
Inter-alpha-trypsin inhibitor heavy chain H1  1272.3869 101.78179 19 
Inter-alpha-trypsin inhibitor heavy chain H2  1230.4769 106.85278 20 
Inter-alpha-trypsin inhibitor heavy chain H3  358.06691 100.07164 7 
Inter-alpha-trypsin inhibitor heavy chain H4  931.96691 103.52107 20 
Kininogen-1  587.1 72.99556 9 
Lumican 94.356909 38.74692 3 
Lymphoid-restricted membrane protein  42.08 62.75334 3 
Mannan-binding lectin serine protease 2  54.95 77.22422 1 
N-acetylmuramoyl-L-alanine amidase  59.2 62.7481 3 
Pigment epithelium-derived factor  263.59 46.48436 6 
Plasma kallikrein  69.496909 73.43264 2 
Plasminogen  427.84691 93.24719 10 
Platelet basic protein  180.02 14.17052 3 
Protein AMBP  100.37 39.88632 3 
Prothrombin  185.47691 71.47468 6 
Putative trypsin-6  75.14 27.0924 2 
Serum amyloid P-component  408.94 25.48517 7 
Spermatogenesis-associated protein 7  45.93 68.18992 2 
Stabilin-1  50.946909 286.92647 3 
Steroid hormone receptor ERR1  39.38 46.10786 3 
Tetranectin  168.5 22.95143 3 
Thrombospondin-1  91.9 133.29106 6 
Vitamin D-binding protein  409.66 54.52563 9 
Vitamin K-dependent protein S  43.21 77.12671 2 
Vitronectin  332.82 55.06947 6 
Zinc-alpha-2-glycoprotein  195.89 34.46519 6 
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Patient 24 (aggressive) 
Protein Score 
MW 
[kDa] # Pept. 
unknown 54.03 0 1 
unknown 52.67 0 2 
unknown 50.02 0 2 
unknown 43.44691 0 5 
unknown 31.3 0 1 
Afamin  118.48 70.96274 3 
Alpha-1-antichymotrypsin  474.77 47.7916 9 
Alpha-1B-glycoprotein  172.41 54.8088 4 
Alpha-2-HS-glycoprotein  223.35 40.09801 5 
Angiotensinogen  83.19 53.40562 1 
Ankyrin repeat domain-containing protein 17  33.07 275.9698 1 
Antithrombin-III  102.57 53.02504 5 
Apolipoprotein A-IV  424.12 45.37147 18 
Apolipoprotein B-100  2480.997 516.6664 55 
Apolipoprotein C-III  101.24 10.8455 1 
Apolipoprotein E  98.44 36.2458 4 
Calpain-15  35.41 119.8622 1 
Ceruloplasmin  1315.688 122.9829 21 
Clusterin  236.9269 53.03122 5 
Coiled-coil domain-containing protein 148  40.95 71.62924 3 
Complement C1q subcomponent subunit B  69.11 26.67049 2 
Complement C1q subcomponent subunit C  54.92 25.98522 1 
Complement C1s subcomponent  55.5 78.17438 2 
Complement C3  297.9569 188.5695 7 
Complement C4-B  1343.501 194.2121 24 
Complement C5  313.75 189.8968 8 
Complement component C8 beta chain  61.4 68.71412 1 
Complement component C8 gamma chain  116.31 22.43461 4 
Complement component C9  191.7269 64.61526 3 
Complement factor B  426.5569 86.84704 10 
Complement factor H  289.68 143.6805 7 
Complement factor H-related protein 1  73.64 38.76639 1 
Complement factor I  56.12691 68.0715 2 
Fibrinogen alpha chain  309.18 95.65569 7 
Fibronectin  209.6369 266.0344 6 
Focal adhesion kinase 1  32.99 119.9556 2 
Gelsolin  307.9 86.04334 7 
Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1  54.59691 208.3674 4 
Hemopexin  644.58 52.38455 14 
Heparin cofactor 2  173.22 57.20527 3 
Histidine-rich glycoprotein  194.06 60.51023 3 
Insulin-like growth factor-binding protein complex acid labile subunit  49.02691 66.73507 2 
Inter-alpha-trypsin inhibitor heavy chain H1  485.29 101.7818 8 
Inter-alpha-trypsin inhibitor heavy chain H2  461.64 106.8528 10 
Inter-alpha-trypsin inhibitor heavy chain H3  163.38 100.0716 4 
Inter-alpha-trypsin inhibitor heavy chain H4  345.37 103.5211 9 
Keratin, type II cytoskeletal 1  56.17 66.17007 2 
Kininogen-1  436.15 72.99556 6 
Leucine-rich alpha-2-glycoprotein  138.11 38.3822 3 
Mannose-binding protein C  64.49 26.52615 3 
Pigment epithelium-derived factor  54.46 46.48436 3 
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Plasminogen  99.12691 93.24719 4 
Platelet factor 4 variant  60.58 11.77337 2 
Plexin-A4  44.78 215.6823 3 
Protein AMBP  44.87 39.88632 2 
Prothrombin  120.9969 71.47468 5 
Serum amyloid P-component  144.94 25.48517 3 
Spermatogenesis-associated protein 7  32.49 68.18992 1 
Stabilin-1  45.6 286.9265 3 
TRIO and F-actin-binding protein  62.31691 264.125 4 
Vitamin D-binding protein  268.84 54.52563 8 
Vitamin K-dependent protein Z  36.7 46.0262 1 
Vitronectin  352.8469 55.06947 6 
Zinc-alpha-2-glycoprotein 97.19 34.46519 4 
 
